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Abstract 
According to the 2012 WHO/UNEP publication 'State of the Science of Endocrine 
Disrupting Chemicals' research into endocrine disrupting chemicals over the last decade 
has indicated that, despite the progress achieved in development and validation of test 
methods for evaluation of endocrine disruptors, there are still several gaps that need to 
be addressed. Considering the expected significant amount of work needed to fill the 
gaps and the limited resources available, it will be important to set priorities for the 
upcoming period (next 5-10 years) for the development and validation of test methods. 
Thus there is a need to focus the European input to the OECD test guideline programme 
to effectively enhance the identification of chemical substances with endocrine disrupting 
properties whilst making best use of existing resources.  
With this objective in mind, DG Environment, supported by JRC, is organising a European 
expert workshop on setting priorities for further development and validation of test 
methods for evaluating endocrine disruption. The workshop will take place on 30 May - 
01 June 2017 in Brussels. The deliberations will focus on what is necessary and 
achievable in the context of resources, timescales and animal welfare considerations.  
In preparation for the workshop, JRC has drawn up a questionnaire to gather input from 
experts in the field on key issues to be used as a basis for the further discussions at the 
workshop. An online survey with the title "Identifying gaps in available test methods for 
evaluation of endocrine disruptors" was performed on the EU Survey platform and open 
for commenting from 19/05/2015 until 15/06/2015. A selected group of experts (EFSA 
Scientific Committee and WG on EDs, ECHA ED WG and RAC, WNT (European members 
from OECD webpage), Experts identified in Annex 3 of the "Roadmap for setting priorities 
for further development and validation of test methods and testing approaches for 
evaluating endocrine disruptors") was invited to participate in the survey.  
Experts were asked to rank endocrine related diseases/disorders regarding the possibility 
to predict them with existing test methods (TMs). They were further asked to rank 
diseases/disorders regarding the need to develop new test methods to better cover 
those. Experts were then requested to provide their views on including further tests 
based on those discussed in the OECD (2012) "Detailed Review Paper on the state of the 
science on novel in vitro and in vivo screening and testing methods and endpoints for 
evaluating endocrine disruptors" and their views on the current OECD Conceptual 
Framework and proposals for improvements. Forty experts representing 15 countries and 
different stakeholder groups (authorities; academia; civil society organisation; industry) 
replied.  
The purpose of this report is to present the detailed survey results. Multiple choice 
questions were evaluated and where possible quantitative rankings were performed. In 
addition, the survey respondents provided a lot of valuable information in numerous free 
text comments. Those are included in the report in tables as they were received, without 
editing them, unless personal information had to be removed. Brief summaries of the 
main points raised are added after each section. 
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1 Survey context and aim 
According to the 2012 WHO/UNEP publication 'State of the Science of Endocrine 
Disrupting Chemicals' research into endocrine disrupting chemicals over the last decade 
has indicated that, despite the progress achieved in development and validation of test 
methods for evaluation of endocrine disruptors, there are still several gaps that need to 
be addressed. Considering the expected significant amount of work needed to fill the 
gaps and the limited resources available, it will be important to set priorities for the 
upcoming period (next 5-10 years) for the development and validation of test methods. 
Thus there is a need to focus the European input to the OECD test guideline programme 
to effectively enhance the identification of chemical substances with endocrine disrupting 
properties whilst making best use of existing resources. With this objective in mind, DG 
Environment, supported by JRC, is organising a European expert workshop on setting 
priorities for further development and validation of test methods for evaluating endocrine 
disruption, which will be held on 30 May – 1 June 2017 in Brussels. 
The workshop will produce a comprehensive overview of the existing test methods on 
endocrine disruptors (EDs), and in doing so identify gaps and most importantly set 
priorities for future work on test method development. In preparation for the workshop, 
JRC has drawn up a questionnaire to gather input from experts in the field on key issues 
the outcome of which is to be used as a basis for the discussions at the workshop. In 
more depth, the aim of this survey was to gather information on approaches, experiences 
and future directions in setting priorities for further development and validation of test 
methods and testing approaches for evaluating endocrine disruptors. 
In the process of the workshop preparation, the survey outcome was further evaluated 
and is currently used to develop a thought-starter document. The thought-stater 
document aims at providing an overview of available test methods (TMs) as regards 
endocrine disrupting properties, identifying gaps in TMs for identification of known ED 
properties, identifying relevant existing TMs and testing approaches to be improved, 
identifying needed enhancements of existing TMs and testing approaches, identifying 
needs for development of new TMs and testing approaches and proposal for prioritisation 
methodology.  
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2 Survey design 
The online EU Survey "Identifying gaps in available test methods for evaluation of 
endocrine disruptors" was launched on 19/05/2015 and closed on 15/06/2015. A 
selected group of experts (EFSA Scientific Committee and WG on EDs, ECHA ED WG and 
RAC, WNT (European members from OECD webpage), Experts identified in Annex 3 of 
the "Roadmap for setting priorities for further development and validation of test 
methods and testing approaches for evaluating endocrine disruptors") were invited to 
participate in the in the survey.  
The questionnaire consisted of the following sections: 
● Information on respondent; 
● Priorities for the development of test methods to predict/identify substances that 
may cause endocrine related diseases/disorders; 
● Criteria for setting priorities for test method development and enhancement; 
● Coverage of endocrine pathways and related tests/endpoints that might be added 
and currently under discussion in OECD; 
● Comments on the OECD conceptual framework for testing and assessment of 
endocrine disruptors (as revised in 2012). 
The experts could use the predefined set of answers as well as comment in free text 
fields. The free text comments are shown in tables as they were received, without 
editing. Only personal information was removed in line with the privacy statement of the 
survey. 
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3 Survey results 
3.1 Information on respondents (Questions B1-B8) 
Responses were received from 40 experts representing 15 countries and different 
stakeholder groups (15 representing authorities; 11 academia; 3 civil society 
organisation; 3 industry; 8 other affiliations). For details see Figure 1:  and Figure 2. 
38 of 40 respondents provided their name, affiliation and e-mail address. Half of the 
respondents replied on behalf of their organisation and the other half in their private 
capacity.  
 
Figure 1: Country of respondent. Survey participants were from 12 different EU countries and 3 
non-EU countries (indicated as "Other": USA, Switzerland, Norway). 
 
Figure 2: Survey respondents' affiliation. The category "other" was further specified by 
respondents as e.g. self-employed, retired, NGO, Social no profit cooperative. 
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3.2 Priorities for the development of test methods to 
predict/identify substances that may cause endocrine related 
diseases/disorders 
The first part of the survey (survey section C) aimed at identifying the priorities for the 
development of test methods to predict/identify substances that may cause endocrine 
related diseases/disorders (Table 1).  
Table 1: List of diseases/disorders addressed in the survey (according to WHO/UNEP, 2012) 
Disease/disorder Examples 
Human female reproductive health 
pubertal timing, fibroids, endometriosis, polycystic ovary 
syndrome, fecundity and fertility 
Wildlife female reproductive health 
uterine fibroids, lower reproductive success, egg shell 
thinning, imposex in snails 
Human male reproductive health 
testicular cancer, semen quality, cryptorchidism, 
hypospadias, reduced anogenital distance, testicular 
dysgenesis syndrome 
Wildlife male reproductive health 
feminising disorders, cryptorchidism, low fertility and 
reproduction rates 
Thyroid-related disorders / 
neurodevelopmental disorders in 
children 
cognitive and behavioural deficits, attention 
deficit/hyperactivity disorder (ADHD), autism 
Hormone related cancers breast, endometrial, ovarian, prostate, thyroid 
Adrenal disorders in humans 
adrenocortical hyperplasia, development of fetal adrenal 
cortex, effects on function of hypothalamic-pituitary-adrenal 
(HPA) axis 
Adrenal disorders in wildlife 
uterine occlusions/strictures, leiomyoma, adrenocortical 
hyperplasia, elevated baseline corticosterone levels 
Metabolic disorders obesity, diabetes, metabolic syndrome 
Immune related disorders in humans 
inflammatory disorders, immune cancers such as lymphoma 
and leukaemia, childhood respiratory disease 
Immune related disorders in wildlife increased susceptibility to infectious diseases 
 
The experts were asked to indicate: 
● whether any of the existing test methods could predict any of endocrine related 
diseases/disorders (Table 1; C.1); 
● their priority for development of new/enhanced test methods for relevant 
endocrine related diseases/disorders (Table 1; C.2); 
● any other disease/disorder of concern and not listed in Table 1 and a need to 
develop new test methods (C.3). 
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3.2.1 Prediction of endocrine related diseases/disorders with existing 
test methods (C.1) 
 
Figure 3: Replies of experts to question C.1: Are you aware of existing test methods for predicting 
the development of the diseases/disorders listed in Table 1? 
 
In order to establish the priority for the areas in which test methods should be 
developed, JRC used the following methodology for ranking:  
Percentages of answers of a certain category were calculated by dividing by the overall 
number of answers (excluding no replies which were 4-11 of 40) and then ratios for 
ranking were calculated as presented in the following equations:  
(Equation 1) 	
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The outcome of the ranking is given in Table 2. 
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Table 2: Ranking of replies of experts to question C.1 "Are you aware of existing test methods for 
predicting the development of the diseases/disorders listed below (i.e. in Table 1)?" Ranking is 
based on ratios of the number of answers  indicating that existing test methods could not predict / 
could partly predict / could predict the respective disease/disorder, as described in Equation 1 and 
2 above. 
#			 
#		 
  
(Eq 1) 
#				!"	 	
#		 
  
(Eq 2) 
Ranking Ratio Ranking  Ratio 
Metabolic disorders 1 18.0 1 33.0 
Immune related disorders in 
wildlife 
2 10.5 3 14.0 
Adrenal disorders in wildlife 3 7.5 4 13.5 
Adrenal disorders in humans  4 6.5 2 15.0 
Thyroid-related disorders / 
neurodevelopmental disorders in 
children 
5 5.7 5 11.0 
Immune related disorders in 
humans 
6 5.0 6 10.3 
Hormone related cancers 7 1.4 9 6.0 
Human female reproductive health 8 0.7 10 4.0 
Wildlife male reproductive health 8 0.7 7 10.0 
Wildlife female reproductive health 10 0.5 8 7.5 
Human male reproductive health  11 0.2 11 1.8 
Ranking: 1-3 highest concern; 4-6 medium concern; 7-9 lower concern; 10-11 lowest concern 
 
According to the replies and the derived ranking, the best coverage with existing TMs is 
available for human and wildlife reproductive health. The highest concern with less TM 
availability to predict those was identified for metabolic disorders, immune related 
disorders in wildlife and adrenal disorders in wildlife and humans. 
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3.2.2 Priority for development of new/enhanced test methods for 
relevant endocrine related diseases/disorders (C.2) 
 
Figure 4: Replies of experts to question C.2: Please indicate your priority for developing test 
methods for predicting the development of diseases/disorders listed in the table below (especially 
for those where you answered "could partly predict" or "could not predict"; in the above table (i.e. 
Figure 3)). (Considering where new or enhanced test methods could lead to the greatest 
contribution to the protection of human health and the environment in either a short or long-term 
perspective).  
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JRC ranked the replies applying the following methodology:  
Percentages of answers of a certain category were calculated by dividing by the overall 
number of answers (excluding no replies which were 5-15 of 40) and then ratios for 
ranking were calculated as presented in the following equations:  
(Equation 3) 	
#			
#	#	
 
(Equation 4) 
#		$	
#	#	
 
 
Table 3: Ranking of replies to C.2: Please indicate your priority for developing test methods for 
predicting the development of diseases/disorders listed in Table 1. Ranking is based on ratios of 
the number of answers indicating high priority and intermediate priority compared to low priority, 
as described in Equation 3 and 4 above. 
 
#	% &%	  "
#	'	  "
  
(Eq 3) 
 
#	% &% ( !	  "
#	'	  "
  
(Eq 4) 
Ranking Ratio Ranking Ratio 
Thyroid-related disorders / 
neurodevelopmental disorders in children 
1 31 1 34 
Metabolic disorders 2 23 2 31 
Immune related disorders in humans 3 11 3 15 
Human female reproductive health  4 7 5 14 
Wildlife female reproductive health 5 7 4 10 
Adrenal disorders in humans 6 6 6 9 
Hormone related cancers 7 5 8 8 
Immune related disorders in wildlife  8 5 7 7 
Wildlife male reproductive health 9 4 9 6 
Human male reproductive health 10 3 10 4 
Adrenal disorders in wildlife 11 2 11 3 
Ranking: 1-3 highest priority; 4-6 medium priority; 7-9 lower priority; 10-11 lowest priority 
 
Table 4 compares the ranking obtained for questions C.1 and C.2 regarding what could 
be predicted with existing test methods (C.1) and the priorities for developing new test 
methods (C.2). The diseases/disorders with the biggest gap in related test methods are 
not necessarily the ones with the highest priorities for filling these gaps. E.g. thyroid 
related disorders are already partly covered with the existing TMs but the highest priority 
for further filling the remaining gaps. In other areas like e.g. immune related disorders 
and adrenal disorders in wildlife large gaps were identified, however they are not under 
the highest priority for TM development. 
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Table 4: Comparison of ranking of replies to C1 and C2 as presented in Table 2 and Table 3. 
 
C.1: Gaps in existing 
TM based on  
(Eq 1) 
C.2: Priority for filling 
gaps based (Eq 3) 
Thyroid-related disorders / 
neurodevelopmental disorders in children 
5 1 
Metabolic disorders 1 2 
Immune related disorders in humans 6 3 
Human female reproductive health 8 4 
Wildlife female reproductive health 10 5 
Adrenal disorders in humans  4 6 
Hormone related cancers 7 7 
Immune related disorders in wildlife 2 8 
Wildlife male reproductive health 8 9 
Human male reproductive health  11 10 
Adrenal disorders in wildlife 3 11 
Ranking regarding concern/priority: 1-3 highest; 4-6 medium; 7-9 lower; 10-11 lowest 
 
3.2.3 Expert opinions on any other disease/disorder not listed and 
possible needs for new test methods (C.3) 
In addition to the two specific questions, experts were invited to name any other 
disease/disorder of concern and not listed in Table 1 and a need to develop new test 
methods (Table 5).  
Table 5: Free text answers to question C.3: Would you like to add any other disease/disorder of 
concern that is likely linked to endocrine disrupting substances and where there is a need for the 
development of new test methods or enhancement of existing test methods? 
General comment 
1. As mentioned in the introduction for the question, the levels of evidence for a link of the listed 
diseases with exposure to chemicals are varying. The diseases mentioned can have a variety 
of causes and the respective diseases are well known to be multifactorial and a causal link 
between such diseases and chemicals in general and endocrine disrupting substances 
specifically is not substantiated. Risk factors (not related to endocrine disrupters) for such 
diseases cannot be dismissed as cause for the diseases. This needs to be considered in 
balancing the need for additional test methods and in prioritization against test method 
development in other areas. 
Comments specific for wildlife toxicity 
2. Screening methods for endocrine disruption in invertebrates 
3. Too little is known about sensitivity of (certain species of) birds to certain EDCs relative to 
other taxa. There is a need to identify which core characteristics (traits) make birds unique in 
their potential responses to EDCs 
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4. Which MOAs and associated specific endpoints give rise to effects in birds that would not be 
seen in mammals or other taxa. Which targeted, step-wise in vitro and small scale in vivo 
protocols should be developed to specifically address these differences between birds and 
other taxa. 
5. thyroid related disorders in wildlife - neurodevelopmental disorders in human and wildlife 
6. Neurodevelopmental disorders might be of interest for wild life species, as well, given the 
wide variety of neurotoxicants in the environment such as axonic excitotoxins (pyrethroids), 
acetylcholine esterase inhibitors (organophosphates and carbamate pesticides). This has been 
shown for zebrafish regarding altered locomotor behavior (Kluever et al. Environ. Sci. 
Technol., 2015, 49 (11), pp 7002-7011). Moreover, thyroid disruptors might have also 
neurodevelopmental effects affecting behavior of wild life species (various environmentally 
relevant thyroid disruptors such as PCBs shown to be also neurotoxicants, although the 
causative link is not yet fully elucidated). 
7. Moreover, thyroid disruptors might have also neurodevelopmental effects affecting 
behavior of wild life species (various environmentally relevant thyroid disruptors such as PCBs 
shown to be also neurotoxicants, although the causative link is not yet fully elucidated). 
Comments specific for human/mammalian toxicity:  
8. PCOS, ovarian, testicular and adrenal hormonal disorders 
9. Prostate adenomas and carcinomas; mammary gland tumors 
10. neurodevelopmental disorders in human 
11. premature reproductive senescence, not detected by current TMs 
12. epigenetic MoA is repeatedly highlighted by OECD working groups as relevant to investigate 
for the ED context as a longer term goal (3x) 
13. Non-genotoxic carcinogenicity, also beyond ED MoA, is also spotted as high priority issue 
by OECD WNT (2x) 
14. Disorders, which are not mentioned in table C.2, are premature senescence and cancers 
arising after exposure in utero 
15. EDCs and bone disorders have been included in Section 2.9 of the WHO/UNEP report. Bone 
disorders like osteoporosis have been considered as one of the metabolic diseases. Many 
pathways like traditional EATS pathways in the OECD CF and those included in DRP 178 like 
PPARs, VDR, RXR, GR etc are involved in the regulation of bone remodeling. Other pathways 
like TGF-ß; etc influence also bone formation and resorption. There are many in vitro, ex vivo 
and in vivo mammalian bone remodeling methods in the medical field. Zebrafish is also used 
to study bone remodeling. There is a need for the development of new test methods. 
Possibilities exist for enhancing existing test methods, like including histology of bone tissue in 
the repeated/reproductive toxicity tests, including some parameters over bone remodelling in 
the developmental toxicity test. 
16. There are no standardized methods for metabolic disorders and measurements of obesity, 
There are apart from the DIT cohort in TG 443 no standardized methods to measure reduced 
immune function 
17. For thyroid-related disorders the definitive identification of thyroid active chemicals is an 
effect on organ weight and histopathological changes. However, some of these changes are 
related to modes of action that have limited relevance for human health. Test method 
development should include clarification of MoAs that are non-human relevant. In addition 
thyroid hormone measures should be used in conjunction with changes in thyroid weight and 
histopathology, not as stand-alone measures. This is particularly true for measures in perinatal 
animals. The fluctuation of thyroid hormone levels in this age of rats (PND13) is very dynamic 
due to large individual differences. Pups at PND 13 are in the middle of dramatic growth period 
and small number of pups will be subjected to measure. Since hormone levels at PND 13 
fluctuate easily based on secondary effects by growth retardation and several stress 
conditions, it is difficult to detect the direct effects on the endocrine system. In order to 
prevent unnecessary concerns, serum levels for thyroid hormones should be evaluated with 
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caution. 
Comments on criteria for ranking 
18. Highest priority in responses to C2 is given to those fields where more mechanistic 
knowledge and methods exist, but MoA information from these methods is incomplete 
and approaches for testing a larger number of substances are not yet available. As soon as 
IATAs have been established for these fields, the experience and resources shall be used to 
extend to other fields.  
19. In the prioritization, it is necessary to take into account the maturity of relevant test 
methods in regard to scientific credibility, relevance, predictivity (sensitivity, specificity), 
readiness for standardization and foreseen regulatory use. 
20. Test method development as well as regulatory acceptance and demand for these tests should 
be restricted to those tests that have accepted relevance to humans and or can be bounded 
by human relevant diagnostic boundaries. Efforts to develop test methods, or expand existing 
test methods to include additional endpoint measurements for which we have no knowledge 
base for understanding the biological or toxicological meaning of the outcome should be of low 
priority. 
21. Need to improve EATS first in vitro so metabolically competent 
 
JRC Summary of the comments in free text fields of Question C.3 regarding 
other endocrine related diseases  
The general comments in this section were reflecting concern about the evidence for 
linking the listed diseases with exposure to chemicals, that might be difficult to establish 
as these "diseases are well known to be multifactorial. Moreover the "Risk factors (not 
related to endocrine disrupters) for such diseases cannot be dismissed as cause for the 
diseases". The experts asked for consideration of these facts in balancing the need for 
additional test methods and in prioritization against test method development in other 
areas.  
The comments regarding the ecotoxicity highlighted the need of screening methods for 
endocrine disruption in invertebrates, differential sensitivity of certain species of birds 
(and birds differences to other taxa) to EDC and need to identify core characteristics 
(traits) that make birds unique in their potential responses to EDCs. A concern was also 
expressed for thyroid disrupters in context of neurodevelopmental effects, as various 
environmentally relevant thyroid disruptors such as PCBs show to be also neurotoxicants, 
although the causative link is not yet fully elucidated. 
In relation to human health the epigenetic and non-genotoxic carcinogenicity MoA were 
highlighted as relevant to investigate in the ED context as a longer term goal. 
Other disorders/diseases that were not addressed in the survey were added, i.e. 
premature senescence and cancers arising after exposure in utero. In the area of 
metabolic disorders, bone disorders and obesity were identified as areas with high 
priority for development of the new or enhanced existing test methods. Experts 
suggested that possibilities exist for enhancing existing test methods, like including 
histology of bone tissue in the repeated/reproductive toxicity tests, including some 
parameters over bone remodelling in the developmental toxicity test. 
Additionally the lack of the standardised methods to measure reduced immune function 
was pointed out. 
In the area of thyroid-related disorders the experts suggested that the test method 
development should include clarification of MoAs that are non-human relevant and that 
serum levels for thyroid hormones should be evaluated with caution in order to prevent 
unnecessary concerns. 
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3.3 Criteria for prioritising the development of new test methods 
or enhancement of existing test methods 
In section D of the survey, experts were asked to: 
● Rate the relevance of criteria proposed for prioritising tests relevant for ED 
identification when considering an overall set of test methods (D.A) and name 
further criteria (D.A.7). 
● Rate the relevance of the criteria proposed below for prioritising tests relevant for 
ED identification when considering a specific test method (D.B) and name further 
criteria (D.B.8). 
3.3.1 Rating the relevance of criteria proposed for prioritising tests 
relevant for ED identification when considering an overall set of 
test methods 
The experts rated the proposed criteria (D.A.1–D.A.6) from: 1 = low relevance to 10 = 
high relevance and results are given in Table 6. 
Table 6: Criteria and their ranking of relevance considered for an overall set of test methods. 
criterion ranking 
relevance score 
median min max 
Coverage of relevant 
diseases/disorders (D.A.1) 
1 10 5 10 
Coverage of relevant life 
stages/exposure time windows (D.A.4) 
1 10 5 10 
Coverage of relevant range of 
species/disorders (D.A.2) 
3 8 1 10 
Coverage of relevant molecular 
targets (D.A.3) 
3 8 3 10 
Consideration of animal welfare 
(D.A.5) 
5 7 1 10 
Consideration of costs (D.A.6) 6 5 1 10 
Note: 2 experts did not reply to this question 
 
The coverage of the relevant diseases/disorders as well as relevant life stages/exposure 
time windows were rated of the highest relevance for developing or enhancing test 
methods. The lowest concern was given to the consideration of the costs.  
 
Table 7: Criteria named by experts for a set of test methods in addition to those listed in Table 6 
(free text answers to question D.A.7 Would you like to comment on the above criteria or add any 
other criterion for a set of test methods?) 
1. Especially human relevance is currently not well established for many models. For example, 
to establish neurodevelopmental effects sexual dimorphism and species differences should be 
taken into account, which is currently not the case. 
2. Costs has been given a lower priority because if cost savings is implemented at the level of 
testing, the potential that society will later have to pay higher medical costs and 
experience lower quality of life is increased. 
3. test simplicity, evaluation model, clinical relevance 
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4. I assume that consideration of animal welfare with a high score does not down prioritize 
experimental animal studies as long as they are performed according to animal welfare 
guidance. 
5. As I hope is reflected in my answers, the principal concerns are vulnerable windows and 
physiological outcomes. 
6. For D.A.3 (coverage of relevant molecular targets): 10 if in vitro, less if in vivo 
7. D.A.5 (animal welfare) and D.A.6 (costs) are highly prioritized but should not be on 
expense of protection of health or environment. C.f. also response under point C.3 
8. Consistent with the current state of the art of endocrine science, the default approach to 
assessing potential EDCs must include low-dose studies relative to human exposures and 
below those dose ranges used for traditional toxicity testing. Assessments should take into 
account that there may be no detectable threshold below which EDC can be presumed to be 
safe, and that potency is an inaccurate predictor for toxic effects, due to variations depending 
on hormonal systems and many other factors. 
9. The aforementioned criteria are mixed for both in vitro and in vivo methods and sometimes 
difficult to clarify in the answers. For instance animal welfare is a highly relevant issue, but 
since the WHO definition asks for information on intact animals it is as yet unavoidable. 
In the future this may be extrapolated from in vitro tests. The development of harmonized TGs 
under MAD could in part address this issue. The same applies for costs, if data from one 
method are accepted in all OECD Member Countries this will save costs. Moreover, if we would 
like to include potency in the regulatory decisions of EDs it is essential that all relevant and 
sensitive endpoints have been addressed/measured. 
10. The sensitivity and integrity of each test method is very important to identify endocrine 
disruptors. If there is even a small possibility of false positive results, the evaluation 
considering the weight of evidence (WoE) needs to be conducted carefully. From the 
perspective of animal welfare, unnecessary additional studies should not be required based 
on the results of studies with low integrity. Typically, coverage of relevant molecular 
targets in an overall set of test methods would be less of a priority versus coverage of 
relevant diseases/disorders and species relevance. However for endocrine disruptors 
RELEVANT molecular targets are a necessary component of the ED identification process. It 
is especially important to understand how modulation of molecular targets is related to 
adversity as the endocrine system is highly adaptive. All the criteria mentioned for endocrine 
disruptor identification and evaluation are important for prioritization based on the WHO/IPCS 
definition and the regulatory consequences in addition the aspect of adversity is key; all new 
test methods intended to be used in the regulatory context should be able to define 
adversity in contrast to e.g. fluctuations of responses within the physiological homeostasis. 
11. Coverage of relevant data gaps - eg which MOAs and associated specific endpoints give rise to 
effects in birds that would not be seen in mammals or other taxa. 
12. A test has to be relevant in first place for a known human ailment, irrespective of molecular 
targets involved. To be used it needs to be relatively inexpensive, and to conform to ethical 
requirements. Most of all it must be relevant in terms of species (human and/or wildlife) 
and in terms of time window. 
13. with regard to relevant molecular targets: Less well understood MoAs should be 
considered as well - regarding relevant range of species: for wildlife: knowledge on the 
endocrine systems and therefore also on disorders is limited for invertebrates, birds, 
amphibians, reptiles, plants and microbes - with regard to relevant life stages/windows of 
exposure: tests for early exposure, late effects in life should be considered - test systems 
for chronic low-dose exposure are missing 
14. Regarding D.A.1 (coverage of diseases) we consider this criteria rather not relevant for 
Environment. Regarding D.A.6 (costs)  the relevance of costs with regard to validation 
exercise and development of a TG are considered 
15. A priority test should address a known biological mechanism - this is critical for building a 
deeper understanding of chemical activity, predicting toxic effects, predicting cumulative, 
cross-species and life-stage effects. 
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16. Of course animal welfare is important in that we need to reduce where possible, and use the 
least number of animals to get the necessary information. Similarly, cost will also be a 
consideration, but at the end of the day a good test method will save costs. 
Non-criteria/general comments: 
17. We propose an integrated and comprehensive long-term toxicity/developmental/carcinogenicity 
bioassay capable of generating information on a broad spectrum of different end-points and 
relevant hypotheses. Sprague Dawley rat, already in use for carcinogenicity bioassays by 
most organizations including the Ramazzini Institute and the National Toxicology Program, and 
the Endocrine Disruptor Screening Program of the U.S. Enviromental Protection Agency [EPA], 
has been demonstrated as an appropriate and relevant model for identifying, extrapolating and 
predicting several toxic effects in humans. Therefore integrated toxicological tests on Sprague 
Dawley rat represents a unique opportunity for investigating multiple toxicological end-points 
at once, sparing animal lives in accordance to the 3Rs (replacement, reduction and 
refinement). An integrated study design based on a stepwise process is described, that 
complies and expands the state of the art of current guidelines: the Organization for Economic 
Co-operation and Development (OECD) Guidelines 453, 443 (OECD 2009, 2011), National 
Toxicology Program (NTP) Guidelines (NTP 2011a, e), and EFSA Guidelines 2013 (EFSA 2013). 
This strategy will provide data for more comprehensive risk assessments, by including prenatal, 
lactational, neonatal exposures as well as continued exposure and observation of animals up to 
at least 30 months (130 weeks) of lifetime post birth. This integrated study design is efficient 
in that the same generational cohort of rats used for studying long-term 
toxicity/carcinogenicity can be monitored in satellite parallel experiments designed to measure 
markers and parameters related to system-specific toxicities, metabolic alterations, and 
endocrine disturbances. 
18. The correlation of endocrine disruptors and humans/wildlife is of high relevance because there 
are many doubts/gaps to be studied yet, and more information (as much as possible) on 
species differences, molecular pathways, life stage susceptibility, and non stress 
conditions for proper comparisons are important. 
19. The development of MoA/AOP informed in vitro/in silico focussed IATAs with improved human 
or environment relevant metabolism and improved (human/environmental) relevance should 
be the main focus of development. This appears essential in order to assess a relevant number 
of substances in forseeable time, to allow regular re-testing of substances along the 
continously ongoing scientific progress in understanding ED MoA Testing and Assessment and 
also to eventually address mixture toxicity. This requires critical characterisation of the 
performance of actual animal testing reference methods (reproducibility and relevance for 
target of evaluation human health or environment) in order to correctly use the uncertainty 
information for the validation of new methods and to define acceptable performance of new 
approaches. Moreover further work for approaches to define adversity on a cellular level as well 
as toxicokinetic in vitro to in vivo extrapolation will be essential. The METiCx consortium from 
the Horizon 2020 call representing 24 scientific institutions is prepared to support these 
developments. (3x) 
20. Test method prioritisation should be linked with AOP development 
See also Comments on Prioritisation listed in 4.3.2 (Table 5) 
 
3.3.2 Rating the relevance of criteria proposed for prioritising tests 
relevant for ED identification when considering a specific test 
method 
The experts rated the proposed criteria (D.B.1–D.B.7) from: 1 = low relevance to 10 = 
high relevance and results are given in Table 8.  
Providing significant information on at least one endocrine related perturbation and 
allowing to distinguish endocrine disrupting effects from general toxicity or indirect 
effects on the endocrine system are the most important criteria that need to be taken 
into account while developing/enhancing a specific test method. 
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Table 8: Criteria and their ranking of relevance considering a specific test method. 
criterion ranking 
relevance score 
median min max 
The test method is providing significant information on at 
least one endocrine related perturbation (D.B.1). 
1 9.0 4 10 
The test method allows to distinguish endocrine 
disrupting effects from general toxicity or indirect effects 
on the endocrine system (D.B.2). 
1 9.0 4 10 
Additional endpoints that could improve the diagnostic 
value or sensitivity of the test method (D.B.3). 
3 8.0 4 10 
Additional endpoints incorporated for test method 
enhancement would not hamper the practical feasibility 
of the test (D.B.4). 
3 8.0 1 10 
The test method is technically feasible, could be 
validated or is already under validation (D.B.5). 
3 8.0 1 10 
The outcome of the test will be accepted for regulatory 
decision making without requiring in most cases further 
additional testing (D.B.6). 
3 8.0 1 10 
The test could be performed in high throughput (D.B.7). 7 6.0 2 10 
Note: 3 experts did not reply to this question 
Table 9: Criteria named by experts for a specific test method in addition to those listed 
in Table 8 (free text answers to question D.B.8 Would you like to comment on the above 
criteria or add any other criterion for a specific test method?) 
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1. compatibility between users, standardization  
2. More than one endpoint is usually better to understand what is happening in the entire 
endocrine system and generally, one single in vivo study can supply it when also performed 
with high throughput techniques as well. Then, a combined study with multiple endpoints 
that characterize the substance mode of action could be helpful for regulatory purposes. 
3. The test needs to be relevant, sensitive and specific. Then it needs to be cheap, ethically 
acceptable, and at least moderate throughput. 
4. Tests having the most impact- that is those that can provide the most meaningful 
information with the most confidence in the conclusion (either negative or positive)- 
should be prioritized the highest for future development. This means the biological 
underpinning supporting the tests utility for informing the question should exist. In vitro HTS 
will only provide limited information concerning the MIE or early key events. Long term 
effects/adversity as a consequence of activation of the MIE need to be established and 
characterized. 
5. In reference to question D.B.1. Although it depends on the case, the identification of 
endocrine disruptors should not be decided from the data of the single study. Measurement of 
a single endocrine related perturbation should not identify a chemical as an endocrine 
disruptor rather it could indicate a potential to interact with the endocrine system. This is a 
key aspect of the EPA Endocrine Screening Program and the reason for a tiered testing 
strategy and battery of tests to evaluate a potential for interaction and adversity. It is also 
important that any test methodology designed to identify endocrine disruptors be able to 
differentiate between adversity due to endocrine disruption and perturbations of the endocrine 
system that are secondary to alternative modes of action. A directly mediated effect is a 
critical aspect of the WHO definition for identify endocrine disruption. 
6. D.B.2. In order to prove that an effect is directly mediated by a certain endocrine effects of 
the chemical (and not by a secondary mechanism provoked by systemic toxicity or other 
pathways), rescue experiments might also be conducted with the co-treatment of the relevant 
hormone, in case not the whole AOP is known for the substance. E.g. chemicals causing 
reduced thyroid hormone production leading to impaired behavior might be co-treated with 
exogenous thyroid hormones. 
7. D.B.2. the differentiation between systemic toxicity and endocrine effects is desirable 
but we must accept especially invertebrate tests where this is not always possible until 
endocrine specific endpoints have been developed and validated. e.g. in the mollusc tests 
under Development! 
8. Ad D.B.2; Establishing endocrine disrupting effects should not be the primary aim, if this is 
not the most relevant MOA. However, when endocrine disrupting effects are suspected, 
appropriate test methods should be available to verify that. HT is secondary to high 
predictivity. 
9. D.B.3 Additional Endpoints: augmentation of existing assays with relevant in vivo biomarkers 
10. D.B.3. Hormonal feedback loops might also be tested, when molecular biomarkers 
assessed in order to investigate the ED relevance of a certain chemical/concentration. As it is 
possible that an organism can "balance out" an ED effect up to a certain concentration due to 
e.g. a negative autoregulatory loop, in order to predict higher tier effects, these feedback 
effects should be taken into account. This can be tested only in in vivo systems. 
11. D.B.6 High Throughput: Important for in vitro methods 
12. Explanation to DB7 (regulatory acceptance): The focus should be on the development of in 
vitro/in silico IATAs, this may require parallel or sequential testing approaches. Also medium 
throughput should be acceptable. see also DA7. 
13. D.B.7 Difficult to answer because the meaning of regulatory decision making spans from very 
strict regulation (e.g. a ban) to less strict regulation (e.g. risk reduction or consumer advise). 
14. D.B.7: Important for in vivo, currently not realistic for in vitro Prioritization: C.f. response 
under point C.3 
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15. D.B.7 Of course it is preferable to have methods that are accepted in regulatory settings and 
that require no further testing. However, such tests would often imply high costs and a lot of 
testing in, different strains/species/taxa. Therefore robust screening methods that would 
reliably predict (and not underpredict) a potential ED mode of actions and potential adverse 
effects is considered highly relevant. 
16. In reference to question D.B.7. one test cannot identify an endocrine disruptor. While it is 
highly relevant (relevance=10) new tests be accepted for regulatory decision making and 
even more ideal that confident conclusions can be drawn from a test outcome (either negative 
or positive), it is unclear how any one positive test can be used for a regulatory decision 
related to endocrine disruption without requiring additional test data to link mechanistic 
activity with a disease/disorder outcome 
17. D.B.7 To us this is a quite theoretical criteria. It might be very valuable to have additional 
tests that give further Information on the mode of Action that on their own do not allow for a 
regulatory decision making. 
Non-criteria/general comments: 
18. These criteria are difficult to answer in theory, as their relative importance depends on other 
characteristics of the test (e.g. over all sensitivity, relevance, animal use). 
19. The integrated protocol we propose permits a reduction in terms of animal use of up to 70% if 
compared with the separate performance of each NTP and OECD protocol currently in use for 
long-term carcinogenicity and toxicity bioassays and one generation reproductive toxicity 
studies (NTP 2011a) (NTP 2011e; OECD 2009, 2011). 
20. Obesity, diabetes and metabolic syndrome are complicated diseases with a multifactorial 
etiology. It will be difficult to have a unique test that will be accepted for regulatory decision. 
21. Endpoints selected include biochemical and physiological endpoints which allow calibration of 
in vivo test results to lower tier assays more applicable to chemicals screening and prediction 
of effects in non-model species. 
22. Metabolism needs to be incorporated, epigenetic mechanisms need to be elucidated and 
added. Increased focus needed on IATA development. To be honest these questions above are 
not helpful. 
23. This exercise is not useful. We need a battery of tests to provide the necessary information. 
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3.4 How well are relevant pathways covered? 
In section E of the survey, experts expressed their opinion on the addition of novel test 
methods (TM) or new endpoints to existing tests (EP) in order to cover additional 
pathways or better cover the pathways already included in the OECD CF. The test 
methods and endpoints addressed in this section were taken from the OECD DRP 178 
(OECD, 2012).  
Table 10 gives an overview on the overall ranking of novel test methods and endpoints 
across the various pathways, whereas chapters 0 - 3.4.7 cover the specific pathways.  
 
JRC used the following methodology to calculate the overall ranking of the TMs and EPs 
indicated by the experts: 
(Equation 5) )!  = 	
+"	+!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,  
identifying the relevance rating by the experts; and 
 
(Equation 6)  )!  = 	
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× 100	[%], 
determining the % of answers identifying practical problems for a relevant 
TM or EP. 
Table 10: Overview on the overall ranking of novel test methods (TM) and endpoints (EP) across 
the various pathways (E.A – E.G) regarding the relevance and practical problems. Ranking is based 
on ratios determined according to Equations 5 and 6 above. 
Pathway Endpoint / Test Method 
Relevance 
Ranking 
(Eq5) 
Practical 
problems 
[%] 
(Eq6) 
HPA (EP) adrenal steroid synthesis (in vivo) 24.0 21 
HPG gestagenic (EP) reduced fertility in fish (TG229; MEOGRT) 22.0 18 
PPAR 
(TM) Adipocyte differentiation in cultured pre-
adipocyte cells 
21.0 19 
HPT (TM) neurite extension assay 14.0 29 
HPT (TM) neural progenitor cell proliferation assay 14.0 29 
HPA (EP) Stress response (in vivo) 12.5 44 
Retinoid (TM) RXR transactivation assay 12.5 12 
HPG gestagenic (TM) Progesterone receptor (PR) transactivation test 11.5 17 
HPG estrogenic 
(EP) Gonad histopathology in chronically exposed 
amphibians (TG 231 AMA; included in LAGDA) 
10.5 14 
HPT 
(TM) XETA (Xenopus Embryonic Thyroid Signaling 
Assay) 
9.5 11 
HPT (TM) thyroid peroxidase assay 7.7 9 
HPT (TM) iodine uptake assays 7.7 9 
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HPT (TM) Tadpole tail explant resorption assay 7.5 27 
retinoid (TM) RAR transactivation assay 7.0 14 
PPAR 
(TM) PPARalpha,beta/delta,gamma transactivation 
assay 
7.0 10 
Retinoid 
(EP) weight gain, increased adipose tissue mass, 
increased lipid accumulation, reduced retinoid levels 
in vivo (TG 415, 416, 443, fish and amphibians) 
6.8 15 
HPT (TM) dendritic arborization assay 6.0 42 
HPT (EP) TH production in thyroid gland explants 6.0 33 
HPA (EP) corticotropin (ACTH) release (in vivo) 5.8 22 
HPT (TM) T4 binding protein displacement assay 5.8 13 
HPG gestagenic 
(TM/EP) assessment in exposed oocytes and sperm 
ex vivo or in oocytes/sperm derived from adult fish 
from TG 229 and MEOGRT 
5.7 29 
HPT (TM) T-screen assay 5.7 18 
HPA 
(TM) adrenal steroid synthesis (in vitro), e.g. 
modified TG 456 
5.3 19 
Vitamin D (TM) VDR transactivation assay 5.0 0 
HPG gestagenic (TM) membrane PR binding assay 4.8 21 
HPG estrogenic 
(EP) GnRH neuron development in brain of 
chronically exposed fish (MEOGRT) 
4.7 14 
Vitamin D (TM) Vitamin D hydroxylase assay (in vivo) 4.3 15 
PPAR 
(EP) Weight gain in chronically exposed animals (TG 
415, 416, 443, LAGDA) 
4.2 5 
HPG androgenic (EP) behavioural assessments in any in vivo study 4.2 40 
Retinoid (EP) EROD induction in in vivo assays 4.0 5 
Vitamin D 
(EP) RIA or EIA for serum vitamin D levels (could 
potentially be applied to any in vivo exposure assay) 
3.8 13 
Vitamin D 
(EP) reduced bone length in juvenile rodent (TG 416, 
443) 
3.2 31 
HPA (TM) GR transactivation test (in vitro) 3.2 21 
retinoid (TM) AhR transactivation assay 3.2 16 
HPT (TM) TR reporter assays 3.2 16 
Retinoid 
(EP) CYP1A mRNA or protein quantification in in vivo 
assays 
2.9 10 
PPAR (TM) Peroxisome proliferation assay 2.8 24 
HPT (TM) AhR reporter assays 2.7 19 
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HPT (TM) CAR reporter assays 2.3 14 
Vitamin D (EP) Brain size measurements in rodent offspring 1.9 46 
somatotropic 
(EP) Fetal birth weight and length in rodent 
multigeneration tests (TG 416, 443) 
1.7 4 
Vitamin D (TM) AhR transactivation assay 1.6 0 
Vitamin D 
(EP) EROD activity assay (biomarker, could 
potentially be applied to any in vivo exposure assay) 
1.3 38 
somatotropic 
(EP) analyses of hepatic GR mRNA levels in 
fish/mammals in vivo assays 
1.1 24 
somatotropic 
(EP) Analyses of hepatic IGF-1 mRNA levels in 
fish/mammal in vivo assays 
1.1 14 
somatotropic (TM) TR and GR transactivation assays 1.0 25 
somatotropic (EP) Growth evaluation in fish assays (MEOGRT) 1.0 20 
HPT (TM) EMSA, DNA pull-down assay 1.0 50 
TM = test method; EP = endpoint; HPA = hypothalamus-pituitary-gonad axis; HPG = hypothalamus-pituitary-
adrenocortical axis; HPT = hypothalamus-pituitary-thyroid axis; PPAR = peroxisome proliferator-activated 
receptor. 
 
The experts expressed the opinions given in Table 11 applying to all pathways. 
Table 11: General comments relevant to all pathways 
1. A good way to determine the appropriateness/need of novel assays is to build relevant 
AOPs and identify likely key events.  
2. At the moment the main focus should be to develop and assess in vitro/in silico focussed 
IATAs for EATS and non-genotoxic carcinogenicity. As soon as IATAs have been 
established for these fields, the experience and resources shall be used to extend to other 
fields. See other comments to this inquiry. 
3. Chronic exposure studies are of high relevance  
4. A key element currently missing from the above approach is the ability to take into account 
metabolism and bioavailability in vitro, which may be addressed through the addition of 
exogenous metabolising systems and the improvement of metabolism/bioavailability 
prediction models (per OECD DRP 97 on the use of metabolising systems for in vitro testing of 
endocrine disruptors; and Jacobs, M.N., Laws, S.C., Willett, K., Schmieder, P., Odum, J., 
Bovee, T.F. 2013. In vitro metabolism and bioavailability tests for endocrine active 
substances: What is needed next for regulatory purposes? ALTEX. 30(3):331-51). This aspect 
needs to be addressed urgently in relation to all axes covered by this survey. 
5. general comment for the survey - the relevance for in vitro and in vivo can differ 
depending on the application of the data - this may influence votes depending on the 
viewpoint of the respondent. 
6. Microarrays 
7. Consider OECD DRP 178, EFSA Opinion on Endocrine active substances (2013), and 
Kortenkamp report 
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3.4.1 Hypothalamus-pituitary-adrenocortical (HPA) axis (E.A) 
In section E.A of the survey, experts were asked to: 
● judge the addition of two test methods tests and three endpoints (listed in Figure 
5 and Table 12) to address effects on the HPA pathway (E.A.1)) . 
● name any other TM or EP (E.A.2, Table 13) 
● give general comments on the assessment of the HPA pathway (E.A.3, Table 14) 
The replies were ranked with the methodology described above. 
 
Table 12: Overview on the ranking of novel test methods and endpoints for the HPA pathway 
(E.A) 
Endpoint / Test methods 
Relevance 
Ranking  
(Eq 5) 
Practical 
Problems 
[%](Eq 6) 
(EP) adrenal steroid synthesis (in vivo) 24.0 21 
(EP) Stress response (in vivo) 12.5 44 
(EP) corticotropin (ACTH) release (in vivo) 5.8 22 
(TM) adrenal steroid synthesis (in vitro), e.g. modified TG 456 5.3 19 
(TM) GR transactivation test (in vitro) 3.2 21 
 
 
Figure 5: Replies of experts to question E.A.1: How would you judge the addition of below 
mentioned tests and endpoints to address effects on the HPA pathway? 
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Table 13: Expert suggestions for any other HPA relevant new test method or endpoint (free text 
replies to question E.A.2  Would you like to suggest any other HPA relevant novel test? If yes, 
please specify the test or relevant endpoints below including a reference) 
General 
1. Microarrays 
2. A good way to determine the appropriateness/need of novel assays is to build HPA-relevant 
AOPs and identify likely key events. 
Test method / endpoint proposals Humans/mammals 
3. Exposure from prenatal life until 130 weeks of age; multiple WOS i.e. prenatal neonatal 
prepubertal pubertal adults (parous and virgin for females rodents) 
4. human primary adrenal cell culture models [e.g. published for testic. cells in Hofer et al., J Clin 
Endo Metab 2014] 
5. GR binding assays. (Commercial e.g. Polar Screen) Mineralocortocoid receptor reporter assays. 
(Any commercial) Human stress response in Human biomonitoring or clinical study. 
6. CRH receptor agonist and antagonist assays  
7. Aryl hydrocarbon Receptor (AhR) Agonist/antagonist assays  
8. Steroid/corticosteroid biosynthesis assays (e.g. 11ß-hydroxysteroid dehydrogenase type 2 
activity in human cells)  
9. There was a SPSF on fish proposed by UK in the OECD program, which is relevant to the HPA. 
There is no specific SPSF on mammals at this stage. Such tests may need to be further 
developed.  
Test method / endpoint proposals Wildlife 
10. More work should be done on the value of cortisol as a stress marker; particularly in fish, this 
can be measured non-invasively (i.e. in the water, see numerous publications by Alexander 
Pickering Scott) at the back of other TGs without any major modifications. In this way we add 
value to the test without using extra animals.  
11. Development and validation of a Test Guideline for chemicals that disrupt the 
hypothalamicpituitary-adrenal (interrenal) axis in vertebrates (fish)  
 
Table 14: Experts general comments on assessing the HPA pathway (free text replies to question 
E.A.3 Do you have any general comment on assessing the HPA pathway in the screening for 
endocrine disrupting substances?) 
General 
1. Chronic exposure studies are of high relevance  
2. functional models should be used 
3. The development of IATAs for the HPA axis should be of intermediate priority. In vitro focussed 
approaches need to be explored for developing practical testing approaches. At OECD level 
much more work was already carried out for the field of EATS. In order to progress this and 
achieve comprehensive, regulatory useful testing and assessment approaches in shorter terms, 
in the moment the main focus should be to develop and assess in vitro/in silico focussed IATAs 
for EATS and non-genotoxic carcinogenicity. As soon as IATAs have been established for these 
fields, the experience and resources shall be used to extend to other fields. See other 
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comments to this inquiry. 
4. Yes, it is a very important pathway, affecting directly and indirectly pretty much the whole 
spectrum of the endocrine system. We have the obligation to look at this in more detail in 
terms of test method development and validation 
5. Information and test aimed at the HPA pathway are of high relevance and importance because 
they will help to distinguish chemical specific effects from general stress response. Carefully 
designing the experimental protocol is critical for the method development for this pathway. 
6. Here, importance needs to be given to tests addressing the establishment of the HPA axis and 
the ED modulation of set-points. 
7. Primary resource focus needs to be ensuring adequate test coverage for EATS, other related 
endocrine endpoints can be addressed next. 
8. We suggest that efforts to assess the effect of substances on the HPA axis should focus on 
building mechanistic understanding of its pathways, and that as such the development of 
assays probing specific, defined biological events will offer more progress than development of 
further tests for apical endpoints in animals. In the absence of an improved understanding of 
the underlying biological mechanisms the complexity of the HPA pathway, its interconnections 
with other endocrine axes, its susceptibility to a range of environmental factors, and its 
homeostatic responsiveness will continue to make it difficult to draw clear conclusions from 
apical studies, and particularly to separate out effects on this pathway from effects on other 
pathways and non-endocrine mediated effects. Given that there already exists a broad 
complement of animal studies likely to catch HPA related adverse effects, priority should be 
given to the development and validation of mechanistic assays, without which further apical 
assays are unlikely to add much useful information. Data from mechanistic assays will be of 
immediate use for informing on endocrine mode of action in individual substance assessments, 
but can also be used to substantiate and further develop adverse outcome pathways for HPA 
axis disruption, in turn informing prioritization of tests probing additional key events. Initially 
these assays may be a combination of in vivo and in vitro methods but as AOPs are more fully 
described, the aim should be creation of an in vitro test battery capable of predicting apical 
consequences through integrated testing approaches. This will help shift regulatory programs 
from needing repeatedly to measure effects of individual substances in multiple species, 
towards scenarios where adverse effects can be predicted for humans and a variety of wildlife 
species, and ultimately, mixture and additive effects can begin to be tackled. A key element 
currently missing from the above approach is the ability to take into account metabolism and 
bioavailability in vitro, which may be addressed through the addition of exogenous 
metabolising systems and the improvement of metabolism/bioavailability prediction models 
(per OECD DRP 97 on the use of metabolising systems for in vitro testing of endocrine 
disruptors; and Jacobs, M.N., Laws, S.C., Willett, K., Schmieder, P., Odum, J., Bovee, T.F. 
2013. In vitro metabolism and bioavailability tests for endocrine active substances: What is 
needed next for regulatory purposes? ALTEX. 30(3):331-51). This aspect needs to be 
addressed urgently in relation to all axes covered by this survey. 
9. The HPA axis is central to homeostatic functions of all vertebrate species, including 
metabolism, growth, immune system function, and reproduction. The HPA axis can be affected 
by many types of environmental factors, including light, temperature and diet, as well as by 
intrinsic circadian rhythms. This centrality and complexity is often used as a rationale for 
testing chemical effects in vivo - as the complexity and interrelated factors co-exist in the 
intact animal. However, this also creates enormous difficulty in interpreting experimental 
results and unraveling cause and effect relationships from incidental, secondary, or unrelated 
effects. Understanding chemical effects on central biological systems such as endocrine and 
hormone systems is therefore particularly suited to Integrated Approaches to Testing and 
Assessment (IATA) based on Adverse Outcome Pathways and related information. Therefore, 
for developing an chemical effective assessment approach, it is critical to focus on assays that 
address defined, specific biological mechanisms. Initially, these assays will likely be a 
combination of in vitro and in vivo methods - until the pathways are described well enough to 
allow prediction of outcome from upstream events sufficiently to answer the regulatory 
question at hand. Several of these mechanistic assays are likely to address more than one 
pathway (e.g. AhR, PPARa). A priority should be building and informing endocrine-related 
pathways, so that both toxicologists and regulators can better understand the biological 
landscape they are attempting to assess. In addition, a focus on mechanistic understanding 
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and pathway building would lead regulatory programs from needing to repeatedly measure 
effects toward the ability to predict effects in humans and wildlife. In addition, there is already 
a broad spectrum of tests that address apical endpoints that would catch possible adverse 
effects; priority should be on tests that provide mechanistic information and inform AOPs. 
Ideally, an assessment program would be built of a battery of mechanistic tests, largely in 
vitro, that will predict downstream apical effects. A major currently missing element of this 
approach is the ability to take into account metabolism, by improving prediction models and 
adding exogenous systems (see OECD DRP 97: DETAILED REVIEW PAPER ON THE USE OF 
METABOLISING SYSTEMS FOR IN VITRO TESTING OF ENDOCRINE DISRUPTORS; Jacobs, M.N., 
Laws, S.C., Willett, K., Schmieder, P., Odum, J., Bovee, T.F. 2013. In vitro metabolism and 
bioavailability tests for endocrine active substances: What is needed next for regulatory 
purposes? ALTEX. 30(3):331-51). 
Humans/mammals 
10. In the event that a histopathological finding in adrenal is observed, it is difficult to evaluate 
whether it causes the adrenal dysfunction or not. It may be an adaptive change to maintain the 
homeostasis but not an adverse effect. To understand the relationship of histopathological 
findings and functional effects is very difficult. For example transportation of animals from test 
cages to necropsy room and method of sacrifice (i.e. cervical dislocation vs. CO2) is known to 
influence stress response signaling. Though these should be randomly distributed across 
treatment groups the increased variability adds complexity to the data interpretation  
11. The corticosteroid metabolism in animals differs in part from the humans, animal testing is not 
always appropriate, therefore it would be desirable to have data from experiments with human 
cell lines and from Human biomonitoring studies or clinical studies if available.  
Wildlife 
12. This is an important area for development because we now know that the hormone response of 
some wildlife to stress is being damaged by environmental pollutants 
13. UK will be reviewing the HPA axis for fish at the OECD.  
3.4.2 Hypothalamus-pituitary-gonad (HPG) axis (E.B) 
In section E.B of the survey, experts were asked to: 
● judge the addition of test methods tests and endpoints (listed in Figure 6 and 
Table 15) to address effects on the estrogen signaling pathway (E.B.1)) . 
● name any other TM or EP (E.B.2) for the estrogen signaling pathway (Table 16) 
● judge the addition of test methods tests and endpoints (listed in Figure 7 and 
Table 15) to address effects on the androgen signaling pathway (E.B.3)) . 
● name any other TM or EP (E.B.4) for the androgen signaling pathway (Table 17) 
● judge the addition of test methods tests and endpoints (listed in Figure 8 and 
Table 15) to address effects on the gestagenic signaling pathway (E.B.5)) . 
● name any other TM or EP (E.B.6) for the gestagenic signaling pathway (Table 18) 
● express general comments on the assessment of the HPG pathway (E.B.7, Table 
19) 
The replies to E.B.1, E.B.3, and E.B.5 were ranked with the methodology described above 
(Equation 5) and the results are given in Table 15.  
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Table 15: Overview on the ranking of novel test methods and endpoints for the HPG pathway 
(E.B) 
Pathway Endpoint or Test Method 
Relevance 
Ranking  
(Eq 5) 
Practical 
Problems 
[%](Eq 6) 
HPG gestagenic (EP) reduced fertility in fish (TG229; MEOGRT) 22.0 18 
HPG gestagenic (TM) Progesterone receptor (PR) transactivation 
test 
11.5 17 
HPG estrogenic (EP) Gonad histopathology in chronically 
exposed amphibians (TG 231 AMA; included in 
LAGDA) 
10.5 14 
HPG gestagenic (TM/EP) assessment in exposed oocytes and 
sperm ex vivo or in oocytes/sperm derived from 
adult fish from TG 229 and MEOGRT 
5.7 29 
HPG gestagenic (TM) membrane PR binding assay 4.8 21 
HPG estrogenic (EP) GnRH neuron development in brain of 
chronically exposed fish (MEOGRT) 
4.7 14 
HPG androgenic (EP) behavioural assessments in any in vivo 
study 
4.2 40 
 
Figures 6-8 display the replies of the experts to questions E.B.1, E.B.3, and E.B.5. 
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Figure 6: Replies of experts to question E.B.1 How would you judge the addition of below 
mentioned tests and endpoints to address effects on the estrogen signaling pathway? 
 
Table 16: Expert suggestions for any other estrogen signaling pathway relevant new test method 
or endpoint (free text replies to question E.B.2 Would you like to suggest any other novel test 
relevant to the estrogen signaling pathway?) 
General 
1. Exposure from prenatal life until 130 weeks of age; multiple WOS i.e. prenatal neonatal 
prepuberal puberal adults (parous and virgin for females rodents) 
2. Since estrogen signalling in vivo mostly acts through non-classical genomic pathways, albeit 
via classical receptors, then in vitro tests need to be included which specifically address these 
pathways and, for example, can target SERM effects as well as classical endpoints. The listed 
reference is not yet sensitive enough but could be made so (Mol Cell Endocrinol. 2007. 276:45-
54. A novel molecular assay to discriminate transcriptional effects caused by xenoestrogens. 
Koohi MK, Walther N, Ivell R.)  
3. To our understanding behavioural assessment is missing. 
4. inclusion of metabolism: see Jacobs et al 2013 ALTEX 
Test method / endpoint proposals Human/Mammalian 
5. human primary testicular (and ovarian) mixed cell culture models [Hofer et al., J Clin Endo 
Metab 2014] 
6. human membrane ER activity; The endocrine mechanism of action is heavily covered by 
existing in vitro and in vivo assay, therefore, priorities for development of new assays lie 
elsewhere. 
Test method / endpoint proposals Wildlife 
7. The regulation of HPG axis in fish models used for testing (i.e. medaka, zebrafish and fathead 
minnow) has no resemblance with the regulation of the HPG axis in the vast majority of fish 
(>95% of species) that have an annual reproductive cycle; we used these models because they 
are convenient, not representative and as such we do not protect the environment.  
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Figure 7: Replies of experts to question E.B.3 How would you judge the addition of below 
mentioned tests and endpoints to address effects on the androgen signaling pathway? 
 
 
Table 17: Expert suggestions for any other androgen signalling pathway relevant new test method 
or endpoint (free text replies to question E.B.4 Would you like to suggest any other novel test 
relevant to the androgen signaling pathway?) 
General 
1. As above, systems targeting non-classical pathways are of great relevance here 
2. inclusion of metabolism see Jacobs et al ALTEX 2013 
3. mechanistic tests for anti-androgenic activity; probably need toxicogenomic studies to develop 
AOP and identify relevant biomarkers for additional assays. 
Test method / endpoint proposals Human/Mammalian 
4. Sperm aneuploydia Epididymal Sperm Aneuploidies in Three Strains of Rats (X. R. Lowe,1 J. M. 
de Stoppelaar,2 J. Bishop,3 M. Cassel,1 B. Hoebee,2 D. Moore II,1 and A. J. 
Wyrobek1*.Environmental and Molecular Mutagenesis 31:125-132) (1998) Detected by 
Multicolor Fluorescence In Situ Hybridization 
5. PSA production in human, prostate derived cell line LNCAP: Lorenzetti S, Marcoccia D, Narciso 
L, Mantovani A. (2010) Cell viability and PSA secretion assays in LNCaP cells: a tiered in vitro 
approach to screen chemicals with a prostate-mediated effect on male reproduction within the 
ReProTect project. Reprod Toxicol. 30(1):25-35.; Smeriglio A, Trombetta D, Marcoccia D, 
Mantovani A, Lorenzetti S. Intracellular distribution and biological effects of plant bioactives in 
a sex steroid-sensitive model of human prostate adenocarcinoma. Anticancer Agents in 
Medicinal Chemistry 2014 14:1386-96 
6. see above, mixed human primary testicular cell culture model (Leydig and Sertoli cells) [Hofer 
D et al. J Clin Endo Metab 2014] 
7. Assessment of testosterone levels in male foetuses in TG 414 
Test method / endpoint proposals Wildlife 
8. The one assay that has not gained regulatory status as yet (is only a guidance document) is 
8
7
10
6
9
0
5
10
15
(EP) behavioural assessments in any in vivo study
very relevant
relevant
relevant but practical
problems
low relevance
 29 
that is highly informative and relevant is the spiggin assay (in the form of the androgenised 
female stickleback screen, AFSS. This must be converted into a TG asap; The recently 
developed spiggin medaka transgenic model can be incorporated to be used as a screen before 
the AFSS. 
 
 
Figure 8: Replies of experts to question E.B.5 How would you judge the addition of below 
mentioned tests and endpoints to address effects on the gestagenic signaling pathway? 
 
Table 18: Expert suggestions for any other gestagenic signaling pathway relevant new test 
method or endpoint (free text answers to question E.B.6 Would you like to suggest any other 
gestagenic signaling pathway relevant novel test?) 
General 
1. Ex vivo investigation of calcium signalling in human sperm could also be relevant: Schiffer, C. 
et al. Direct action of endocrine disrupting chemicals on human sperm. EMBO Rep. (2014). 
doi:10.15252/embr.201438869  
2. The relevance of the listed assays is unknown and reduced fertility is non-specific. It is unlikely 
that gestagenic effects would be missed given adequate coverage of E and A pathways. 
Test method / endpoint proposals Wildlife 
3. The problem with TG229 is that it requires the fish to be in an optimal reproductive state 
before the test begins; effects then are not easily assessed within the 21d window; we need 
more time to observe the whole spectrum of effects and unravel the mechanism 
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Table 19: Expert general comments on assessing the HPG pathway (free text answers to the 
question E.B.7 Do you have any general comment on assessing the HPG pathway in the screening 
for endocrine disrupting substances?) 
General 
1. Clearly, the PR is relevant for many endocrine processes, but the added value of a single PR 
transactivation test (or any other single NR) is limited. 
2. Gene expression in human primary endocrine cell culture models and whole blood RNA 
expression covers a large range of relevant genes as "liquid biopsies" - pathway/biomarker 
identification and evaluation is ongoing 
3. In silico/in vitro focussed IATAs for the HPG axis, including improved metabolism and 
human/environmental relevance should be a high priority field for development. OECD progress 
is already available in this field. See earlier comments and references in the final remarks. The 
METiCx consortium is prepared to support these developments.  
4. Assesment of oxytocin and AMH (anti- Mullerian hormone) should also be considered. 
Oxytocin (OXT) (Greek, "quick birth") is a mammalian hormone that also acts as a 
neurotransmitter in the brain. In addition to its well-known peripheral hormonal functions (i.e., 
induction of labour and milk ejection), OXT acts as an important neuronal messenger within the 
brain regulating social and emotional behaviours in a wide variety of animal species including 
humans(Lee et al 2009). Oxytocin plays an organisational role in the central nervous system 
and the oxytocin neural system is also thought to be involved in the underlying mechanisms 
that guide the development of social behaviours (e.g. maternal behaviour), reproduction and 
stress responses (Mogi et al 2014). References: Lee HJ, Macbeth AH, Pagani JH, Young WS. 
Oxytocin: the great facilitator of life. Prog Neurobiol. 2009;88(2):127-151. Mogi K, Ooyama R, 
Nagasawa M, Kikusui T Effects of neonatal oxytocin manipulation on development of social 
behaviors in mice. Physiol Behav. 2014 Jun 22;133:68-75. doi: 
10.1016/j.physbeh.2014.05.010. Epub 2014 May 21. Since the serum levels of AMH has been 
shown to correlate with follicle pool in rats (Yeh et al. 2007) it could have the potential to be 
used as an endpoint in toxicological tests when assessing exhaustion of follicle reserve due to 
chemical insult. Indeed, it has been used as a biomarker to assess the degree of ovarian 
damage caused by exposure to the chemotherapeutic agent cisplatin (Yeh et al. 2006). 
Cisplatin is a very potent chemical and it must be assumed that most endocrine disrupting 
chemicals exerts much more subtle effects on the follicle pool. If the AMH-measurement is to 
be a useful biomarker of effects on ovarian follicle pool of endocrine disrupters, it could be 
argued that it must be able to detect the effects caused by less potent chemicals than 
Cisplatin. References: Yeh J, Kim B, Liang YJ, Peresie J (2006) Mullerian inhibiting substance as 
a novel biomarker of cisplatin induced ovarian damage. Biochem Biophys Res Commun 
348:337-344 Yeh J, Kim B, Peresie J, Liang YJ, Arroyo A (2007) Serum and ovarian Mullerian 
inhibiting substance, and their decline in reproductive aging. Fertil Steril 87:1227-1230 98 
5. There are more molecular pathways involved in the HPG axis. One example is activin, inhibin, 
and follistatin. Nitrobenzene is a known chemical targeting inhibins. The development of 
endpoints/methods for these additional pathways should be taken into account. 
6. None of the above mentioned tests address the establishment of the HPG axis during early 
pregnancy, or at puberty, i.e. during the dynamic phases of endocrine establishment. 
7. higher relevance within next years 
8. Please see response to E.A.3: comments re. the advantages of prioritising development of 
mechanistic assays to provide mode of action data and elucidation of AOPs also apply to 
assessment of the HPG pathway. Numerous apical animal tests capable of catching adverse 
effects on reproductive systems already exist, but mechanistic assays for non-nuclear-receptor 
mediated modes of action are what is lacking. 
9. Similar to the HPA axis, it is critical to focus on assays that address defined, specific biological 
mechanisms. Initially, these assays will likely be a combination of in vitro and in vivo methods 
- until the pathways are described well enough to allow prediction of outcome from upstream 
events sufficiently to answer the regulatory question at hand. Several of these mechanistic 
assays are likely to address more than one pathway (e.g. AhR, PPARa). A priority should be 
building and informing endocrine-related pathways, so that both toxicologists and regulators 
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can better understand the biological landscape they are attempting to assess. In addition, a 
focus on mechanistic understanding and pathway building would lead regulatory programs from 
needing to repeatedly measure effects toward the ability to predict effects in humans and 
wildlife. In addition, there is already a broad spectrum of tests that address apical endpoints 
that would catch possible adverse effects; priority should be on tests that provide mechanistic 
information and inform AOPs. Ideally, an assessment program would be built of a battery of 
mechanistic tests, largely in vitro, that will predict downstream apical effects. A major currently 
missing element of this approach is the ability to take into account metabolism, by improving 
prediction models and adding exogenous systems (see OECD DRP 97: DETAILED REVIEW 
PAPER ON THE USE OF METABOLISING SYSTEMS FOR IN VITRO TESTING OF ENDOCRINE 
DISRUPTORS; Jacobs, M.N., Laws, S.C., Willett, K., Schmieder, P., Odum, J., Bovee, T.F. 2013. 
In vitro metabolism and bioavailability tests for endocrine active substances: What is needed 
next for regulatory purposes? ALTEX. 30(3):331-51). 
Human/Mammalian 
10. As a general comment it is important to understand that many hormones e.g. FSH, LH, 
testosterone, are secreted in pulses in rodents. Thus, when measuring these hormones in 
serum of rodents a high variability is to be expected and the group size needs to be high 
enough (20 to have a 80% chance to see a 25% change) to make sure to cover a real effect 
(see e.g. Vidal et al 2013, reproductive system and mammary gland, in Toxicologic pathology 
(edited by Sahota, Popp, Hardisty, Gopinath, CRC). 
11. Behavioral assessments are complex and can be highly variable. 
12. The relevance of findings to human adversity is difficult to characterize and they are only likely 
to pick up compounds with profound effects which would be identified by other test 
parameters. Before developing new test methods a review of the relevance of the existing 
methods (retrospective analysis of data etc) would be beneficial.  
Wildlife 
13. Fish models are not representative of real species with annual reproduction and as such 
regulation. We must face this! 
 
3.4.3 Somatotropic axis (E.C) 
In section E.C of the survey, experts were asked to: 
● judge the addition of test methods tests and endpoints (listed in Figure 9 and 
Table 20) to address effects on the somatotropic signalling pathway (E.C.1) . 
● name any other TM or EP (E.C.2) for the somatotropic signalling pathway (Table 
21) 
● express general comments on the assessment of the somatotropic pathway 
(E.C.3, Table 22) 
 
The replies were ranked with the methodology described above and the results are given 
in Table 20). 
 
Table 20: Overview on the ranking of novel test methods and endpoints for the somatotropic 
pathway (E.C) 
Endpoints or Test methods 
Relevance 
Ranking  
(Eq 5) 
Practical 
Problems 
[%](Eq 6) 
(EP) Fetal birth weight and length in rodent multigeneration tests 1.7 4 
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(TG 416, 443) 
(EP) analyses of hepatic GR mRNA levels in fish/mammals in vivo 
assays 
1.1 24 
(EP) Analyses of hepatic IGF-1 mRNA levels in fish/mammal in vivo 
assays 
1.1 14 
(TM) TR and GR transactivation assays 1.0 25 
(EP) Growth evaluation in fish assays (MEOGRT) 1.0 20 
 
 
 
Figure 9: Replies of experts to question E.C.1 How would you judge the addition of below 
mentioned tests and endpoints to address effects on the somatotropic pathway? 
 
Table 21: Expert suggestions for any other somatotropic pathway relevant new test method or 
endpoint (free text answers to the question E.C.2  Would you like to suggest any other novel test 
relevant for the somatotropic axis? If yes, please specify the test or relevant endpoints below 
including a reference.) 
JRC Note: no specific test named but references were given: 
 
Kortenkamp et al., State of the Art Assessment of Endocrine Disrupters, 2011 
http://ec.europa.eu/environment/chemicals/endocrine/pdf/sota_edc_final_report.pdf  
EFSA Scientific Opinion on the hazard assessment of endocrine disruptors 
http://www.efsa.europa.eu/de/search/doc/3132.pdf 
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Table 22: Expert general comments on assessing the somatotropic pathway (free text answers to 
the question E.C.3 Do you have any general comment on assessing the somatotropic axis in the 
screening for endocrine disrupting substances?) 
General 
1. Today IATAs for this axis should be of lower priority, see earlier comments. However where 
there is specific interest and resources are available, the OECD DRP 178 provides a starting 
point for further developments. 
2. Chemicals interfering with pathways of thyroid, corticosteroids etc may disrupt the 
somatotropic axis. Methods and endpoints to be developed should indicate the specific effects 
on the somatotropic axis and should be used for the regulatory identification of EDCs. 
3. In in vivo studies, it is hard to distinguish the secondary (indirect) effects derived from the 
deterioration of physical condition and the primary (direct) effects on the HPG axis. The 
identification of endocrine disruptors should be conducted in combination with some in vitro 
and in vivo studies but not a single study. For example, it is well known severely reduced body 
weight gain or renal toxicity frequently causes the secondary effects such as hormone 
imbalance by the deterioration of physical condition. Since growth alteration is not necessarily 
endocrine specific, addition of this endpoint is not relevant for assessing the somatotropic axis. 
Assessment of this axis is of low relevance. The impact of EDCs on this axis is unknown and the 
promiscuous nature of chemicals means that if the chemical in question is capable of causing 
ED then it will be detected during the assessment of other more relevant axes.  
4. Dynamic tests are required which will mimic more the influence of EDcs on the pubertal and 
prepubertal growth spurts. 
5. As effects on the somatotropic axis are likely to occur via interactions with estrogen, androgen, 
thyroid or corticosteroid signaling, tests aimed at this axis per se are not a priority. Building 
AOPs for these other pathways should help identify whether there are additional key events 
that need addressing. 
6. Is unlikely this system will be missed given coverage of E, A, T and corticosteroid systems, plus 
lack of chemical MoA for this pathway suggests this pathway is a low priority for assay 
development. Potential missing Key Events could be identified by building the relevant AOPs for 
this pathway. 
Wildlife 
7. MEOGRT: In order to differentiate endocrine effects from systemic toxicity, more somatotropic 
pathway rel. endpoints need to be addressed in the hypothesized adverse outcome pathway 
(lower tiered e.g. molecular endpoints) 
 
3.4.4 Retinoid signalling pathway (E.D) 
In section E.D of the survey, experts were asked to: 
● judge the addition of test methods tests and endpoints (listed in Figure 10 and 
Table 23) to address effects on the retinoid signalling pathway (E.D.1) . 
● name any other TM or EP (E.D.2) for the retinoid signalling pathway (Table 24) 
● express general comments on the assessment of the retinoid pathway (E.D.3, 
Table 25) 
The replies were ranked with the methodology described above and the results are given 
in Table 23. 
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Table 23: Overview on the ranking of novel test methods and endpoints for the retinoid signaling 
pathway (E.D) 
Endpoints or Test methods 
Relevance 
Ranking  
(Eq 5) 
Practical 
Problems 
[%](Eq 6) 
(TM) RXR transactivation assay 12.5 12 
(TM) RAR transactivation assay 7.0 14 
(EP) weight gain, increased adipose tissue mass, increased lipid 
accumulation, reduced retinoid levels in vivo (TG 415, 416, 443, 
fish and amphibians) 
6.8 15 
(EP) EROD induction in in vivo assays 4.0 5 
(TM) AhR transactivation assay 3.2 16 
(EP) CYP1A mRNA or protein quantification in in vivo assays 2.9 10 
 
 
Figure 10: Expert replies to question E.D.1 How would you judge the addition of below mentioned 
tests and endpoints to address effects on the retinoid signalling pathway? 
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Table 24: Expert suggestions for any other retinoid signalling pathway relevant new test method 
or endpoint (free text answers to question E.D.2  Would you like to suggest any other novel test 
relevant for the retinoid signalling pathway?) 
General 
1. This is already being explored in a new DRP on retinoic acid signalling, and is being led by 
Sweden. Advisable to wait for outcome. 
2. DRP 178 is a starting point. 
Test method / endpoint proposals Human/Mammalian 
3. droplet formation in 3T3-L1 cells, PPARgamma transactivation (Pereira-Fernandez et al., 2013 
4. Adipocyte differentiation in vitro where mechanism can be evaluated (OECD DRP 178). 
Test method / endpoint proposals Wildlife 
5. We need an invertebrate model there; they are by far more sensitive and informative 
 
Table 25: Expert general comments on assessing the retinoid signalling pathway (free text 
answers to question E.D.3 Do you have any general comment on assessing the retinoid signalling 
pathway in the screening for endocrine disrupting substances?) 
General 
1. Sweden has initiated a SPSF for the retinoid system within the OECD 
2. IATAs for the Retinoid Acid axis should be of intermediate priority. A detailed review paper for 
testing and assessment in this field is planned at OECD WNT by SE. At OECD level much more 
work was already carried out for the field of EATS. In order to progress this and achieve 
comprehensive, regulatory useful testing and assessment approaches in shorter terms, in the 
moment the main focus should be to develop and assess in vitro/in silico focussed IATAs for 
EATS and non-genotoxic carcinogenicity. As soon as IATAs have been established for these 
fields, the experience and resources shall be used to extend to other fields. See other 
comments to this inquiry. 
3. Retinoic acid concentration in vivo in serum is very low and quite difficult to measure. Careful 
concentration on the correct marker is necessary before proposing something like this.  
4. RXR transactivation; The ligand specificity of RXRs is not so high and they can be activated by 
many natural components such as oleic acid, one of the major fatty acid in the mammalian 
body, in addition to 9-cis RA, DHA (Lengqvist et. al, Molecular & Cellular Proteomics 3.7 692 
(2004)). Therefore, it is easily expected that many positive result would be obtained by this 
test method. It may be difficult to predict overall outcome in vivo by the "positive" compound 
in the presence of 9-cis RA and abundant natural fatty acid.  
5. AhR transactivation; "The mechanism in which retinoid levels is reduced by AhR agonists is not 
fully understood" (ENV/JM/MONO (2012) 23). Their primary target is AhR, but not RAR/RXR, 
suggesting indirect mechanism. An effect on retinoid pool would accompany other toxic effects 
by AhR. AhR affects so many biological functions. It is difficult to know whether an effect on 
retinoid level is an independent effect or a secondary effect by other toxicity. EROD induction, 
CYP1A mRNA; These are markers for AhR agonist activity (ENV/JM/MONO (2012) 23).  
6. Weight gain, increased adipose: These are not specific marker for RAR/RXR signaling. 
"Maintenance of lipid homeostasis in the whole organism is complex and changes in lipid would 
not definitively indicate the involvement of RXR" (ENV/JM/MONO (2012) 23). Systemic toxicity 
can secondary change these parameters. In addition, many of these endpoints can be affected 
by ligands for nuclear receptors such as PPAR and FXR, and natural ligands for PPAR and FXR 
are not hormones. Thus, positive result for these endpoints might include effects other than 
RAR/RXR pathway. Many of endpoints listed in the table above are lacking specificity for 
RAR/RXR signaling pathway. In addition, a possible in vivo effect by a compound with RAR/RAR 
agonist/antagonist would be hard to be predicted in the presence of homeostasis (e.g. by 
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natural agonists for RXR). These test results would be useful for understanding MOA of the 
chemicals that exerts in vivo effect such as developmental abnormalities, but less useful for 
screening EDs.  
7. Please see response to E.A.3: comments re. the advantages of prioritising development of 
mechanistic assays to provide mode of action data and elucidation of AOPs also apply to 
assessment of the retinoid signaling pathway. As aspects of the retinoid signaling pathway, 
RXR signaling in particular, have such a central role in numerous endocrine processes, assays 
providing mechanistic data on this pathway could be considered of especially high relevance 
and prioritised for further development/standardisation. DRP 178 suggests RAR, RXR and AhR 
reporter assays could be used to discern anchoring molecular events triggering assessment 
along multiple adverse outcome pathways, and that RXR reporter assays should have a 
prominent role in any endocrine screening program. Apical in vivo measurements such as 
altered lipid or retinoid levels are unlikely to support firm conclusions re. disruption of retinoid 
signaling in the absence of data from mechanistic assays as above, as DRP 178 also indicates.  
Human/Mammalian 
8. see above, use of human liver cell cultures 
Wildlife 
9. retinoids might have environmental relevance as it has been shown that some cyanobacteria 
are able to produce and release retinoid-like compounds into the environment at 
concentrations equivalent to those causing e.g. teratogenicity in zebrafish (A. Jonas et al. 
Aquatic Toxicology 155 (2014) 283-290). Furthermore, the crosstalk between the retinoic and 
thyroid signaling pathways underlines also the environmental relevance of the retinoid 
signaling pathway for wild life species. 
 
3.4.5 Hypothalamus-pituitary-thyroid (HPT) axis (thyroid signalling 
pathway)(E.E) 
In section E.E of the survey, experts were asked to: 
● judge the addition of test methods tests and endpoints (listed in Figure 11 and 
Table 26 to address effects on the HPT pathway (E.E.1) . 
● name any other TM or EP (E.E.2) for the retinoid signalling pathway (Table 27) 
● express general comments on the assessment of the retinoid pathway (E.E.3, 
Table 28) 
The replies were ranked with the methodology described above and the results are given 
in Table 26. 
 
Table 26: Overview on the ranking of novel test methods and endpoints for the HPT pathway (E.E) 
Endpoints or Test methods 
Relevance 
Ranking  
(Eq 5) 
Practical 
Problems 
[%](Eq 6) 
(TM) neurite extension assay 14.0 29 
(TM) neural progenitor cell proliferation assay 14.0 29 
(TM) XETA (Xenopus Embryonic Thyroid Signaling Assay) 9.5 11 
(TM) thyroid peroxidase assay 7.7 9 
(TM) iodine uptake assays 7.7 9 
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(TM) Tadpole tail explant resorption assay 7.5 27 
(TM) dendritic arborization assay 6.0 42 
(EP) TH production in thyroid gland explants 6.0 33 
(TM) T4 binding protein displacement assay 5.8 13 
(TM) T-screen assay 5.7 18 
(TM) TR reporter assays 3.2 16 
(TM) AhR reporter assays 2.7 19 
(TM) CAR reporter assays 2.3 14 
(TM) EMSA, DNA pull-down assay 1.0 50 
 
 
Figure 11: Expert replies to question E.E.1 How would you judge the addition of below mentioned 
tests and endpoints to address effects on the HPT pathway? 
 
10
4
6
14
12 12
1 1 1 1
5
3 3
9
6
9
6
7
9
8
2
6
9 9 9 9
8 8
3 3
2 2 2
3 3
5
4 4
3
6
4
2
5 5
6
3 3
4
6
2
1 1
3 3
2 2
1 1
0 0 0 0 0 0 0 0 0 0 0 0
15
18
20
14 14
13
28
26
25 25
20
19
23
19
0
5
10
15
20
25
30
very relevant relevant relevant but practical problems
low relevance not relevant don't know + no reply
 38 
Table 27: Expert suggestions for any other HPT pathway relevant new test method or endpoint 
(free text answers to question E.E.2 Would you like to suggest any other novel test relevant for the 
HPT axis?) 
General 
1. This is the holy grail in endocrinology test method development; we need more models than 
amphibians! 
2. See OECD Thyroid scoping document  DRP 207 (comment received 4x) 
Test method / endpoint proposals Human/Mammalian 
3. Stably transfected human TR reporter assays (same for other reporter assays); TRH release 
assay, TRH receptor activation assay in cell line; T3, T4 deiodinization assays; TH membrane 
transporter activity assay. See OECD DRP 207: NEW SCOPING DOCUMENT ON IN VITRO AND 
EX VIVO ASSAYS FOR THE IDENTIFICATION OF MODULATORS OF THYROID HORMONE 
SIGNALLING. 
Test method / endpoint proposals Wildlife 
4. Similarly to XETA, alternative fish embryonic assays with high throughput potential and 
integrative capacity for thyroid disruptors with multiple mode of action are available (Fetter et 
al. Reprod Toxicol. 2015 May 8. p: S0890-6238(15)00067-2 and Thienpont et al Environ. Sci. 
Technol. 2011, 45, 7525-7532). 
 
Table 28: Expert general comments on assessing the HPT axis (free text answers to question 
E.E.3 Do you have any general comment on assessing the HPT axis in the screening for endocrine 
disrupting substances?) 
General 
1. general comment for the survey - the relevance for in vitro and in vivo can differ depending on 
the application of the data - this may influence votes depending on the viewpoint of the 
respondent. 
2. Only few compounds seem to interact with the TR, despite QSAR-based predictions. More 
relevant seems production of thyroid hormones and interactions with transport/metabolism. 
3. The development of IATAs for the HPT axis should be of high priority. A great amount of OECD 
work is available defining the priority needs in the field. See reference in final remarks and 
earlier comments. The METiCx consortium is prepared to support this work.  
4. The development/standardisation of biologically relevant in vitro tests as well as IATA 
development is highly needed. 
5. No other than that the complexity of this system requires an open approach; I would start from 
massive parallel sequencing to fish out candidate biomarkers in existing animal models 
6. Most of the assays are in vitro assays assessing one specific molecular initiating action of 
thyroid disruption. For compounds with unknown or multiple mode of action on the thyroid 
signaling pathway (such as phenyltiourea which is a thyroidperoxidase and a deiodinase 
inhibitor) higher tier effects might be underestimated.  
7. A well developed pre validation plan has been developed by the METiCx consortium 
8. Please see response to E.A.3: comments also apply to assessment of the HPT axis. In addition 
to building on the thyroid scoping document and taking forward the assays therein identified as 
in a high state of readiness for Test Guideline development, current work on thyroid AOPs 
within the OECD programme should be used to provide a framework for guiding prioritisation. 
9. This is a critical pathway that has immediate need for AOP development and screening-level 
assay development. Previous comments (i.e. E.A.3) also apply. 
10. We need screens and tests which include endpoints of thyroid hormone action. 
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Human/Mammalian 
11. In the event that the effects on thyroid gland are observed in in vivo studies using rodent (e.g. 
rats, mice), the possibility that those are secondary effects via liver toxicity is considered to be 
comparatively high. Many chemicals are known as a hepatic microsomal enzyme inducer, and 
induce UGT, which enhances metabolism of T4 by conjugation and biliary excretion of the 
conjugated hormone. Induction of hepatic microsomal enzyme results in a decrease in T3 and 
T4 half-life. As a result of the feedback function for decreased circulating thyroidal hormones 
on the hypothalamic-pituitary-thyroid axis, the pituitary gland enhances the release of TSH. 
Therefore, it is anticipated the validated test methods to verify the secondary effects via liver 
toxicity are necessary. Addition of thyroid hormone measurements in dams and pups would be 
problematic. First, in pups, insufficient information is available to fully understand inherent 
variability, etc. While thyroid hormones in adult males typically have fairly low variability, it is 
expected one would see greater variability in the pups, and likely in the females as well. It 
should be remembered that lactating females are in a slightly hypothyroid condition. This could 
result in a decreased potential for detecting effects due to variability, etc? Also, the females will 
be receiving the test material for differing durations due to differences in co-housing duration 
prior to confirmed pregnancy. In addition, as written, if the TGs are being used for non-oral 
studies, where administration may stop on GD19, the animals will be without test substance 
exposure for 2 weeks prior to blood collection, which will likely diminish any ability to detect 
test substance-related effects. If thyroid hormones are to be measured, it would be prudent to 
understand these issues prior to inclusion in the test guideline. An alternative is to measure 
thyroid hormones in the P1 males, which will not have as many variables to confound data 
interpretation, and would still provide information on whether a typical pattern of thyroid 
hormone modulation is occurring. The other concern is that MOST, i.e., >90%, of compounds 
that alter liver weight will cause transient effects on thyroid hormones that do not necessarily 
manifest in long-term thyroid hormone modulation leading to adverse thyroid effects. Given 
that, there are large concerns over how this data would be interpreted and used for regulatory 
decision making 
Wildlife 
12. I marked the TR assay of low relevance because of the very high specificity of the TR LBD for 
T3 ( and TRIAC). Current knowledge suggests that the TR is not a primary target - but more 
chemicals affects I- uptake, organification and distribution/ metabolism. 
13. Regarding XETA, only those substances can be assessed that act through the thyroid hormone 
receptor. However, given that this is an in vivo system, mechanisms leading to altered thyroid 
hormone level, might also be assessed 
 
3.4.6 Vitamin D Signalling Pathway (E.F) 
In section E.F of the survey, experts were asked to: 
● judge the addition of test methods tests and endpoints (listed in Figure 12 and 
Table 29 to address effects on the Vitamin D signalling pathway (E.F.1) . 
● name any other TM or EP (E.F.2) for the Vitamin D signalling pathway (Table 30) 
● express general comments on the assessment of the Vitamin D signalling pathway 
(E.F.3, Table 31) 
The replies were ranked with the methodology described above and the results are given 
in Table 26. 
 
Table 29: Overview on the ranking of novel test methods and endpoints for the on the Vitamin D 
signalling pathway (E.F) 
Endpoints or Test methods 
Relevance 
Ranking  
Practical 
Problems 
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(Eq 5) [%](Eq 6) 
(TM) VDR transactivation assay 5.0 0 
(TM) Vitamin D hydroxylase assay (in vivo) 4.3 15 
(EP) RIA or EIA for serum vitamin D levels (could potentially be 
applied to any in vivo exposure assay) 
3.8 13 
(EP) reduced bone length in juvenile rodent (TG 416, 443) 3.2 31 
(EP) Brain size measurements in rodent offspring 1.9 46 
(TM) AhR transactivation assay 1.6 0 
(EP) EROD activity assay (biomarker, could potentially be 
applied to any in vivo exposure assay) 
1.3 38 
 
 
 
Figure 12: Expert replies to question E.F.1 How would you judge the addition of below mentioned 
tests and endpoints to address effects on the Vitamin D signaling pathway? 
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Table 30: Expert suggestions for any other Vitamin D signaling pathway relevant new test method 
or endpoint (free text answers to question E.F.2 Would you like to suggest any other novel test 
relevant for the Vitamin D signalling pathway?) 
General 
1. Vitamin D binding protein and other vitamin D associated genetics, NGS 
 
Table 31: Expert general comments on assessing the Vitamin D signalling pathway (free text 
answers to question E.F.3 Do you have any general comment on assessing the Vitamin D signalling 
pathway in the screening for endocrine disrupting substances?) 
General 
1. very relevant, hereditary and environmental factors under development [Trummer O et al. J 
Clin Endo Metab 2012, Saternus R et al, Endocrinology 2015]  
2. Today the development of IATAs for this axis should be of lower priority. However where there 
is specific interest and resources are available, the OECD DRP 178 provides a starting point for 
further developments. 
3. not as urgent as EATS 
4. Please see response to E.A.3: comments also apply to assessment of the Vitamin D signalling 
pathway. 
5. As with the above axes, it is critical to focus on assays that address defined, specific biological 
mechanisms. Initially, these assays will likely be a combination of in vitro and in vivo methods 
- until the pathways are described well enough to allow prediction of outcome from upstream 
events sufficiently to answer the regulatory question at hand. Several of these mechanistic 
assays are likely to address more than one pathway (e.g. AhR, PPARa). A priority should be 
building and informing endocrine-related pathways, so that both toxicologists and regulators 
can better understand the biological landscape they are attempting to assess. In addition, a 
focus on mechanistic understanding and pathway building would lead regulatory programs from 
needing to repeatedly measure effects toward the ability to predict effects in humans and 
wildlife. In addition, there is already a broad spectrum of tests that address apical endpoints 
that would catch possible adverse effects; priority should be on tests that provide mechanistic 
information and inform AOPs. Ideally, an assessment program would be built of a battery of 
mechanistic tests, largely in vitro, that will predict downstream apical effects. A major currently 
missing element of this approach is the ability to take into account metabolism, by improving 
prediction models and adding exogenous systems (see OECD DRP 97: DETAILED REVIEW 
PAPER ON THE USE OF METABOLISING SYSTEMS FOR IN VITRO TESTING OF ENDOCRINE 
DISRUPTORS; Jacobs, M.N., Laws, S.C., Willett, K., Schmieder, P., Odum, J., Bovee, T.F. 2013. 
In vitro metabolism and bioavailability tests for endocrine active substances: What is needed 
next for regulatory purposes? ALTEX. 30(3):331-51). 
Human/Mammalian 
6. Measurement of vitamin D in serum is not a good biomarker due to its low half-life in serum. 
The correct biomarker for assessing vitamin D status is 25-hydroxy vitamin D3 (see relevant 
peer-reviews e.g. Ross et al 2011, Dietary Reference Intakes for Calcium and Vitamin D, ISBN 
978-0-309-16394-1). Further RIA or EIA methods do not deliver accurate measurements, LC-
MS is much better.  
 
3.4.7 PPAR Signalling Pathway (E.G) 
In section E.G of the survey, experts were asked to: 
● judge the addition of test methods tests and endpoints (listed in Figure 13 and 
Table 32 to address effects on the PPAR signalling pathway (E.G.1) . 
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● name any other TM or EP (E.G.2) for the PPAR signalling pathway (Table 33) 
● express general comments on the assessment of the PPAR signalling pathway 
(E.G.3, Table 34) 
The replies were ranked with the methodology described above and the results are given 
in Table 32. 
 
 
Table 32: Overview on the ranking of novel test methods and endpoints for the on the PPAR 
signaling pathway (E.G) 
Endpoints or Test methods 
Relevance 
Ranking  
(Eq 5) 
Practical 
Problems 
[%](Eq 6) 
(TM) Adipocyte differentiation in cultured pre-adipocyte cells 21.0 19 
(TM) PPARalpha,beta/delta,gamma transactivation assay 7.0 10 
(EP) Weight gain in chronically exposed animals (TG 415, 416, 
443, LAGDA) 
4.2 5 
(TM) Peroxisome proliferation assay 2.8 24 
 
 
Figure 13: Expert replies to question E.G.1 How would you judge the addition of below mentioned 
tests and endpoints to address effects on the PPAR signaling pathway? 
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Table 33: Expert suggestions for any other PPAR signaling pathway relevant new test method or 
endpoint (free text answers to question E.G.2 Would you like to suggest any other novel test 
relevant for the PPAR signalling pathway?) 
General 
1. Weight gain in animals may not significantly change, however they may have an increase in 
adiposity. Fat weight should be measured.  
 
 
 
Table 34: Expert general comments on assessing the PPAR signalling pathway (free text answers 
to question E.G.3 Do you have any general comment on assessing the PPAR signalling pathway in 
the screening for endocrine disrupting substances?) 
General 
1. Today the development of IATAs for this axis should be of lower priority. However where there 
is specific interest and ressources are available, the OECD DRP 178 provides a starting point for 
further developments.  
2. A species comparative approach is being taken in the VMG-NA. Important for metabolic 
syndrome, lipid metabolism etc. but lower priority compared to EATS Generally, this survey is 
fragmented and piecemeal in its approach, should instead be approaching the testing needs as 
part of an IATA approach, then one can suggest priorities for test method development in a 
more substantive and integrated way. 
3. Please see response to E.A.3: comments also apply to assessment of the PPAR signalling 
pathway. The potential anchoring role of PPAR events in a number of AOPs (e.g. connections 
with HPG axis, and interaction with RXR) suggest assays probing PPAR mechanisms would be 
useful to prioritise. Plus, as noted in DRP 178, species differences are of significance with this 
axis so it will be essential to understand underlying mechanisms before results of animal 
studies can be interpreted more usefully. Again, there are various PPAR AOPs under 
development within the OECD programme and these should be used to guide prioritisation of 
relevant assays for further work. 
4. This is a critical pathway that has immediate need for AOP development and screening-level 
assay development. Previous comments (i.e. E.A.3 and E.D.3) also apply. 
Human/Mammalian 
5. The relevance of certain endpoints following PPAR activation are not relevant to humans. It will 
be important to differentiate human relevant effects from those that have been deemed to be 
non-human relevant. Activation of PPARs have also been shown to have beneficial effects in 
humans. This is not to say activation of PPARs by environmental chemicals is beneficial, but it 
highlights the importance of associating activation with adversity. In general assessment of this 
axis is of low relevance. The impact of EDCs on this axis is unknown and the promiscuous 
nature of chemicals will lead to the detection of ED in other pathways if the chemical in 
question is capable of causing ED.  
 
3.4.8 Potential use of epigenetic tests within the OECD endocrine 
disruptor testing conceptual framework 
This part F.E of the survey was included under the questions on the OECD Conceptual 
Framework in the survey section F. However, it should have been addressed in section E 
together with the other new approaches that might be relevant for inclusion in the OCED 
CF. Therefore in the report we address it here below. 
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In Annex 1 of the Detailed Review Paper (OECD DRP, No. 178, 2012) it is concluded that 
the evidence "is highly-suggestive of a role for epigenomic dysregulation mediating the 
effects of exposures to endocrine disruptors". Therefore experts were asked about their 
views on including epigenetic endpoints in the OECD CF. Possible endpoints that were 
considered in the survey to be included in the tests are listed below (for more details see 
the Detailed Review Paper):  
● DNA modifications (cytosine methylation) 
● miRNA and RNA expression studies 
● studies of chromatin components and structure 
● multivariate/systems analysis to identify key regulatory factors 
● luminometric methylation analysis (LUMA) for global methylation analyses 
An overview of TMs that could potentially be adapted for epigenomic studies of effects of 
endocrine disruptors, was presented in the survey and is shown in Table 35 below based 
on the overview in the OECD DRP (2012).  
In this section F.E of the survey, experts were asked to: 
● rate the relevance of updating tests in the OECD CF to include epigenetic 
endpoints/tests (Figure 14) 
● provide any comments regarding the inclusion of epigenetic tests for the 
identification of endocrine disruptors (Table 36). 
 
Table 35: OECD TGs that could potentially be adapted for epigenomic studies of effects of 
endocrine disruptors (Table 7 of Annex 1 of the detailed review paper OECD No 178, OECD 2012) 
Type of study Test Guidelines (TG) Description 
  • Zebrafish embryo epigenetic toxicity 
assay 
General exposure studies • TG 451 
• TG 452 
• TG 453 
• Carcinogenicity Studies 
• Chronic Toxicity Studies 
• Combined Chronic 
Toxicity/Carcinogenicity Studies 
Post-mitotic cell studies • TG 424 • Neurotoxicity Study in Rodents 
Prenatal effects • TG 414 
• TG 426 
• Prenatal Development Toxicity Study 
• Developmental Neurotoxicity Study 
Reproductive effects • TGs 415, 416 
 
• TG 421 
 
• TG 422 
 
 
 
• TG 443 
• One and Two-Generation Reproduction 
Toxicity 
• Reproduction/Developmental Toxicity 
Screening Test 
• Combined Repeated Dose Toxicity Study 
with the Reproduction/Developmental 
Toxicity Screening Test 
• Extended One-Generation Reproductive 
Toxicity Study 
Potentially relevant tests 
to be used in combination 
• TG 473 • In vitro Mammalian Chromosome 
Aberration Test 
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Figure 14 Expert replies to the question "Please rate the relevance of updating tests in the OECD 
CF (tests further specified in table above) to include epigenetic endpoints/tests." (F.E.1). Note: The 
percentage of experts not replying or answering "don’t know" was 53-65%. 
 
Table 36: Expert comments on the inclusion of epigenetic tests (replies in free text fields to 
question "Add here any other comments related to including epigenetic tests for the identification 
of endocrine disruptors" (F.E.2)). 
1. Whether epigenetics play a role in environmental chemical induced endocrine disease is still an 
open question. Therefore development of test methods for epigenetics in premature. 
2. This is still an area of research. Also epigenetic changes are not specific to endocrine disrupters 
3. For sure, epigenetic changes should be taken into account in future testing strategies, especially 
in context of developmental neurotoxicological effects. However, currently knowledge on normal, 
physiological epigenetic variation is largely lacking, let alone effects of EDC-induced epigenetic 
changes as well as transgenerational effects. Therefore, I'm not sure if we are ready yet to 
implement epigenetic endpoints in ED identification. 
4. miRNA and mRNA whole blood gene expression for candidate genes 
5. Epigenetic MoA is a field repeatedly indicated by OECD working groups, it appears to be a high 
priority issue from the view of scientific and policy awareness. Nevertheless regulatory applicable 
IATAs inclusive for this may not be achievable in short term but rather intermediate or long term, 
be it in vitro or combined in vivo approaches. A structured, explorative approach is necessary 
focussing on the long term development and assessment of in vitro focussed approaches. The 
METiCx consortium is prepared to support these developments. 
6. Please take note of the recommenations in Table 7 of Greally & Jacobs, 2013 Ref. Greally JM, 
Jacobs MN.In Vitro and In Vivo Testing Methods of Epigenomic Endpoints for Evaluating Endocrine 
Disruptors, ALTEX. 2013;30(4):445-71. 
7. Not yet sufficiently familar with these tests to comment. 
8. We would support the recommendations as outlined in Greally & Jacobs, Altex 2014: Greally & 
Jacobs. In vitro and in vivo Testing Methods of epigenetic Endpoints for evaluating endocrine 
Disruptors, ALTEX (2014), 7/13. 
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9. Where are the fish tests that are so much easier to develop focusing on epigenetic effects? The 
FET (TG246) is an amazing platform for this and is not even considered an animal test! 
10. A major practical problem in the rodent tests is to identify the target organ/tissue for epigenetic 
modifications, which may be distinct from the organ/tissue showing the apical effect (e.g. 
epigenetic effects in the hypothalamus may underlie obesogenic effects), and such models are 
therefore not suitable for screening of epigenetic effects. In general, there is insufficient 
knowledge on the mechanistic role of epigenetic modifications in the pathway between initiation 
and apical effect, but ED dependent epigenetic effects can be identified in dedicated models (cell 
culture models, zebrafish embryos, viable yellow agouti (Avy) mouse) and associated with an 
altered phenotype (e.g. respectively differentiation, development, coat color). The zebrafish 
embryo epigenetic toxicity assay given in the first row of the above copied Table 7 of Annex 1 of 
the detailed review paper OECD No 178 is missing in the questionaire F.E.1 table . 
11. The field of epigenetics is still advancing and needs to advance even further before informed 
introduction of epigenetic endpoints should be considered for addition into existing guideline 
studies. 
12. Specific methylation targets rather than global methylation assays would be preferred here, once 
sensitive gene regions have been identified. 
13. Extended one generation or two generation tests (TG 415/416, 443) might give the possibility to 
monitor both somatic epigenetic modifications, and more evident, inherited epimutations linked 
to endocrine disruption. Assays including only one generation might be useful to gain indications 
for epigenetic modifications linked to endocrine disruption or provide supporting information. 
However, these tests might not give sufficient evidence for an epigenetic endocrine disruption 
mechanism. Epigenetic modifications of the nervous system might be detected the best during 
development of individuals (TG 414, TG 426), rather than in adult individuals (TG 424). 
Development might represent the more sensitive window for endocrine disruption whereas in the 
adult endocrine disruption might be compensated. Non-mammalian tests should be taken into 
account as well (e.g. zebrafish embryos). Consider this a general view, as we are not experts in 
epigenetics. 
14. Fundamental research is required prior to (1) evaluating the uncertainty in the ERA that is caused 
by epigenetic effects and (2) including epigenetic effects in environmental risk assessment 
procedures (OECD 2011f, Vandegehuchte &amp; Janssen 2011, Head et al. 2012). 
15. but this needs a great deal of exploratory work first, and a workshop is being held in November 
2015 to start to explore this.. 
16. We do see value in tests probing epigenetic processes, to the extent that such tests could provide 
mechanistic data on the biological processes underlying endocrine disruption. Addition of 
epigenetic endpoints to existing studies will be useful if this information is used to inform AOPs. 
We support the recommendation of DRP 178 that an important goal will be the development of in 
vitro and short term assays for epigenetic changes predictive of adverse outcomes. Given the 
amount of further fundamental research needed however these are not so high a priority for 
resource allocation as other aspects, in particular metabolism. In addition to Table 7 above, DRP 
178 indicates that adding epigenetic endpoints to relevant in vitro assays will also in principle be 
feasible - this should also be considered in any further discussion. 
17. Since the molecular mechanism of epigenetic transmission are as yet not well described, the 
focus should be on first elucidated mechanism(s) - in vitro or in vivo - and designing diagnostic 
endpoints before considering modification of any of these animal-ingestive test methods. 
18. I do not have any experience with the potentiall use of epigenetic tests 
19. An updated 2 generation test would be useful to identify epigenetic effects 
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3.5 Views on current OECD Conceptual Framework 
In this section, experts were asked to express their opinion on current tests/screens 
included in the OECD Conceptual Framework (CF), existing tests that are not included in 
the OECD CF and the need for the development of new ones. This section is divided into 
5 subsections, specific for: 
1. In vitro tests 
2. In vivo mammalian studies 
3. Non-mammalian vertebrate in vivo studies 
4. Invertebrate studies 
 
Table 37 gives an overview on the overall ranking regarding relevance of mammalian 
and non-mammalian vertebrate test methods of the OECD conceptual framework 
regarding their diagnostic value to detect endocrine related perturbations. More detail on 
all individual tests is provided in sections 3.5.1 - 3.5.4 showing the results for survey 
sections F.A.- F.D.  
 
JRC used the following equation to calculate the overall ranking of the TMs indicated by 
the experts: 
(Equation 7)  !  = 	
#+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Table 37: Overview on the overall ranking of test methods (TM) included in the OECD Conceptual 
Framework (E.A – E.G) based on Equation 7 above. (* In some cases for the non-mammalian 
tests, there were no answers stating "no or low relevance", so they should be considered of high 
relevance even if they have no numerical score.) 
Test method 
Ranking 
(Eq7) 
Amphibian metamorphosis assay (AMA, TG 231) * 
Fish sexual development test (FSDT, TG 234) * 
Medaka extended one-generation reproduction test (MEOGRT) * 
Extended one-generation reproductive toxicity study (TG 443) 29.0 
Larval amphibian growth and development assay (LAGDA) 20.0 
Xenopus embryonic thyroid signalling assay (XETA) 20.0 
Fish short term reproduction assay (FSTRA, TG 229) 17.0 
Developmental neurotoxicity (TG 426) 8.7 
Pubertal development and thyroid function assay in intact juvenile/peripubertal male 
rats (OCSPP 890.1500) 
7.7 
Detection of endocrine active substances, acting through estrogen receptors, using 
transgenic cyp19a1b-GFP zebrafish embryos (EASZY) 
7.5 
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Pubertal development and thyroid function assay in intact juvenile/peripubertal 
female rats (OCSPP 890.1450) 
7.3 
Androgenised female stickleback screen (AFSS, GD 140) 5.3 
21-day fish assay (TG 230) 4.7 
Two-generation reproduction toxicity study (TG 416) 4.6 
Prenatal developmental toxicity study (TG 414) 4.4 
Fish reproduction partial lifecycle test (no validation ongoing) 3.0 
Uterotrophic bioassay in rodents (TG 440) 2.8 
Avian reproduction test (TG 206) 2.8 
Avian two-generation test (ATGT) 2.8 
Combined 28 day reproductive screening test (TG 421+422) 2.7 
Hershberger bioassay in rats (TG 441) 2.6 
Combined chronic toxicity / carcinogenicity study (TG 453) 2.0 
One-generation reproduction toxicity study (TG 415) 1.8 
Fish life cycle toxicity test (FLCTT) (no validation ongoing) 1.6 
Repeated dose 28 day study (TG 407) 1.6 
Repeated dose 90 day study (TG 408) 1.4 
* In some cases for the non-mammalian tests, there were no answers stating "no or low relevance", so they 
should be considered of high relevance even if they have no numerical score. 
 
3.5.1 In vitro methods (F.A) 
In section F.A of the survey, experts were asked to: 
● comment on the technical performance, weaknesses, limitations, regulatory 
acceptance etc. of in vitro test methods in the OECD CF (F.A.1 and F.A.2, Table 
38) 
● name any other relevant in vitro TM not included in the current OECD CF (F.A.3, 
Table 39) 
● propose the development of new in vitro tests (F.A.4, Table 40) 
 
Table 38: Overview of comments on the technical performance, weaknesses, limitations, 
regulatory acceptance of in vitro TMs (free text comments to the question "Please add here your 
comment on any current OECD CF in vitro test (F.A.2)). 
General comments 
1. need to combine with metabolism. 
2. Test materials of in vitro assays (e.g. cell lines) should be open to the public and affordable. 
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3. The in vitro tests are only useful for identification but at the moment not useful for quantitative 
risk assessment mainly because only the nominal concentration is given whereas the actual 
concentration should be assessed esp. in the tests where cells are exposed to the test 
substance (see also Blaauboer BJ, Boekelheide K, Clewell HJ, Daneshian M, Dingemans MML, 
Goldberg AM, et al. The use of biomarkers of toxicity for integrating in vitro hazard estimates 
into risk assessment for humans. ALTEX. 2012;29(4):411-25. 
4. Steroid binding and transactivation assays all make the mistake of assuming that EDs with 
disruptive effects are all likely to act directly as steroid receptor ligands. This is most likely not 
true, as in the case of phthalates which are anti-androgenic not by any interaction with the 
androgen receptor, but by disrupting Leydig cell development within a critical androgen-
dependent time-window, Steroidogenesis assays using secondary cell lines represent steady 
state adult-like situations which are relatively insensitive compared to those cell types during 
their differentiation and development in vivo. This is especially true for secondary Leydig cell 
lines, which in many cases do not even indicate the full complement of steroidogenic enzymes, 
and do not reflect events during Leydig cell differentiation. 
5. OECD has recently approved a human recombinant ER binding assay that should replace the 
rat cytosol test or any other non-human mammalian ER test. Note also that TG 455 has been 
updated to include anti-estrogenic activity. 
ER binding assay Note by JRC: since July 2015 OECD TG 493 
6. low sensitivity 
7. tests on binding/transactivation should be integrated with functional assays using human-
relevant biomarkers (such as the PSA assay). These assays would be the next step, 
downstream to receptor interactions, in building Adverese Outcome Pathways for endocrine 
disrupters 
8. Actual tests used with estrogen receptors are based in the classical model of ERs acting as 
transcription factors binding to ERE in the DNA. Now we know that ERs act outside the nucleus 
activating other signaling pathways. It is already accepted by endocrinologist that extranuclear 
initiated signaling is important in multiple endocrine systems. Moreover, it has been 
demonstrated using genetically modified mice that both ERs when outside the nucleus mediate 
low dose actions of environmental estrogens such as bisphenol-A. Therefore, it is necessary to 
incorporate new tests related to ER activation outside the nucleus. 
AR binding assay 
9. low sensitivity 
10. AR binding assay - rat cytosol from castrated rats may not be specific for other species 
11. need to combine with metabolism. 
12. despite promising results, these were dropped by the lead country (US) in pre validation 
Estrogen receptor transactivation (TG 455) 
13. very useful, high sensitivity 
14. need to combine with metabolism. 
15. Actual tests used with estrogen receptors are based in the classical model of ERs acting as 
transcription factors binding to ERE in the DNA. Now we know that ERs act outside the nucleus 
activating other signaling pathways. It is already accepted by endocrinologist that extranuclear 
initiated signaling is important in multiple endocrine systems. Moreover, it has been 
demonstrated using genetically modified mice that both ERs when outside the nucleus mediate 
low dose actions of environmental estrogens such as bisphenol-A. Therefore, it is necessary to 
incorporate new tests related to ER activation outside the nucleus. 
Androgen receptor transactivation Note by JRC: since July 2016 OECD TG 458 
16. very useful, high sensitivity 
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Steroidogenesis assay (TG 456) 
17. very useful, high sensitivity 
18. Current T456 guideline only describes the assessment of T and E2 production in H295R. In 
recent publications, often metabolic profiling of hormone production is performed. This is a 
valuable addition to the current test guideline and could be considered for implementation. 
19. Valuable test, presently E2 and testosterone is included in the OECD TG. Could be improved by 
including several other steroid hormones as well. 
20. Steroidogenesis shows quite high variability but is still very usable. Validation of the method for 
hormones other than Estradiol and Testosterone (e.g. progesterone) could be great. 
Aromatase assay 
21. very useful, high sensitivity 
22. The steroidogenesis assay is also able to measure aromatase activity.  
23. has not yet been specified in the OECD CF and should be included if the OECD test guideline is 
available or under development 
24. Aromatase assay is limited as it only detects inhibition of the enzyme; however increased 
aromatase activity is equally important information to have as increased activity is associated 
with effects on puberty and reproductive functioning. To some extent this test is redundant as 
the steroidogenesis assay provides more relevant functional information. 
MCF-7 cell proliferation assay 
25. very useful as the most integrative estrogen sensitive in vitro assay, but results need to be 
interpreted in connection with ER transactivation 
26. This is not a specific assay for ER activation. Still valuable for screening for effects of breast 
cancer cell proliferation 
27. The project for MCF-7 cell proliferation assay was stopped. This assay should be deleted. 
28. MCF-7 cell proliferation assay is not specific for estrogenic/anti-estrogenic chemicals - the 
relevance of the data for identifying EDs is questionable.   
 
Table 39: Overview of suggestions for the inclusion of other existing in vitro TMs into the OECD CF 
(free text comments to the question "Apart from what was addressed above, are you aware of any 
existing additional in vitro test that could add value and should be further considered? (F.A.3)). 
1. there are a LOT of in vitro tests not mentioned here that are upstream or downstream of the 
targeted biology. 
2. CYP17 activity assay, nuclear receptor coregulator assays 
3. AhR assay PPARgamma PPARalfa 3T3 adipocyte differentiation assay 
4. We agree with the OECD press release made after the last EDTA meeting (Oct. 2014) that there 
is a particular need for development of in vitro tests investigating key events of the AOP for 
thyroid hormone disruption/perturbations of the thyroid system. For example one promising key 
event which could be covered by development of an OECD TG seems to be an in vitro assay for 
thyroid peroxidase activity (TPO). 
5. We are developing a Leydig cell differentiation test, which is using relatively undifferentiated 
Leydig cells and differentiating these in vitro, under the influence of various factors, including 
EDs. 
6. This is well developed in the METICX consortium proposal. 
7. In line with comments under Section E on the importance of mechanistic approaches, it is 
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generally necessary for the Conceptual Framework to be updated to refer to a greater variety of 
in vitro tests, including methods relevant beyond the EA modalities currently covered. Although 
additional in vitro methods stand in varying states of validation and standardisation, many are 
already capable of adding valuable insights, used appropriately as part of weight of evidence 
analyses. As the Conceptual Framework is not restricted to Test Guideline methods or intended to 
act as a prescriptive testing strategy, it will be more useful if it takes a broader and more 
inclusive approach. The thyroid scoping document identifies a number of in vitro assays as in an 
advanced state of development, these are obvious candidates to be included. Assays addressing 
endocrine and androgen mechanisms of action in the ToxCast 
(http://www.epa.gov/ncct/toxcast/) and Tox21 (http://www.epa.gov/ncct/Tox21/) programs 
should also be included. Focus on the addition of in vitro assays targeting molecular events 
playing a role in more than one pathway, (e.g. RXR and AhR reporter assays) could also be 
considered. These would provide information relevant to a variety of potential adverse outcomes, 
which would be helpful in individual assessments, but their use and further development would 
also help progress the characterisation of endocrine AOPs in a systematic manner. In vitro 
assessment of metabolism is an area needing urgent further work, but it should already be 
mentioned in the Conceptual Framework, as previous analysis (OECD DRP 97, Jacobs et al. 
ALTEX. 30(3):331-51) has concluded that some of the necessary tools for incorporating the 
effects of metabolism and bioavailability are already available. The DRP specifically comments 
that although ideal solutions for simultaneously testing endocrine potential and metabolism are a 
way off, this should not prevent the use of the best combination of tests already available. 
8. Assays addressing endocrine and androgen mechanisms of action in the ToxCast 
(http://www.epa.gov/ncct/toxcast/) and Tox21 (http://www.epa.gov/ncct/Tox21/) programs 
should be included. 
Table 40: Overview of proposals for the development of new in vitro TMs (free text comments to 
the question "Apart from what was addressed above, do you see a need for developing new in vitro 
tests to better assess endocrine disrupting substances? Will there be any added value from such 
new tests from a regulatory perspective?" (F.A.4)). 
1. Yes and Yes 
2. Not necessarily new tests, but rather smart use/combination of testing would enhance 
applicability for regulatory purposes. More effort should be placed on smart combination of test 
results together with implementation of PBPK/QIVIVE strategies. 
3. I wish to stress the major importance of developing in vitro/in vivo assays relevant to metabolic 
syndrome and diabetes, See above section E for relevant examples (e.g., PPAR signalling) 
4. development of human in vitro tests from primary human testicular mixed cell culture 
5. The focus of further work should be the development of in vitro/in silico focussed IATAs with 
improved metabolism relevant for human and/or environment. The current CF informs on 
potentially relevant assays and also the OECD GD 150 provides a basis, but does not intend to 
represent an IATA. See earlier comments including to DA7. 
6. There is a great need for developing assays based on human induced pluripotent stem cells based 
on e.g. High Content Imaging. Such an assay can predict effect on developmental toxicity 
7. There is a need for development of new in vitro tests to get information on deseases/disorders 
with potential endocrine MoA like diabetes or obesitas. The biological relevance shoul be high. 
8. C.f. the response above (F.A.3) In general, in order to address which in vitro tests to focus 
development of, it might be feasible to consider development of AOPs as the first step, and target 
MIEs and KEs with development of promising in vitro tests to assure mechanistic relevance and 
predictivity. Furthermore, we find it of very high priority to work on inclusion of metabolic 
capacity in all in vitro systems. 
9. it urges tests related to extranuclearly initiated actions of steroid receptors. 
10. The problem with in vitro tests is that they are giving many false positives; there's no organic 
chemical in the literature that doesn't have at least one reference as an EDC from in vitro tests; 
this is very disappointing in terms of the 3Rs but endocrine disruption is unfortunately a field that 
requires relevant in vivo data for proper regulation; if not we are risking over-regulating or 
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missing important activities. 
11. Yes. The aforementioned assays were only for a limited number of pathways. Many pathways like 
PPAR, RXR, etc have not yet been included. As the regulatory identification of endocrine 
disruptors is not limited to EATS pathways, the addition of assays for other pathways is highly 
relevant. 
12. Whatever test is used or developed a causal link between the parameter evaluated and the long 
term adverse effect must be established. Understanding the AOP/MOA is critical before pertinent 
tests can be validated. 
13. Leydig cells are the key intermediate in most ED effects leading to androgen-dependent aspects 
of TDS and cryptorchidism, which together represent one of the most frequent and obvious 
consequences of ED exposure in the human population. As mentioned above, Leydig cell 
development is not addressed by any of the existing tests (including secondary, immortalized 
Leydig cell lines), even though these cells are known in vivo to be major targets of phthalate 
exposure. 
14. - in vitro transactivation assays for orphan receptors, i.e. estrogen related receptors (EER) may 
be of relevance (e.g. rather strong binding of BPA and its metabolites). 
15. IATA development. 
16. Yes, in line with previous responses, development of in vitro tests in general should be a priority 
for better assessment of endocrine disrupting substances. Mechanistic data from such tests 
informs on the existence of an endocrine mode of action, which is essential from a regulatory 
perspective within the current EU legal framework and under each of the options being suggested 
for horizontal criteria on identification of endocrine disruptors. An improved battery of in vitro 
tests will help address mixtures and cumulative effects which is also very important from a 
regulatory perspective -in vitro methods capable of rapid/low cost turnover will be essential for 
this. Concerning human health effects, in vitro methods offer improved scope for ensuring that 
data is human relevant, counteracting the limitations inherent in animal studies arising through 
species differences. Considering environmental effects, understanding of underlying biology 
obtainable from in vitro tests will enable accurate assessments of the relevance of a particular 
result to multiple wildlife species/taxa. 
17. Assays that address thyroid mechanisms of action (as described in the OECD Thyroid Scoping 
Document 207) and metabolism (described in OECD DRP 97, Jacobs et al. ALTEX. 30(3):331-51) 
of componds should be a high prioirity for development (as suggested in DRP 178). There is 
definite added value of additional in vitro tests as these tests provide essential mechanistic 
information regarding potential endocrine mode of action - a requirement under current EU 
legislation and likely to be critical for defining ED chemicals under future EU policy. The benefits 
of prioritizing in vitro mechanistic assays include: increased assessment through-put for 
screening existing and new chemicals as well as mixtures; the ability to include tests based on 
human biology (and to account for species differences); the eventual possibility to move away 
from apical animal tests to more predictive Integrated Approaches to Testing and Assessment 
based on upstream events along a series of AOPs (see OECD Guidance, Templates and 
knowledgebases for creating, assessing and using AOPs: 
http://www.oecd.org/chemicalsafety/testing/adverse-outcome-pathways-molecular-screening-
and-toxicogenomics.htm). As mentioned above, a critical aspect of relying on in vitro methods is 
to account for metabolism. Options for including metabolism in in vitro assessments have been 
described in OECD DRP 97 and by Jacobs et al. ALTEX. 30(3):331-51. 
18. Yes - to prioritise substances for more in depth testing. New and improved in vitro tests are also 
needed for getting better regulatory acceptance of in vitro studies for ED identification in the long 
run (important for reducing animal testing and in cases where in vivo tests are not feasible/not 
allowed as in cosmetics regulation). Also, we need to focus on in vitro test for mechanisms 
currently not covered by existing in vitro tests. 
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JRC Summary of the comments in free text fields of Questions F.A regarding in 
vitro TMs 
The most important aspect mentioned for in vitro tests for the identification of EDs, was 
their use in smart combination in a Weight of Evidence approach. In vitro tests should 
ideally be combined in a mechanistically based framework addressing specific key events 
in relevant AOPs. The current OECD CF tests focus on estrogenic and androgenic effects, 
this should be widened to other relevant pathways. Another important aspect was to 
consider metabolism when using in vitro tests. 
 
3.5.2 Mammalian in vivo test methods (F.B) 
In section F.B of the survey, experts were asked to: 
● rate the mammalian in vivo studies of the OECD CF regarding their relevance 
considering their diagnostic value to detect endocrine related perturbations (F.B.1, 
Figure 15) 
● comment on the diagnostic value to detect endocrine related perturbations (F.B.2 
and F.B.3, Table 41) 
● comment on the TMs concerning their ability to distinguish endocrine effects from 
general toxicity and indirect effects on the endocrine system (F.B.4 and F.B.5, 
Table 41) 
● propose relevant enhancements of mammalian in vivo TMs (F.B.6 and F.B.7, 
Table 41) 
● mention additional existing in vivo TMs for consideration (F.B.8) 
● propose the development of new mammalian in vivo studies to better identify 
endocrine disrupting substances considering the added value from regulatory 
perspective (F.B.9, Table 42). 
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Figure 15: Replies of experts to question F.B.1: Please rate the mammalian in vivo studies below 
regarding their relevance considering their diagnostic value to detect endocrine related 
perturbations in the test alone or in combination with other tests. (Note: The percentage of experts 
not replying or answering "don’t know" was 25-38%.) 
 
 
Table 41: Expert comments on mammalian in vivo studies regarding (1) their diagnostic value to 
detect endocrine related perturbations in the TM alone or in combination with other tests (F.B.2/3), 
(2) regarding the TM ability to distinguish endocrine related effects from general toxicity or indirect 
effects on the endocrine system (F.B.4/5), (3) proposing enhancements to the TMs (F.B.6/7). 
General comments on mammalian in vivo test methods 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination with 
other tests 
1. Note we had difficulty with the question because it was not clear whether diagnoses of MoA was 
meant or diagnoses of adverse effects or both. We have answered the questions as diagnoses 
MoA. If adverse effects should be included as well the high relevance of the mechanistic studies 
should be changed into relevant instead of high relevance 
2. The level 4 and 5 studies in the current OECD Conceptual Framework are of highest diagnostic 
value, as they are able to define adversity, potency and the leading health effect of a substance 
on the whole organism. The data generated from TGs 440, 441 and the male and female pubertal 
development assays are heavily influenced by the general state of the animal. It is, therefore, 
sometimes difficult to interpret the data and to differentiate the effects due to general toxicity 
from those due to ED 
3. General comment: usually a combination of tests needed for diagnostic purposes - TG 443 being 
the most diagnostic. But of course the TG 440 and Tg 441 in intact animals will also be diagnostic 
4. We note that you use the wording perturbations, not MoA and adverse effects, respectively. This 
might confuse the reader and the responses. In the tables above (F.B.1 and F.B.2), the question 
cannot be answered in general but depend on case by case evaluations of substances and effects. 
5. Most acute or semi-acute studies carried out in adult rodents are of little value, since they are 
relatively insensitive, and only address more reprotox issues rather than ED-related endpoints. 
6. No single test alone can be used to get a diagnostic for ED. 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on the 
endocrine system 
7. All tests may provide, albeit with different accuracy, NOAEL for endocrine effects and NOAEL for 
other toxic effects. Endocrine disruption may be identified by individual effects (thyroid changes) 
or y recognized effect patterns (e.g., those resulting from aromatase inhibition) 
8. Depends on dosing and effects 
9. The question is unclear as it is in many cases difficult to distinguish between effect induced due 
to endocrine disruption or other modes of action due to the lack of assessment of endpoints for 
mode of action. 
10. In many cases it is not possible to answer clear yes or no to this question (F.B.4). In some cases 
the assays will allow to distinguish, in other cases they will not. It depends on the substance and 
which other MoAs/AOPs it acts through. 
11. The answer depends upon dosages tested. 
12. Assays like Uterotrophic, Hershberger tests etc are not designed to detect general toxicity. It is 
possible to use assays like repeated dose, reproductive toxicity tests, etc to assess chemical 
specific effects. This is often done by using a weight of evidence approach to take into account 
toxicity results together with mechanistic information. 
13. To distinguish whether an effect is direct or secondary a set of in vivo studies is necessary 
covering a broad range of durations (from single to long-term) and consequently a set of studies. 
It appears this is only possible by expert judgment in a weight-of-evidence approach on a case-
by-case basis. As a general rule effects seen at doses which produce excessive toxicity (e.g. 
markedly reduced body weight gain or severe histopathological lesions) are not useful to assess a 
primary effect on the endocrine system. 
14. difficult to distinguish general tox from ED with only one test... 
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15. As summarised in OECD GD150 with respect to TGs 415 and 416, plus 421 and 422: as all the 
endpoints are apical, it is difficult to discern mechanism of action from [these tests] alone. 
Information on mechanism of action needs to be obtained from in vitro EATS assays or in vivo 
lower tier tests (p. 343, p. 496). Though data from apical studies can and should be used where 
possible to inform AOP development until pathways are better characterised, this is a key reason 
why they are not a priority for future work on identifying endocrine disruptors. 
• proposals for enhancing them 
16. General comments: All methods should be upgraded with new ED-endpoints once they are 
validated for one in vivo test and suitable to include in other TG 
17. Enhancing may be useful, where sufficient data available for validation with regard to reliability 
and relevance, but not a high priority. See response to DA7. 
18. see Greally and Jacobs ALTEX 2013 and Annex to DRP 178.Enhancing may be useful, where 
sufficient data available for validation with regard to reliability and relevance. Enhancing may be 
valid, but experimental work needed first. 
19. Generally, we support the addition of further mechanistic endpoints to the above indicated 
existing animal studies as an interim measure until pathways are better understood; this 
information should be used to inform AOPs and identify key events that can be targeted by new 
or existing in vitro methods. 
Uterotrophic bioassay in rodents (TG 440) 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination with 
other tests 
20. quite insensitive, the ER AR transactivation assays are mostly providing the information needed 
21. provide a limited and "narrow" information. Adding more enpoints (e,g,, gene expression) could 
improve the value of these assays.  
22. not sensitive 
23. In view of costs and animal welfare this will only be asked in some rare cases. Moreover, it does 
not provide information on apical endpoints, it only provides information on ER MoA  
24. Detection of estrogen antagonists is not currently validated 
25. this assay is relevant to screen endocrine active substances but if performed on ovariectomized 
females, other data are needed to decide if the substance is an endocrine disruptor as the animal 
is not intact.  
26. TG 440 and 441 are mechanistic assays that can be replaced by in vitro assessments 
(publications on this have been submitted by US EPA and NIH and should be available soon) 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on the 
endocrine system 
- 
• proposals for enhancing them 
27. The current uterotrophic and Hershberger provide a limited and "narrow" information. Adding 
more enpoints (e,g,, gene expression) could improve the value of these assays. 
Hershberger bioassay in rats (TG 441) 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination with 
other tests 
28. quite insensitive, the ER AR transactivation assays are mostly providing the information needed 
29. provide a limited and "narrow" information. Adding more enpoints (e,g,, gene expression) could 
improve the value of these assays.  
30. not sensitive 
31. This test is relevant but has ethical issues with surgical castration; it would be nice to be replaced 
32. See previous but then for AR 
33. Liver enzyme inducers can confound results due to an increase in testosterone metabolism. 
Potent estrogens can increase seminal vesicle weights.  
34. this assay is relevant to screen endocrine active substances but as it is performed on castrated 
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males, other data are needed to decide if the substance is an endocrine disruptor as the animal is 
not intact. 
35. TG 440 and 441 are mechanistic assays that can be replaced by in vitro assessments 
(publications on this have been submitted by US EPA and NIH and should be available soon) 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on the 
endocrine system 
- 
• proposals for enhancing them 
36. The current uterotrophic and Hershberger provide a limited and "narrow" information. Adding 
more enpoints (e,g,, gene expression) could improve the value of these assays. 
37. A sensitive, quali and quantitative tool to evaluate endocrine disruptors are the morphometric 
analysis of the uterus, the epididymis and testes (could be applied to any in vivo exposure 
assays). In the uterus, is possible to evaluate the endometrium thickness, diameter and number 
of glands, which are also indicative endpoints related to endocrine disruptors activity (i.e. 
estrogenicity). In males, sperm parameters, testicular and epididymal histo-morphometry are 
very important, informative and could also be applied to any in vivo exposure assays. Plasma 
hormone levels (estradiol, FSH, LH and testosterone) are very relevant and indicative information 
on steroidogenesis and HPG axis in vivo evidence, applied to any assay as well. A suggestion for 
evaluation of these hormones also in adult female animals is important, but the comparison of 
groups can only be between the rats that are in the same cycling period (e.g estrous). 
Testosterone can also be measured in female animals even at very low levels when using the 
radioimmunoassay as the most sensitive and quantifying method. More than one time point of 
collection on the same treatment dose would also reduce the bias of hormonal variation, increase 
the statistical significance and confirm a pattern. Alternatively to the standard Hershberger test 
that adopts surgical male castration, Ashby et al. (2004) and Tinwell et al. (2007) proposed an 
assay lasting 10 days in intact immature weanling rats (submitted to chemical castration with 
testosterone propionate or flutamide) thus avoiding the surgical procedure. With the entire male 
reproductive system intact, this assay can be used for the detection of compounds with 
anti/androgenic activities. Specifically on the pubertal development and thyroid function assay in 
intact juvenile/peripubertal female rats (OCSPP 890.1450), the period of estrous cycling 
evaluation should be higher, especially because, when the females are immature, there are 
differences between species first day of vaginal opening and ovary maturation. Then, the current 
20 days of observation is not enough to proper characterize the days of cycling period into the 
categories proposed. A minimum of more 20 days would be necessary to better evaluate at least 
3-4 complete cycles and establish a correct pattern for this endpoint. Guerra MT, de Toledo FC, 
Kempinas Wde G. In utero and lactational exposure to fenvalerate disrupts reproductive function 
in female rats. Reprod Toxicol 2011; 32:298-303; Weibel ER: Principles and methods for the 
morphometric study of the lung and other organs. Lab Invest 1963, 12(1):131-155; Leblond CP, 
Clermont Y: Spermiogenesis of rat, mouse, hamster and guinea pig as revealed by the periodic 
acid-fuchsin sulfurous acid technique. Am J Anat 1952, 90(2):167-215; Robb GW, Amann RP, 
Killian GJ: Daily sperm production and epididymal sperm reserves of pubertal and adult rats. J 
Reprod Fertil 1978, 54(1):103-107; Ashby J, Lefevre PA, Tinwell H, Odum J, Owens W. 
Testosterone-stimulated weanlings as an alternative to castrated male rats in the Hershberger 
anti-androgen assay. Regul Toxicol Pharmacol 2004; 39:229-38; Tinwell H, Friry-Santini C, 
Rouquie D, Belluco S, Elies L, Pallen C, et al. Evaluation of the antiandrogenic effects of 
flutamide, DDE, and linuron in the weanling rat assay using organ weight, histopathological, and 
proteomic approaches. Toxicol Sci 2007; 100:54-65. 
Repeated dose 28 day study (TG 407) 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination with 
other tests 
38. at best only giving very indirect information about endocrine disruption  
39. exposure time frame misses important developmental windows, too low number of animals to 
evaluate hormone levels (power analysis should be applied to address this question), protocol 
does not require that females are sacrificed in same stage of estrous leading to high variability of 
endpoints  
40. have severe limitations due to lack of (mandatory) endocrine specific endpoints and to lack of 
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exposure during sensitive windows of development. 
41. not sensitive 
42. endocrine-relevant endpoints added to TG 407 have been shown to be relatively insensitive and 
therefore of limited utility 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on the 
endocrine system 
43. TG 407 and 408 can normally not distinguish indirect effects from endocrine disrupting effects, do 
not cover windows of susceptibility 
44. TG 407, 408, 416 lack of endocrine specific endpoints 
45. Does not differentiate 
• proposals for enhancing them 
46. There are inconsistencies between TG 407 (Repeated Dose 28-Day Oral Toxicity Study in 
Rodents) and TG 408 (Repeated Dose 90-Day Oral Toxicity in Rodents) since the updating of TG 
407, and these include omissions in blood and tissue examinations in TG 408. However for some 
classes of substances, such as food flavourings, in some jurisdictions (e.g. Europe) TG 408 is 
required, even though in some cases, with the new added endpoints, the updated TG 407 has 
more relevant tissue and blood measurements. Regulatory authorities would find it very helpful to 
have similar endpoints included in the 90 day studies also. Can the ED relevant endpoints and 
tissues be amended in TG 408 as for TG 407, without going through a full validation process? 
Would a retrospective data analysis help such a process? There are other examples of lower level 
tests where there need to be more consistent revisions in line with updated TGs, and similarly 
there may also such examples in the ecotoxicity TG series.Both the 28 and the 90-day studies 
(OECD TG 407 and OECD TG 408, respectively) are included in level 4 of the OECD Conceptual 
Framework, however, only OECD TG 407 has been updated and validated for the detection of 
endocrine disrupters. To increase the ability for detection of ED effects in OECD TG 408 it is 
recommended to include as mandatory similar endpoints as in OECD TG 407, incl. the current 
optional ED related endpoints. Ref: http://www.cend.dk/rapporter/EDtestingstrategy.pdf A 
feasibility study for minor enhancements of TG 414 (Prenatal Developmental Toxicity Study) with 
ED-relevant endpoints have been proposed by DK and is included on the OECD Workplan. 
Assessment of testosterone levels and anogenital distance (AGD) in male foetuses as well as an 
enhancement with some additional text giving guidance on evaluation of abnormalities of male 
and female genitalia would be relevant.  
47. In our view, the optional ED related endpoints in the repeated dose 28-day study TG407 
(including weight of uterus and ovaries, oestrus cyclicity, histopathologic changes in mammary 
glands and pituitary and circulating levels of T3, t4 and TSH) should become mandatory. Under 
REACH they could possibly become mandatory if requested as a default or in cases where there 
are any available information indicative of endocrine activity of the substance, even though these 
parameters are not mandatory (needed as a default in all cases) according to the OECD TG. It 
could be considered whether the provisions of REACH make it impossible to request these 
parameters as a default (i.e. mandatory) in all dossier evaluation cases under REACH 
Repeated dose 90 day study (TG 408) 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination with 
other tests 
48. at best only giving very indirect information about endocrine disruption  
49. have severe limitations due to lack of (mandatory) endocrine specific endpoints and to lack of 
exposure during sensitive windows of development. 
50. not sensitive 
51. Relevant for REACH etc although more ED related parameters could/should be included to 
increase the sensitivity,  
52. this assay should be updated by adding the same endocrine sensitive endpoints included in the 
updated version of the repeated dose 28 day study (TG407) 
53. the current TGs 408, 415, 453, combined repro, and 416 do not contain endocrine-specific 
endpoints and therefore do not inform ED mechanisms of action. 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on the 
endocrine system 
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54. TG 407 and 408 can normally not distinguish indirect effects from endocrine disrupting effects, do 
not cover windows of susceptibility 
55. TG 407, 408, 416 lack of endocrine specific endpoints 
56. Does not differentiate 
57. do not contain endocrine-specific endpoints and therefore do not inform ED mechanisms of action 
58. without the addition of the endocrine sensitive endpoints, the assay will not give sufficient 
information to distinguish general effects from endocrine-disrupting effects  
59. do not contain endocrine-specific endpoints and therefore do not inform ED mechanisms of action 
• proposals for enhancing them 
60. There are inconsistencies between TG 407 (Repeated Dose 28-Day Oral Toxicity Study in 
Rodents) and TG 408 (Repeated Dose 90-Day Oral Toxicity in Rodents) since the updating of TG 
407, and these include omissions in blood and tissue examinations in TG 408. However for some 
classes of substances, such as food flavourings, in some jurisdictions (e.g. Europe) TG 408 is 
required, even though in some cases, with the new added endpoints, the updated TG 407 has 
more relevant tissue and blood measurements. Regulatory authorities would find it very helpful to 
have similar endpoints included in the 90 day studies also. Can the ED relevant endpoints and 
tissues be amended in TG 408 as for TG 407, without going through a full validation process? 
Would a retrospective data analysis help such a process? There are other examples of lower level 
tests where there need to be more consistent revisions in line with updated TGs, and similarly 
there may also such examples in the ecotoxicity TG series.Both the 28 and the 90-day studies 
(OECD TG 407 and OECD TG 408, respectively) are included in level 4 of the OECD Conceptual 
Framework, however, only OECD TG 407 has been updated and validated for the detection of 
endocrine disrupters. To increase the ability for detection of ED effects in OECD TG 408 it is 
recommended to include as mandatory similar endpoints as in OECD TG 407, incl. the current 
optional ED related endpoints. Ref: http://www.cend.dk/rapporter/EDtestingstrategy.pdf A 
feasibility study for minor enhancements of TG 414 (Prenatal Developmental Toxicity Study) with 
ED-relevant endpoints have been proposed by DK and is included on the OECD Workplan. 
Assessment of testosterone levels and anogenital distance (AGD) in male foetuses as well as an 
enhancement with some additional text giving guidance on evaluation of abnormalities of male 
and female genitalia would be relevant.  
61. TG 408: The repeated dose 90-day study TG 408 should in our view be updated to include as 
mandatory similar endpoints as in TG 407, including the currently optional ED related endpoints 
mentioned above.  
62. Repeated dose toxicity has been proposed to update for enhancement. 
63. Senstive, ED-specific endpoints could be added to the indicated assays if doing so does not affect 
the stastical power of the other endpoints. This information should be used to inform AOPs and 
identify key events that could be queried by new or existing in vitro methods. 
One-generation reproduction toxicity study (TG 415) 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination with 
other tests 
64. sensitivity of endpoints is not adequate  
65. Outdated method that does not or hardly measure essential mechanistic parameters, nor does it 
measure all relevant apical endpoints  
66. the current TGs 408, 415, 453, combined repro, and 416 do not contain endocrine-specific 
endpoints and therefore do not inform ED mechanisms of action 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on the 
endocrine system 
67. Does not differentiate 
68. do not contain endocrine-specific endpoints and therefore do not inform ED mechanisms of 
action; As summarised in OECD GD150 with respect to TGs 415 and 416, plus 421 and 422: as 
all the endpoints are apical, it is difficult to discern mechanism of action from [these tests] alone 
69. do not contain endocrine-specific endpoints and therefore do not inform ED mechanisms of action 
• proposals for enhancing them 
70. TG 415 and TG 416: In our view, they should be deleted from the OECD TGs after the adoption of 
TG 443.  
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71. should be deleted, has become redundant and we have better methods available 
72. For TG443, TG 415 and TG 416, these might be improved by addition of tail-bleed sampling to 
assess INSL3 as a new parameter to measure the dynamics of Leydig cell differentiation and 
impacts on the HPG axis. (Insulin-like factor 3 as a monitor of endocrine disruption. Anand-Ivell 
R, Ivell R. Reproduction. 2014.147:R87-95) 
Pubertal development and thyroid function assay in intact juvenile/peripubertal male rats 
(OCSPP 890.1500) 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination with 
other tests 
73. could have a enhanced relevance if they become juvenile toxicity tests assessing effects in the 
critical phase of post-natal development (see Maranghi F, Mantovani A. Targeted toxicological 
testing to investigate the role of endocrine disrupters in puberty disorders. Reproductive 
Toxicology 2012, 33(3):290-6; Fucic A., Mantovani A. Puberty dysregulation and increased risk of 
disease in adult life: possible modes of action. Reproductive Toxicology 2014; 44C:15-22) 
74. not all relevant exposure time windows are included, hormone measurement have wide 
physiological variability and n=15 may or may not provide enough power to determine 
differences 
75. not sensitive 
76. Relevant, for EATS pathways  
77. Many factors can affect age at preputial separation for example body weight/composition. Effects 
that decrease bodyweight gain can effect this endpoint in a non-endocrine mediated pathway 
78. as the animals are exposed during a very critical period of their development sensitive to 
endocrine disruption, this assay is certainly useful and could be updated by adding some 
additional endpoints not yet covered (immune system, …) 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on the 
endocrine system 
79. May not be able to differentiate depending on other effects in the study (i.e. decreased weight 
gain) 
• proposals for enhancing them 
80. The pubertal development assays (males/females) could have a enhanced relevance if they 
become juvenile toxicity tests assessing effects in the critical phase of post-natal development 
(see Maranghi F, Mantovani A. Targeted toxicological testing to investigate the role of endocrine 
disrupters in puberty disorders. Reproductive Toxicology 2012, 33(3):290-6; Fucic A., Mantovani 
A. Puberty dysregulation and increased risk of disease in adult life: possible modes of action. 
Reproductive Toxicology 2014; 44C:15-22) 
Pubertal development and thyroid function assay in intact juvenile/peripubertal female 
rats (OCSPP 890.1450) 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination with 
other tests 
81. could have a enhanced relevance if they become juvenile toxicity tests assessing effects in the 
critical phase of post-natal development (see Maranghi F, Mantovani A. Targeted toxicological 
testing to investigate the role of endocrine disrupters in puberty disorders. Reproductive 
Toxicology 2012, 33(3):290-6; Fucic A., Mantovani A. Puberty dysregulation and increased risk of 
disease in adult life: possible modes of action. Reproductive Toxicology 2014; 44C:15-22) 
82. not all relevant exposure time windows are included, hormone measurement have wide 
physiological variability and n=15 may or may not provide enough power to determine 
differences 
83. not sensitive 
84. Relevant, for EATS pathways  
85. Many factors can affect age at vaginal opening, for example body weight/composition. Effects 
that decrease bodyweight gain can affect this endpoint in a non-endocrine mediated pathway.  
86. as the animals are exposed during a very critical period of their development sensitive to 
endocrine disruption, this assay is certainly useful and could be updated by adding some 
additional endpoints not yet covered (immune system, …) 
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• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on the 
endocrine system 
87. May not be able to differentiate depending on other effects in the study (i.e. decreased weight 
gain) 
• proposals for enhancing them 
88. The pubertal development assays (males/females) could have a enhanced relevance if they 
become juvenile toxicity tests assessing effects in the critical phase of post-natal development 
(see Maranghi F, Mantovani A. Targeted toxicological testing to investigate the role of endocrine 
disrupters in puberty disorders. Reproductive Toxicology 2012, 33(3):290-6; Fucic A., Mantovani 
A. Puberty dysregulation and increased risk of disease in adult life: possible modes of action. 
Reproductive Toxicology 2014; 44C:15-22) 
89. A sensitive, quali and quantitative tool to evaluate endocrine disruptors are the morphometric 
analysis of the uterus, the epididymis and testes (could be applied to any in vivo exposure 
assays). In the uterus, is possible to evaluate the endometrium thickness, diameter and number 
of glands, which are also indicative endpoints related to endocrine disruptors activity (i.e. 
estrogenicity). In males, sperm parameters, testicular and epididymal histo-morphometry are 
very important, informative and could also be applied to any in vivo exposure assays. Plasma 
hormone levels (estradiol, FSH, LH and testosterone) are very relevant and indicative information 
on steroidogenesis and HPG axis in vivo evidence, applied to any assay as well. A suggestion for 
evaluation of these hormones also in adult female animals is important, but the comparison of 
groups can only be between the rats that are in the same cycling period (e.g estrous). 
Testosterone can also be measured in female animals even at very low levels when using the 
radioimmunoassay as the most sensitive and quantifying method. More than one time point of 
collection on the same treatment dose would also reduce the bias of hormonal variation, increase 
the statistical significance and confirm a pattern. Alternatively to the standard Hershberger test 
that adopts surgical male castration, Ashby et al. (2004) and Tinwell et al. (2007) proposed an 
assay lasting 10 days in intact immature weanling rats (submitted to chemical castration with 
testosterone propionate or flutamide) thus avoiding the surgical procedure. With the entire male 
reproductive system intact, this assay can be used for the detection of compounds with 
anti/androgenic activities. Specifically on the pubertal development and thyroid function assay in 
intact juvenile/peripubertal female rats (OCSPP 890.1450), the period of estrous cycling 
evaluation should be higher, especially because, when the females are immature, there are 
differences between species first day of vaginal opening and ovary maturation. Then, the current 
20 days of observation is not enough to proper characterize the days of cycling period into the 
categories proposed. A minimum of more 20 days would be necessary to better evaluate at least 
3-4 complete cycles and establish a correct pattern for this endpoint. Guerra MT, de Toledo FC, 
Kempinas Wde G. In utero and lactational exposure to fenvalerate disrupts reproductive function 
in female rats. Reprod Toxicol 2011; 32:298-303; Weibel ER: Principles and methods for the 
morphometric study of the lung and other organs. Lab Invest 1963, 12(1):131-155; Leblond CP, 
Clermont Y: Spermiogenesis of rat, mouse, hamster and guinea pig as revealed by the periodic 
acid-fuchsin sulfurous acid technique. Am J Anat 1952, 90(2):167-215; Robb GW, Amann RP, 
Killian GJ: Daily sperm production and epididymal sperm reserves of pubertal and adult rats. J 
Reprod Fertil 1978, 54(1):103-107; Ashby J, Lefevre PA, Tinwell H, Odum J, Owens W. 
Testosterone-stimulated weanlings as an alternative to castrated male rats in the Hershberger 
anti-androgen assay. Regul Toxicol Pharmacol 2004; 39:229-38; Tinwell H, Friry-Santini C, 
Rouquie D, Belluco S, Elies L, Pallen C, et al. Evaluation of the antiandrogenic effects of 
flutamide, DDE, and linuron in the weanling rat assay using organ weight, histopathological, and 
proteomic approaches. Toxicol Sci 2007; 100:54-65. 
Combined chronic toxicity / carcinogenicity study (TG 453) 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination with 
other tests 
90. The carcinogenicity endpoint is not diagnostic for most hormonal cancers via a hormonal 
mechanism, such as breast, testis, prostate cancer 
91. the minimal number of animals (rats) for a 2-year combined chronic toxicity and carcinogenicity 
bioassay for a three-dose study (plus the control) performed according to the NTP protocol is 440 
(50 animals per dose group of both sexes, plus 20 animals per sex used as sentinel animals); for 
the OECD TG 453 protocol the minimal number is 480; for the OECD TG443 the minimal number 
is 1200 (Schiffelers et al. 2015) and for the NTP Modified One- Generation Study 3680 animals. 
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Only few endpoints are examined through these experimental plans and further multiple distinct 
experiments are requested to allow a broad-based toxicologic evaluation and more global realistic 
risk assessment. The protocol we proposed reduces/spares animals and resources because the 
main long-term bioassay is integrated into several subsets of toxicity testing using different 
schedules of treatment through planning of interim kills and satellite groups in specific WOS. 
92. sensitivity of endpoints not sufficient, no prenatal exposure 
93. Relevant, although the sensitivity is highly dependent on the strain and species and very limited 
MoA included. Another disadvantage of these tests is that they only measure the effects from let 
us say pubetry to early old age. Early life exposure is not covered.  
94. the current TGs 408, 415, 453, combined repro, and 416 do not contain endocrine-specific 
endpoints and therefore do not inform ED mechanisms of action. 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on the 
endocrine system 
95. Does not differentiate 
96. do not contain endocrine-specific endpoints and therefore do not inform ED mechanisms of action 
• proposals for enhancing them 
97. the minimal number of animals (rats) for a 2-year combined chronic toxicity and carcinogenicity 
bioassay for a three-dose study (plus the control) performed according to the NTP protocol is 440 
(50 animals per dose group of both sexes, plus 20 animals per sex used as sentinel animals); for 
the OECD TG 453 protocol the minimal number is 480; for the OECD TG443 the minimal number 
is 1200 (Schiffelers et al. 2015) and for the NTP Modified One- Generation Study 3680 animals. 
Only few endpoints are examined through these experimental plans and further multiple distinct 
experiments are requested to allow a broad-based toxicologic evaluation and more global realistic 
risk assessment. The protocol we proposed reduces/spares animals and resources because the 
main long-term bioassay is integrated into several subsets of toxicity testing using different 
schedules of treatment through planning of interim kills and satellite groups in specific WOS 
Combined 28 day reproductive screening test (TG 421+422) Note by JRC: these TGs have 
been updated in 2016 to include some endocrine disruptor relevant endpoints 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination with 
other tests 
98. the minimal number of animals (rats) for a 2-year combined chronic toxicity and carcinogenicity 
bioassay for a three-dose study (plus the control) performed according to the NTP protocol is 440 
(50 animals per dose group of both sexes, plus 20 animals per sex used as sentinel animals); for 
the OECD TG 453 protocol the minimal number is 480; for the OECD TG443 the minimal number 
is 1200 (Schiffelers et al. 2015) and for the NTP Modified One- Generation Study 3680 animals. 
Only few endpoints are examined through these experimental plans and further multiple distinct 
experiments are requested to allow a broad-based toxicologic evaluation and more global realistic 
risk assessment. The protocol we proposed reduces/spares animals and resources because the 
main long-term bioassay is integrated into several subsets of toxicity testing using different 
schedules of treatment through planning of interim kills and satellite groups in specific WOS. 
99. exposure period, low number of animals 
100. The relevance has increased after the recent update, although It is stressed that in view of 
the low number of animals and the limited number of parameters the predictive power is still 
poor (only detects very potent substances).But as long as there is no regulatory obligation to 
conduct/provide in vitro screening, this method will provide at least some information on 
potential EDs. It is stressed that a negative outcome does not indicate the substance is not an ED 
(the same applies for TG 407 and 408) 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on the 
endocrine system 
101. Does not differentiate 
102. do not contain endocrine-specific endpoints and therefore do not inform ED mechanisms of 
action; As summarised in OECD GD150 with respect to TGs 415 and 416, plus 421 and 422: as 
all the endpoints are apical, it is difficult to discern mechanism of action from [these tests] alone 
• proposals for enhancing them 
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103. TG 421/422: has just been enhanced with endpoints of ED relevance (adoption and release of 
the revised TGs are foreseen in the autumn) 
104. Senstive, ED-specific endpoints could be added to the indicated assays if doing so does not 
affect the stastical power of the other endpoints. This information should be used to inform AOPs 
and identify key events that could be queried by new or existing in vitro methods. 
Prenatal developmental toxicity study (TG 414) 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination with 
other tests 
105. the minimal number of animals (rats) for a 2-year combined chronic toxicity and 
carcinogenicity bioassay for a three-dose study (plus the control) performed according to the NTP 
protocol is 440 (50 animals per dose group of both sexes, plus 20 animals per sex used as 
sentinel animals); for the OECD TG 453 protocol the minimal number is 480; for the OECD TG443 
the minimal number is 1200 (Schiffelers et al. 2015) and for the NTP Modified One- Generation 
Study 3680 animals. Only few endpoints are examined through these experimental plans and 
further multiple distinct experiments are requested to allow a broad-based toxicologic evaluation 
and more global realistic risk assessment. The protocol we proposed reduces/spares animals and 
resources because the main long-term bioassay is integrated into several subsets of toxicity 
testing using different schedules of treatment through planning of interim kills and satellite 
groups in specific WOS. 
106. will become relevant if enhanced with ED endpoints and this is already on the workplan of 
OECD.  
107. The study does not provide definitive mechanistic information, it does provide information on 
some apical endpoints 
108. Endpoints are apical in nature and could be impacted by non-endocrine active effects. How 
will we determine if that effect is specifically endocrine related? Is it important for human health 
to determine if the effect is specifically endocrine related? 
109. as the development of many systems are not yet achieved at birth in the rat, this assay 
seems us too short to give sufficient information on endocrine disrupting effects 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on the 
endocrine system 
110. DNT test is not sensitive and can only provide ancillary info 
111. Does not differentiate 
• proposals for enhancing them 
112. A feasibility study for minor enhancements of TG 414 (Prenatal Developmental Toxicity 
Study) with ED-relevant endpoints have been proposed by DK and is included on the OECD 
Workplan. Assessment of testosterone levels and anogenital distance (AGD) in male foetuses as 
well as an enhancement with some additional text giving guidance on evaluation of abnormalities 
of male and female genitalia would be relevant. 
113. TG 414: Enhancement is on the OECD TGP workplan with Denmark as lead country. 
114. TG 414, is currently being updated 
115. Senstive, ED-specific endpoints could be added to the indicated assays if doing so does not 
affect the stastical power of the other endpoints. This information should be used to inform AOPs 
and identify key events that could be queried by new or existing in vitro methods 
Developmental neurotoxicity (TG 426) 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination with 
other tests 
116. the minimal number of animals (rats) for a 2-year combined chronic toxicity and 
carcinogenicity bioassay for a three-dose study (plus the control) performed according to the NTP 
protocol is 440 (50 animals per dose group of both sexes, plus 20 animals per sex used as 
sentinel animals); for the OECD TG 453 protocol the minimal number is 480; for the OECD TG443 
the minimal number is 1200 (Schiffelers et al. 2015) and for the NTP Modified One- Generation 
Study 3680 animals. Only few endpoints are examined through these experimental plans and 
further multiple distinct experiments are requested to allow a broad-based toxicologic evaluation 
and more global realistic risk assessment. The protocol we proposed reduces/spares animals and 
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resources because the main long-term bioassay is integrated into several subsets of toxicity 
testing using different schedules of treatment through planning of interim kills and satellite 
groups in specific WOS. 
117. sensitivity of endpoints is not adequate 
118. See previous, no or limited information on MoA but does provide information on specific 
apical endpoints 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on the 
endocrine system 
119. DNT test is not sensitive and can only provide ancillary info 
120. Does not differentiate 
• proposals for enhancing them 
121. TG 426: In our view, this guideline could be enhanced to include some behavioral endpoints 
of relevance for ED effects, such as mating and nursing behavior, since studies of EDs have 
shown gender-related effects on behavior. References: Hass et al., OECD Conceptual Framework 
for Testing and Assessment of Endocrine Disrupters as a basis for regulation of substances with 
endocrine disrupting properties, TemaNord 2004:555, http://www.diva-
portal.org/smash/get/diva2:702046/FULLTEXT01.pdf Hass et al., Information/testing strategy for 
identification of substances with endocrine disrupting properties, Danish Centre on Endocrine 
Disrupters, 2013, http://www.cend.dk/rapporter/EDtestingstrategy.pdf 
122. Senstive, ED-specific endpoints could be added to the indicated assays if doing so does not 
affect the stastical power of the other endpoints. This information should be used to inform AOPs 
and identify key events that could be queried by new or existing in vitro methods. 
Extended one-generation reproductive toxicity study (TG 443) 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination with 
other tests 
123. study is informative for in vivo antiandrogens if anogenital distance and nipple retention is 
inorporated 
124. the minimal number of animals (rats) for a 2-year combined chronic toxicity and 
carcinogenicity bioassay for a three-dose study (plus the control) performed according to the NTP 
protocol is 440 (50 animals per dose group of both sexes, plus 20 animals per sex used as 
sentinel animals); for the OECD TG 453 protocol the minimal number is 480; for the OECD TG443 
the minimal number is 1200 (Schiffelers et al. 2015) and for the NTP Modified One- Generation 
Study 3680 animals. Only few endpoints are examined through these experimental plans and 
further multiple distinct experiments are requested to allow a broad-based toxicologic evaluation 
and more global realistic risk assessment. The protocol we proposed reduces/spares animals and 
resources because the main long-term bioassay is integrated into several subsets of toxicity 
testing using different schedules of treatment through planning of interim kills and satellite 
groups in specific WOS. 
125. period of senescence is not evaluated, recommended 10 animals for hormone measurements 
is too low, number of animals is too low if females not sacrificed in same phase of estrous cycle, 
too high variability. 
126. Highly relevant provided the cohorts 2 and 3 are included 
127. Currently TG 443 is the only protocol that contains sensitive, ED-specific endpoints. 
128. should have both DNT and immunotox cohorts mandatory, as these endpoints are very 
important. 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on the 
endocrine system 
129. During maternal exposure to substances that cause haematological effects (e.g. 
methaemoglobin formation) the parental systemic anaemia could cause reduced number of 
litters, post implantation loss, reduced pups weight, retarded development, etc. Then, to 
distinguish secondary endocrine system impairment, other endocrine disruption endpoints only 
have to be investigated within the above studies. 
130. Does not differentiate 
131. AGD 
132. is the only protocol that contains sensitive, ED-specific endpoints 
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133. Currently TG 443 is the only protocol that contains sensitive, ED-specific endpoints 
• proposals for enhancing them 
134. the minimal number of animals (rats) for a 2-year combined chronic toxicity and 
carcinogenicity bioassay for a three-dose study (plus the control) performed according to the NTP 
protocol is 440 (50 animals per dose group of both sexes, plus 20 animals per sex used as 
sentinel animals); for the OECD TG 453 protocol the minimal number is 480; for the OECD TG443 
the minimal number is 1200 (Schiffelers et al. 2015) and for the NTP Modified One- Generation 
Study 3680 animals. Only few endpoints are examined through these experimental plans and 
further multiple distinct experiments are requested to allow a broad-based toxicologic evaluation 
and more global realistic risk assessment. The protocol we proposed reduces/spares animals and 
resources because the main long-term bioassay is integrated into several subsets of toxicity 
testing using different schedules of treatment through planning of interim kills and satellite 
groups in specific WOS. 
135. Additional endpoints in extended one-generation tests should become mandatory. 
136. TG 443 should include mandatory assessment of mammary gland development (Whole 
mount). The mammary gland is a target of endocrine active substances and evaluation of this in 
some protocols might provide information on developmental abnormalities or adverse outcomes 
not available from other endpoints. The mammary gland whole mount has been proposed as a 
more powerful method to evaluate organizational effects during development. 
137. TG 443: In our view, this guideline should be enhanced to include investigation of mammary 
gland development, since the mammary gland is a target of endocrine active substances and 
evaluation of this in some protocols might provide information on developmental abnormalities or 
adverse outcomes not available from other endpoints. The mammary gland whole mount has 
been proposed as a more powerful method to evaluate organizational effects during 
development. We are pleased that this particular investigation has been requested in a couple of 
relevant recent substance evaluation decisions under REACH and we are of the opinion that the 
same approach should be used in similar future cases.  
138. For TG443, TG 415 and TG 416, these might be improved by addition of tail-bleed sampling 
to assess INSL3 as a new parameter to measure the dynamics of Leydig cell differentiation and 
impacts on the HPG axis. (Insulin-like factor 3 as a monitor of endocrine disruption. Anand-Ivell 
R, Ivell R. Reproduction. 2014.147:R87-95) 
Two-generation reproduction toxicity study (TG 416) 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination with 
other tests 
139. lack of relevant endocrine endpoints 
140. the minimal number of animals (rats) for a 2-year combined chronic toxicity and 
carcinogenicity bioassay for a three-dose study (plus the control) performed according to the NTP 
protocol is 440 (50 animals per dose group of both sexes, plus 20 animals per sex used as 
sentinel animals); for the OECD TG 453 protocol the minimal number is 480; for the OECD TG443 
the minimal number is 1200 (Schiffelers et al. 2015) and for the NTP Modified One- Generation 
Study 3680 animals. Only few endpoints are examined through these experimental plans and 
further multiple distinct experiments are requested to allow a broad-based toxicologic evaluation 
and more global realistic risk assessment. The protocol we proposed reduces/spares animals and 
resources because the main long-term bioassay is integrated into several subsets of toxicity 
testing using different schedules of treatment through planning of interim kills and satellite 
groups in specific WOS. 
141. low number of animals particularly for hormone measurements  
142. Less relevant than TG443, because less ED parameters are included, less apical endpoints 
and it uses more animals 
143. Endpoints are apical in nature and could be impacted by non-endocrine active effects. How 
will we determine if that effect is specifically endocrine related? Is it important for human health 
to determine if the effect is specifically endocrine related? 
144. the extended one-generation reproductive toxicity study is to be preferred for ED relevant 
endpoints 
145. the current TGs 408, 415, 453, combined repro, and 416 do not contain endocrine-specific 
endpoints and therefore do not inform ED mechanisms of action. 
146. does not contain endocrine-specific endpoints and therefore do not inform ED mechanisms of 
action. 
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• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on the 
endocrine system 
147. TG 407, 408, 416 lack of endocrine specific endpoints 
148. During maternal exposure to substances that cause haematological effects (e.g. 
methaemoglobin formation) the parental systemic anaemia could cause reduced number of 
litters, post implantation loss, reduced pups weight, retarded development, etc. Then, to 
distinguish secondary endocrine system impairment, other endocrine disruption endpoints only 
have to be investigated within the above studies. 
149. Does not differentiate 
150. do not contain endocrine-specific endpoints and therefore do not inform ED mechanisms of 
action; As summarised in OECD GD150 with respect to TGs 415 and 416, plus 421 and 422: as 
all the endpoints are apical, it is difficult to discern mechanism of action from [these tests] alone 
151. do not contain endocrine-specific endpoints and therefore do not inform ED mechanisms of 
action 
• proposals for enhancing them 
152. TG 415 and TG 416: In our view, they should be deleted from the OECD TGs after the 
adoption of TG 443.  
153. TG 415 and TG 416: In our view, they should be deleted from the OECD TGs after the 
adoption of TG 443.  
154. TG 416, as for the one generation toxicity study, deletion should be considered in view of the 
fact that new methods have become available (TG 443) 
155. For TG443, TG 415 and TG 416, these might be improved by addition of tail-bleed sampling 
to assess INSL3 as a new parameter to measure the dynamics of Leydig cell differentiation and 
impacts on the HPG axis. (Insulin-like factor 3 as a monitor of endocrine disruption. Anand-Ivell 
R, Ivell R. Reproduction. 2014.147:R87-95) 
156. TG 416 should be updated wtih endpoints that are in the EOGRTS - at a stroke. 
 
Experts were further asked to mention existing additional mammalian in vivo studies that 
could add value and should be further considered (F.B.8). The only proposal received 
was "The NTP guidelines enhances the sensitivity for some EDs-related endpoints". 
 
Table 42: Expert proposals for the development of new mammalian in vivo studies to better 
identify endocrine disrupting substances (free text comments to question "Apart from what was 
addressed above, do you see a need for developing new mammalian in vivo tests to better identify 
endocrine disrupting substances? Will there be added value from such new tests from a regulatory 
perspective?" (F.B.9)). 
1. No -rather than developing new tests, need to think how to enchance existing ones 
2. A comprehensive juvenile toxicity test would be of paramount importance for hazard 
charactrerization in the post-natal window, from weaning through to pubertuy and sexual 
maturation 
3. yes, if standardized 
4. Efforts should be made to overcome the fact that we have no current studies that cover the full 
Life cycle (exposure in utero - late effects) 
5. See response to DA7. 
6. In general, in order to address which in vivo tests to possibly develop, it might be feasible to 
consider development of AOPs as the first step to get an overview of the biological 
understanding, and target MIEs, KEs and AOs with development of promising in vivo tests. 
7. Yes, for instance methods aimed at the metabolic disorders, immune function etc. 
8. Most in vivo tests use rodents, and consequently their relevance can be called into question, 
besides issues of high variance, hence large and ethically questionable animal usage. 
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9. New apical mammalian studies would continue to present similar interpretive difficulties as 
existing tests with respect to distinguishing endocrine-mediated from other effects, unraveling 
significant effects from homeostatic responses, and translating conclusions across species, where 
underlying mechanisms continue to be poorly understood. In view of this, and considering 
resource limitations, developing additional mammalian in vivo tests will contribute less to our 
ability to identify endocrine disruptors than assays supplying mechanistic information and efforts 
to arrange this into predictive AOPs. 
 
 
JRC Summary of the comments in free text fields of Questions F.B regarding 
mammalian in vivo TMs 
The replies indicate that most of the available mammalian in vivo assays do not contain 
endocrine-specific endpoints and therefore do not inform ED mechanisms of action. The 
extended one-generation reproductive toxicity study (TG 443) is to be preferred for ED 
relevant endpoints.  Usually a combination of tests is needed for diagnostic purposes - 
TG 443 being the most diagnostic, although the Uterotrophic (TG 440) and Hershberger 
(TG 441) assays in intact animals could also be diagnostic. Others considered that the 
current Uterotrophic and Hershberger assays were quite insensitive and limited in scope. 
Some experts indicated that adding more endpoints (e.g. gene expression) could improve 
the value of these assays. Some considered that in vitro ER/AR transactivation assays 
are mostly providing the information needed and that it might be possible to replace 
them by in vitro assessments referring to recent publications on this from US EPA and 
NIH. 
It was also stated that data generated from TGs 440, 441 and the male and female 
pubertal development assays are heavily influenced by the general state of the animal, 
consequently it is sometimes difficult to interpret the data and to differentiate the effects 
due to general toxicity from those due to ED. The pubertal and thyroid function assays in 
male and female rats were considered to have issue of non-specificity since many factors 
could affect age of preputial separation and vaginal opening in males and females 
respectively. Other experts indicated that the tests could have an enhanced relevance if 
they become juvenile toxicity tests assessing effects in the critical phase of post-natal 
development.  
The combined carcinogenicity bioassay TG 453 was considered not diagnostic for most 
hormonal cancers via a hormonal mechanism, such as breast, testis, prostate cancer and 
early life stage exposure was not included  
 
Both the 28 and the 90-day studies (OECD TG 407 and OECD TG 408, respectively) were 
considered to have severe limitations due to lack of (mandatory) endocrine specific 
endpoints and to lack of exposure during sensitive windows of development. Although 
OECD TG 407 has been updated and validated for the detection of endocrine disrupters 
(including weight of uterus and ovaries, oestrus cyclicity, histopathological changes in 
mammary glands and pituitary and circulating levels of T3, T4 and TSH) these endpoints 
are only optional. Some experts consider that these endpoints should be made 
mandatory others indicate that the additional endpoints have been shown to be relatively 
insensitive and therefore of limited utility. However, to increase the ability for detection 
of ED effects in OECD TG 408 it was recommended to include as mandatory the current 
optional ED related endpoints from TG 407. The proposal on the OECD workplan from 
Denmark for a feasibility study for minor enhancements of TG 414 (Prenatal 
Developmental Toxicity Study) with ED-relevant endpoints was also highlighted. 
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General comments in relation to proposals for enhancement of existing test guidelines: 
varied from: 
— all TGs should be upgraded with new ED-endpoints once they are validated for one in 
vivo test,  
— enhancing may be useful where sufficient data are available for validation with regard 
to reliability and relevance, but not a high priority,  
— enhancements supported as an interim measure until pathways are better understood 
— sensitive ED-specific endpoints could be added to indicated assays if doing so did not 
affect the statistical power of the other endpoints.  
Generated mechanistic information from the enhancements should be used to inform 
AOPs and identify key events that can be targeted by new or existing in vitro methods. 
 
Specific proposals for enhancement of TG 443 included investigation of mammary gland 
development and addition of tail-bleed sampling to assess INSL3 (as a new parameter to 
measure the dynamics of Leydig cell differentiation and impacts on the HPG axis). 
 
3.5.3 Non-mammalian vertebrate in vivo studies (F.C) 
 
In section F.C of the survey, experts were asked to: 
● rate the non-mammalian in vivo studies of the OECD CF regarding their relevance 
considering their diagnostic value to detect endocrine related perturbations (F.C.1, 
Figure 16) 
● comment on the diagnostic value to detect endocrine related perturbations (F.C.2 
and F.C.3, Table 43) 
● comment on the TMs concerning their ability to distinguish endocrine effects from 
general toxicity and indirect effects on the endocrine system (F.C.4 and 
F.C.5,Table 43) 
● propose relevant enhancements of non-mammalian vertebrate in vivo TMs (F.C.6 
and F.C.7, Table 43) 
● add any additional comment on the non-mammalian vertebrate in vivo TMs within 
the OECD CF (F.C.8, Table 44) 
● mention additional existing non-mammalian vertebrate in vivo TMs for 
consideration (F.C.9, Table 45) 
● propose the development of new non-mammalian vertebrate in vivo studies to 
better identify endocrine disrupting substances considering the added value from 
regulatory perspective (F.C.9, Table 46). 
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Figure 16: Replies of experts to question F.C.1: Please rate the non-mammalian vertebrate in vivo 
studies below regarding their relevance considering their diagnostic value to detect endocrine 
related perturbations in the test alone or in combination with other tests. (Note: The percentage of 
experts not replying or answering "don’t know" was 42-70 %.)  
(Abbreviations: AMA=amphibian metamorphosis assay; FSTRA=fish short term reproduction assay; FSDT=fish 
sexual development test; AFSS=androgenised female stickleback screen; LAGDA=larval amphibian growth and 
development assay; XETA=xenopus embryonic thyroid signalling assay; MEOGRT=medaka extended one 
generation reproduction test; EASZY=detection of endocrine active substances, acting through estrogen 
receptors, using transgenic cyp19ab-GFP zebrafish embryos; FRPLT=fish reproduction partial life cycle test; 
FLCTT=fish life cycle toxicity test; ATGT= Avian two generation test.) 
Table 43: Expert comments on non-mammalian vertebrate in vivo studies regarding (1) their 
diagnostic value to detect endocrine related perturbations in the TM alone or in combination with 
other tests (F.C.2/3), (2) regarding the TM ability to distinguish endocrine related effects from 
general toxicity or indirect effects on the endocrine system (F.C.4/5), (3) proposing enhancements 
to the TMs (F.C.6/7). 
General comments: 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination 
with other tests 
1. We note that you use the wording perturbations, not adverse effects and MoA respectively. 
This might confuse the reader and the responses. Some of the assays provide information 
regarding MoA, others provide information regarding adverse outcomes. Both are relevant for 
assessing endocrine disruption. Most definitive /conclusive are assays which are at the 
highest tier of the OECD Conceptual Framework for endocrine disruption and which provide 
information about both endocrine activity and adverse effects, like the Fish Sexual 
Development test (TG 234) or The Enhanced One Generation Reproductive Toxicity Test (TG 
443). 
2. a) Both fish and amphibian tests could identify endocrine MOAs. These tests, however, focus 
only on EATS pathways. The diagnostic value of these tests is limited in terms of other 
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pathways. b) The aforementioned tests may produce false positive or negative results due to 
factors like concentrations, stress responses etc. The diagnostic value of a single test alone 
may be limited. Weight of evidence approach for taking all tests into account is important. c) 
Some tests like TG230 and the EASZY have only a diagnostic value and cannot be used for 
risk assessment. Other tests like TG229, 234 etc can be used for both MOAs and for adverse 
effects. Due to the complexity of these assays, there is a need for developing guidance 
documents for the interpretation of these assay results in the context of identification, 
classification and risk assessment of EDCs. 
3. Ecotoxicity studies are conducted to assess the safety to the environment of the substance 
under investigation. Therefore apical endpoints related to the protection goal (populations) 
are most relevant. No test in isolation is capable of identifying a potential endocrine 
disrupter. Therefore the relevance of a given test is compound specific and depends on the 
outcome of other mechanistic or apical studies. 
4. There is a need for an extended one-generation reproduction test with other species, e.g. 
Danio rerio. 
5. The fish and amphibian tests indicated include endpoints that are fairly specific and sensitive 
to EDC. 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on 
the endocrine system 
6. In many cases it is not possible to answer clearly yes or no to this question. In some cases 
the assays will allow to distinguish, in other cases they will not. It depends on the substance 
and which other MoAs/AOPs it acts through. 
7. Some modification of the existing test protocols like carefully choosing test concentrations, 
extra sampling points, extra endpoints, etc may be needed. Stress responses may confound 
the diagnostic value of the tests. Extra controls or in vitro results may be used to clarify the 
uncertainties. 
8. None of the above mentioned tests in isolation is capable of distinguishing endocrine 
disrupting effects from general toxicity or indirect effects on the endocrine system. 
9. They could with further exploratory work, which would also be applicable to mammalian 
hazard assessment. 
• proposals for enhancing them 
10. METiCx consortium proposals. 
AMPHIBIAN 
Amphibian metamorphosis assay (AMA, TG 231) 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination 
with other tests 
11. With exception of thyroid pathology the other endpoints are non-specific growth 
measurement 
12. Both the AMA and XETA provide very good diagnostic input for disruption of the thyroid axis 
at any level (metabolism/ distribution/ thyroid gland function). 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on 
the endocrine system 
13. not designed to detect general toxicity 
• proposals for enhancing them 
- 
Larval amphibian growth and development assay (LAGDA) – Note by JRC: since July 2015 
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OECD TG 241 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination 
with other tests 
14. LAGDA is useful, but misses out the important reproductive stage of the amphibian lifecycle 
15. XETA and LAGDA assays are performed in FETAX medium that is lacking iodine. Effects of 
sodium-iodide symporter inhibitors might be overestimated when iodine is not present in the 
exposure medium. (Note by JRC: the XETA under validation is no longer using FETAX 
medium; LAGDA uses water) 
16. limited validation of LAGDA and MEOGRTS, see summary record of WNT 2015 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on 
the endocrine system 
17. It is possible to use assays like TG234, LAGDA etc to distinguish endocrine MOAs from 
general toxicity. 
• proposals for enhancing them 
18. An amphibian model is needed which provides a practical option for conducting full lifecycle 
tests 
Xenopus embryonic thyroid signalling assay (XETA) (ongoing validation) 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination 
with other tests 
19. dynamic range appears to be limited 
20. Both the AMA and XETA provide very good diagnostic input for disruption of the thyroid axis 
at any level (metabolism/ distribution/ thyroid gland function). 
21. XETA and LAGDA assays are performed in FETAX medium that is lacking iodine. Effects of 
sodium-iodide symporter inhibitors might be overestimated when iodine is not present in the 
exposure medium. (Note by JRC: the XETA under validation is no longer using FETAX 
medium; LAGDA uses water) 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on 
the endocrine system 
22. not designed to detect general toxicity 
• proposals for enhancing them 
23. The XETA test could be enhanced in three prinicpal ways: (i) incorporation of a second 
fluorescent marker providing more precise readout of thyroid gland activity (eg NIS reporter), 
(ii) investment in robotisation methods to enable high throughput screening (iii) modulation 
of test conditions (eg use of low iodide) to optimise detection of certain chemical categories. 
FISH 
Fish short term reproduction assay (FSTRA, TG 229) 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination 
with other tests 
- 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on 
the endocrine system 
- 
• proposals for enhancing them 
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24. A combination of TG 229 and TG 234 would cover all relevant life stages and be diagnostic 
(identifying ED in the environment) 
25. TG229 should be enhanced to be used for both screening and testing. The current protocol 
with three concentrations can only be used as a screening assay. Due to such a design, this 
assay cannot be used to derive a NOEC for risk assessment. As fecundity is an important 
reproduction parameter, enhancing this test by an inclusion of 5 test concentrations is 
important. 
21-day fish assay (TG 230) 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination 
with other tests 
- 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on 
the endocrine system 
26. not designed to detect general toxicity 
• proposals for enhancing them 
- 
Fish sexual development test (FSDT, TG 234) 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination 
with other tests 
27. There remains a question regarding the FSDT (OECD TG 234) with regard to how a significant 
result is determined (methods of statistical analysis when using ratios) and what degree 
perturbation of sex ratio of offspring is needed before an outcome can be considered an 
apical effect (although any significant change in sex ratio can indicate endocrine disruption 
per se). 
28. TG 234 is the fish test with population relevance which is cheapest, shortest and uses least 
animals 
29. … there are assays which provide information about both endocrine activity and adverse 
effects, like the Fish Sexual Development test (TG 234) …. (Note JRC: extracted from reply 1 
under general) 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on 
the endocrine system 
30. It is possible to use assays like TG234, LAGDA etc to distinguish endocrine MOAs from 
general toxicity. 
• proposals for enhancing them 
31. A combination of TG 229 and TG 234 would cover all relevant life stages and be diagnostic 
(identifying ED in the environment). 
Androgenised female stickleback screen (AFSS, GD 140) 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination 
with other tests 
32. This should be a full TG as it is superior to the Hershberger assay; the way I view it if spiggin 
was present in zebrafish or fathead minnow this test should have been a TG; because it is 
normally expressed only in the stickleback is a GD; this make no scientific sense. 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on 
the endocrine system 
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33. not designed to detect general toxicity 
• proposals for enhancing them 
34. The AFSS can be improved in terms of the 3Rs by incorporating the transgenic fish model 
(spiggin medaka) as a screen 
Medaka extended one-generation reproduction test (MEOGRT) –  Note by JRC: since July 
2015 OECD TG 240 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination 
with other tests 
35. limited validation of LAGDA and MEOGRTS, see summary record of WNT 2015 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on 
the endocrine system 
- 
• proposals for enhancing them 
36. as noted under F.C.3 there is a need for an extended one-generation reproduction test with 
other species, e.g. Danio rerio. 
Detection of endocrine active substances, acting through estrogen receptors, using 
transgenic cyp19a1b-GFP zebrafish embryos (EASZY) (ongoing validation) 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination 
with other tests 
- 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on 
the endocrine system 
37. not designed to detect general toxicity 
• proposals for enhancing them 
- 
Fish reproduction partial lifecycle test (FRPLT) 
• no replies 
Fish life cycle toxicity test (FLCTT)  
• diagnostic value to detect endocrine related perturbations in this test alone or in combination 
with other tests 
- 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on 
the endocrine system 
38. TG 206 and FLCTT - lack of endocrine specific endpoints (2x) 
• proposals for enhancing them 
39. A combination of TG 229 and TG 234 would cover all relevant life stages and be diagnostic 
(identifying ED in the environment) 
BIRDS 
Avian reproduction test (TG 206) 
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• diagnostic value to detect endocrine related perturbations in this test alone or in combination 
with other tests 
40. TG 206 has limited diagnostic value as it is relatively short-term. 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on 
the endocrine system 
41. TG 206 and FLCTT - lack of endocrine specific endpoints  
42. not designed to distinguish endocrine effects from general toxicity since no specific endocrine 
endpoints are evaluated in this test. 
43. I am not sure if this test allows to clearly distinguish ED from general toxicity. 
44. TG 206 currently contains only apical endpoints which do not solely respond to EDs; some of 
the endpoints are potentially affected by EDs. 
45. The two avian tests cannot distinguish ED modes of action. 
• proposals for enhancing them 
46. I recommend that a research programme be set up with the aim of developing an optimized, 
targeted approach to protecting birds against endocrine disrupters which leave room for 
reconsideration and possible adaptation of the current avian tests. This research programme 
will address the following three questions: 1) Which core characteristics (traits) make birds 
unique in their potential responses to (certain) endocrine disrupting chemicals. 2) Which 
MOAs (modes of action) and associated specific endpoints give rise to effects in birds that 
would not be seen in mammals or other taxa. 3) Which targeted, step-wise in vitro and small 
scale in vivo protocols should be developed to specifically address these differences between 
birds and other taxa. The resulting thesis project will provide the following four deliverables; 
Filling the data gap of fundamental differences between birds and other taxa which would 
make it necessary to establish the risk of endocrine disruptors to birds as well. b) A 
comprehensive testing approach that will allow the regulatory process to protect birds from 
endocrine disruptors with optimal use of resources including minimal animal testing. c) The 
development of more dedicated, specific mechanism-based in vitro and in vivo assays, to be 
able to provide no more and no less information than is needed based on the information 
already available for a compound. d) Reduction of animal use according to the 3Rs (Note 
JRC: this reply was also given to Avian two-generation test (ATGT)). 
Avian two-generation test (ATGT) 
• diagnostic value to detect endocrine related perturbations in this test alone or in combination 
with other tests 
47. Avian two-Generation test: It has not been sufficiently established in the validation process to 
date that this study is sensitive and focused enough to identify unequivocal endocrine effects 
in birds that would not be revealed in mammalian test systems. In the validation study of the 
Japanese quail two-generation study there were no substantial responses in Japanese Quail 
in any of the inter-laboratory tests performed with a known endocrine disrupting compound, 
vinclozoline (EPA Report, May 2013). Furthermore because of the lack of response it is 
difficult to differentiate test endpoints which are sensitive and informative from those which 
are not. 
• allow to distinguish endocrine disrupting effects from general toxicity or indirect effects on 
the endocrine system 
48. See TG 206 
• proposals for enhancing them 
49. See TG 206 
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Table 44: Expert other comments on non-mammalian vertebrate tests in the OECD CF (F.C.8)  
1. The very limited validation of the LAGDA and MEOGRTS were discussed at the last OECD WNT 
meeting and introduced in the introduction of the TG. Also the difficulties to build up historical 
control databases for such complex, expensive animal testing methods was discussed, which 
is further complicated by the fact that there is no OECD agreement yet on a single or limited 
number of fish species to be used for testing. This reflects the general difficulties with the 
validation of complex, expensive animal tests and consequently with the reliance on such 
complex animal tests for regulation. 
2. In our view, the current ED CF (Conceptual Framework); GD 150 (Guidance Document On 
Standardised Test Guidelines For Evaluating Chemicals For Endocrine Disruption) should be 
supplemented with some general recommendations in testing strategies to consider ED 
activity/related effects across species. Currently, in vitro screens are relevant for effects in 
humans and vertebrate wildlife because many of them are based on highly conserved 
hormone receptors or interaction with key enzymes or other key molecules involved in the 
regulation of hormone levels in all vertebrates. Chemicals that bind to these receptors or 
otherwise interfere with key processes of hormone regulation have the potential to cause 
adverse effects in vivo both in non-mammalian vertebrate species and mammalian species 
(including wildlife species and humans). A novel paper concludes that when comparing data 
from fish and rat assays, a high concordance was seen with respect to identifying chemicals 
that impacted specific endocrine pathways of concern (Ankley and Gray, 2013). Although 
most chemicals were detected as positive in both the rat and fish assays, eliminating data 
from one class of vertebrate would weaken the battery. For example, the effects of 
competitive inhibitors of steroid hormone synthesis were far more obvious in the fish assay, 
whereas the activity of androgen receptor antagonists was clearer in mammalian assays 
(Ankley and Gray, 2013). Due to the similarities between different vertebrate species it seems 
to be relevant to consider ED related concerns identified in one species (e.g. in fish or 
amphibians) as of potential relevance for other species (such as rat or humans); in particular 
in cases when no or only limited data is available for the latter mentioned species. The current 
ED Conceptual Framework and Guidance Document do not at the higher levels (from level 3 
and onwards) reflect this adequately. Instead the current approach is that "human health 
concerns" are covered by rat /rodent TGs/data only, whereas environment by those available 
on fish, amphibian/birds and to some extent invertebrate data only (It is as far as we know 
currently concluded that the endocrine system of invertebrates - besides perhaps ecdysone 
system in insects- is not well enough known to be able to establish links between hormone 
activity and adverse effects indisputably). In our view, this needs further discussion e.g. of 
the need for supplementing the current Conceptual Framework or GD 150 with some (more) 
considerations: concerns in e.g. fish for estrogenicity or thyroid effects in amphibians and 
absence / or clear limitations in availability of relevant data in rodents does in our view give 
concerns for potential effects in mammalians (e.g. rat and humans) and vice versa. Currently 
TGs with rodents are typically only regarded as relevant for human health. But, as already 
mentioned at OECD EDTA meetings and in recent discussions in the REACH Member State 
Committees concerning substance evaluation cases and nomination proposals for the 
candidate list, rodent data should be considered in relation to humans health as well as for 
mammalian wildlife with respect to information regarding endocrine disruption.  
3. When evaluating the potential for a substance to act as an ED in the environment an adverse 
effect with negative consequences on the population must be demonstrated. Several of the 
above non-mammalian test include endpoints that, while may be useful in a weight-of-
evidence approach, do not in and of themselves demonstrate adverse impacts (e.g. VTG 
induction). Thus, when evaluating adverse population effects, higher priority should be placed 
on those studies that directly measure fertility, fecundity and/or reproduction. Additionally, in 
assays which require aqueous exposures care should be taken to ensure environmentally 
relevant test concentrations. 
4. See avian tests above: proposed research programme with the aim of developing an 
optimized, targeted approach to protection birds against endocrine disrupters which leave 
room for reconsideration and possible adaptation of the current avian tests. 
5. General remark: A number of endocrine modes of action (e.g. effects on the corticosteroid 
system and on the endocrine control of neural development will most likely not be detected 
with the available fish screening tests. If aquatic vertebrates shall be protected from all 
adverse endocrine effects, this is a shortcoming of the current testing framework. Concerning 
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fish tests: Based on reviews and the evaluation of a number of studies it is concluded that 
effects on indicative and / or apical endpoints of fish screening tests and the fish full life-cycle 
test are generally at least as sensitive as effects on fish reproductive behaviour that are 
evaluated in current standard test (see sections 2.5.1 and 3 of UBA report). Thus, there is a 
low risk that significant effects of sexual endocrine disruptors on fish are missed, if the 
assessment of endocrine effects is based on the tiered testing strategy as included in 
Appendix 7.8-5 of R.7b (ECHA 2008a). Effects on spermatogenesis and oogenesis, i.e. non-
standard endpoints, exhibited a particularly high sensitivity to bisphenol A, especially for 
trout. The LOEC derived for effects of bisphenol A on sperm density and sperm motility in 
brown trout. - the endpoint is often delayed maturity of sperma, meaing fish can only 
reproduce later, therefore this is a population relevant endpoint. Similar effects were seen 
with alcylphenoles (here seasonal spawning fish were affected more than frequent spawners 
like medaka. Concerning ATGT: From a regulatory point of view, it should be preferred to gain 
evidence of endocrine disrupting properties in non-mammalian vertebrates from enhanced 
one-generation tests and make full use of the information that could be obtained from these 
rather than leaving too many questions open to be answered by a two-generation test. 
 
Table 45: Expert comments regarding additional non-mammalian vertebrate in vivo TMs (free text 
comments to question " Apart from what was addressed above, are you aware of any existing 
additional non-mammalian vertebrate in vivo test that could add value and should be further 
considered?" (F.C.9)). 
1. Numerous fluorescent fish embryo based tests are being developed for all the major 
endocrine axis. 
2. The OECD CF did not include fish long term toxicity tests required by REACH and BPR (biocidal 
product regulation). These tests include fish early life stage test (TG210), fish Short-term 
Toxicity Test on Embryo and Sac-fry Stages (TG212) and fish juvenile growth test (TG215). 
These tests may have limited diagnostic value but can indicate the adverse effects, which is 
important for identification, classification and risk assessment of EDCs. Specifically, TG210 is 
requested by various pieces of EU legislation including REACH, PPPR, BPR, Regulations for 
veterinary and human pharmaceuticals, and Regulation for the feed additives. It is suggested 
that at least TG210 should be included in the OECD CF. 
3. See avian tests above: proposed research programme with the aim of developing an 
optimized, targeted approach to protection birds against endocrine disrupters which leave 
room for reconsideration and possible adaptation of the current avian tests. 
 
Table 46: Expert proposals for the development of new non-mammalian vertebrate in vivo studies 
to better identify endocrine disrupting substances (free text comments to question " Apart from 
what was addressed above, do you see a need for developing new non-mammalian vertebrate in 
vivo tests to better assess endocrine disrupting substances? Will there be added value from such 
new tests from a regulatory perspective?" (F.C.10)). 
1. Efforts should be made to overcome the fact that we have no current studies that cover the 
full Life cycle (exposure embryo/fetal stage - late effects) 
2. Many of these fluorescent fish embryo based tests will provide added value from a regulatory 
point of view. 
3. In general, in order to address which in vivo tests to possibly develop, it might be feasible to 
consider development of AOPs as the first step, and target MIEs, KEs and AOs with 
development of promising in vivo tests. 
4. Yes. For example, the fish test method for addressing the HPA axis is currently under 
development. Zebrafish has been used for studying bone disorders and obesity. Such fish 
models are of high value for regulating EDs. 
5. Most of the chronic toxicity and ecotoxicity studies do not match typical exposure scenarios 
for crop protection chemicals. While in the toxicity studies exposure is kept constant, 
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exposure of organisms in the field is short-term and maybe repeated. Therefore such test 
designs could help to elucidate whether unacceptable endocrine disrupting effects could occur 
under relevant field conditions. 
6. See avian tests above: proposed research programme with the aim of developing an 
optimized, targeted approach to protection birds against endocrine disrupters which leave 
room for reconsideration and possible adaptation of the current avian tests. 
7. It may be necessary to develop new tests with regard to MoAs other than EATS (for example 
stress response, PPAR, Vitamin D and so on) with further knowledge it may be necessary to 
develop test for other species (birds, reptiles) or add relevant species to existing TGs 
8.  …they can be used for exploratory work to identify key biomarkers applicable to current TGs.  
9. Please see comments under F.B.9 - also applies here: New apical mammalian studies would 
continue to present similar interpretive difficulties as existing tests with respect to 
distinguishing endocrine-mediated from other effects, unraveling significant effects from 
homeostatic responses, and translating conclusions across species, where underlying 
mechanisms continue to be poorly understood. In view of this, and considering resource 
limitations, developing additional mammalian in vivo tests will contribute less to our ability to 
identify endocrine disruptors than assays supplying mechanistic information and efforts to 
arrange this into predictive AOPs. (Note JRC: copied from F.B.9) 
 
JRC Summary of the comments in free text fields of Question F.C.2-F.C.10 
regarding non-mammalian vertebrate TMs 
Birds 
There is agreement that neither the avian reproduction assay (OECD TG206) nor the 
avian two generation assay are diagnostic for ED or can distinguish ED effects from 
general toxicity effects. Research is proposed which would address ED MoAs specific for 
birds and not be found with any other assay, e.g. mammalian. 
 
Amphibian 
Current amphibian tests (AMA, LAGDA, XETA [ongoing validation]) are diagnostic for "T". 
With the LAGDA it is possible to distinguish ED effects from general toxicity effects, 
however, it does not cover reproduction and there is limited experience with the LAGDA.  
 
Fish 
There is agreement that current fish tests are diagnostic for EAS. Tests like TG234 or 
MEOGRT (TG 240) are able to distinguish ED effects from general toxicity effects. 
Combination of TG229 and TG234 is considered of added value, since this would cover all 
relevant life stages and be diagnostic (identifying ED in the environment). 
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3.5.4 Invertebrate test methods (F.D) 
In section F.D of the survey, experts were asked to: 
● comment on invertebrate tests in the OECD CF regarding e.g. their usefulness for 
endocrine disruptor identification, technical performance, weaknesses and 
limitations, regulatory acceptance, etc. (F.D.1/2, Table 47) 
● mention additional existing invertebrate TMs for consideration (F.D.3, Table 45) 
● propose the development of new invertebrate studies to better identify endocrine 
disrupting substances considering the added value from regulatory perspective 
(F.D.4,Table 48). 
 
Table 47: Expert comments on invertebrate studies in the OECD CF (free text comments to 
question "Do you have any comments on any invertebrate test from the OECD CF (e.g. usefulness 
of test for endocrine disruptor identification, comments on technical performance, weaknesses and 
limitations, regulatory acceptance, etc.)? (F.D.1/2) 
General comments 
1. More research is needed in relation to Development of endocrine specific endpoints in 
molluscs (and other invertebrates)  
2. Most of these assays are useful apical tests, but none have diagnostic value. 
3. Due to the limited knowledge in endocrinology of invertebrates, the diagnostic value of the 
above tests is rather poor and for most tests, hardly known. The current development of 
mollusc toxicity test, for example did not include any diagnostic endpoints. These tests are 
often used for detecting adverse effects but not for MOAs . Test methods with diagnostic 
value should be further developed. 
4. The majority of invertebrate tests has the reproductive output as its only ED-relevant 
endpoint. Without additional endpoints like sex ratio or intersex, and in particular endpoints 
that can link the reproductive output to a specific MoA, these tests will be difficult to use for 
ED identification and have only limited diagnostic value. Effects may not be clearly 
distinguishable from general toxicity. Only the three marked tests (Note JRC: Mysid life cycle 
toxicity test; Copepod reproduction and development test;Sediment water Chironomid life 
cycle toxicity test (TG 233)) allow the conclusion of ED activity. The existing invertebrate tests 
should be enhanced with biomarkers for ED MoAs were possible to be of more use in a 
regulatory context. Furthermore, in vitro test should be developed for relevant invertebrate 
MoAs. 
5. Invertebrate tests will be needed for regulatory environmental risk assessment (e.g. REACH, 
pharmaceuticals). None of the tests mentioned above allow to distinguish between systemic 
toxicity and endocrine related effects. Thus they are not useful at the moment for the 
identification of EDs. UBA published a scientific report on an Evaluation of uncertainties in the 
environmental risk assessment of endocrine active substances (submitted separately, 
especially chapter 5 is of relevance here). That report states that it should be noted that the 
apical endpoints of such life-cycle tests allow the identification of adverse effects of EDCs, but 
do not provide causal evidence of an endocrine mode of action (OECD 2006a, 2010a, LeBlanc 
2007). In order to unequivocally identify endocrine disruption as the underlying mode of 
action, specific diagnostic endpoints are required. However, considerable gaps in the 
knowledge on endocrine system of most invertebrate taxa with the exception of insects, 
crustaceans (DeFur et al. 1999b, IPCS 2002) and, partly, gastropods hamper the 
identification and development of appropriate diagnostic endpoints (see sections 2.1.5 and 
2.2.6 of the report). As emphasised for example by Soin & Smagghe (2007), more research is 
needed in most cases to allow a mechanistic understanding of the relationship between the 
mechanism of action of the substance and the adverse effect in invertebrates. The specificities 
in invertebrate endocrinology (e.g. the importance of ecdysteroids and terpenoids) are likely 
to result in specific susceptibilities to endocrine disrupting chemicals (IPCS 2002). In 
combination with the fact that invertebrates are not adequately represented in REACH 
 78 
guidance document R.7b, there is a high risk to miss effects of an EDC on certain invertebrate 
species / taxa (Lafont 2000, Oehlmann & Schulte-Oehlmann 2003, OECD 2006a, Hutchinson 
2007), i.e. a considerable uncertainty with regard to the protection of wildlife invertebrates. 
This is exemplified by the high sensitivity of molluscs to tributyltin and triphenyltin and the 
associated population declines in many prosobranch species. In addition, molluscs, copepods 
and echinoderms proved to be particularly sensitive to bisphenol A and 4-tert-octylphenol, i.e. 
invertebrates possessing vertebrate-type hormones may exhibit a higher sensitivity to 
substances interacting with vertebrate-type endocrine processes than vertebrates. An 
environmental risk assessment procedure for potential endocrine disrupters should be based 
on tests with representatives from the most relevant taxonomic groups, including cnidarians, 
annelids, crustaceans, insects, molluscs and echinoderms (Hutchinson 2002, Matthiessen 
2003, Oehlmann & Schulte-Oehlmann 2003, OECD 2006a). 
6. Need to know more about comparative endocrinology 
Mollusc partial lifecycle assay & full lifecycle assay & Mollusc Reproductive Toxicity Test 
(JRC note: in the meantime available: OECD TG 242 Potamopyrgus antipodarum 
Reproduction Test and OECD TG 243 Lymnaea stagnalis Reproduction Test) (same replies to 
the three tests, merged)  
7. With particular regard to the CF which specifies EATS effects (paragraph A.11 of GD 150) 
Molllusc assays (repro, partial and full life cycle): Two species are currently included; 
Potamopyrgus anitpodarum is parthenogenetic, making it unsuitable for assesing effects on 
the male. Lymnaea stagnalis is hermaphroditic, making assessments on the male difficult, and 
the species appears less sensitive to potential effects than dioecious species, possibly as they 
can self fertilize. 
8. More research is needed in relation to Development of endocrine specific endpoints in 
molluscs (and other invertebrates) 
9. The mollusc partial life cycle assay is now almost ready to be published as an OECD test 
guideline. 
Chironomid toxicity test (TG 218-219) 
10. Chironomid assay (TG 218/219): is not suitable as a test on the EATS pathway since it does 
not cover reproduction. 
Daphnia reproduction test (with male induction) (TG 211) & Daphnia multigeneration 
assay (same reply to both tests, merged) 
11. Daphnia reproduction test and multigen assay: is not a suitable representative for the 
crustacea as while this group appears to be sensitive to vertebrate steroids, this test does not 
cover effects on the male, as the species is parthenogenetic unless environmentally stressed. 
Earthworm reproduction test (TG 222) 
12. The species used are hermaphroditic making assessment on male effects difficult 
13. In general, they seem to have a significant limitation to distinguish ED effects from general 
toxicity. 
Enchytraeid reproduction test (TG 220) 
14. The species used are hermaphroditic making assessment on male effects difficult 
15. In general, they seem to have a significant limitation to distinguish ED effects from general 
toxicity. 
Sediment water lumbriculus toxicity test using spiked sediment (TG 225) 
16. Lumbriculus test: is essentially a biomass endpoint, so not relevant. 
Predatory mite reproduction test in soil (TG 226) 
17. Predatory mite test: effects on the male are not assessed as males are not introduced into the 
test. 
18. In general, they seem to have a significant limitation to distinguish ED effects from general 
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toxicity. 
Collembolan reproduction test in soil (TG 232) 
19. Collembolan reproduction test: species commonly used (Folsomia candida) is parthenogenetic 
so that effects on the male are not assessed. 
20. In general, they seem to have a significant limitation to distinguish ED effects from general 
toxicity. 
Mysid life cycle toxicity test 
- 
Copepod reproduction and development test 
- 
Sediment water Chironomid life cycle toxicity test (TG 233) 
- 
 
Table 48: Expert replies regarding additional invertebrate TMs (comments in free text fields to 
question " Are you aware of any additional invertebrate test already available that would add 
value? & Do you see any need for developing additional tests on invertebrates? Will there be added 
value from such tests from a regulatory perspective? (F.D.3 and F.D.4)). 
General 
1. There is a general need for Development of (non-vertebrate) endocrine specific endpoints in 
invertebrates 
2. Yes, we urgently need a range of invertebrate endocrine mechanistic screening assays, but 
this will depend on progress being made in understanding invertebrate endocrinology in 
greater depth. 
3. Yes. Endocrinology of invertebrates differ greatly from that of vertebrates. Some pesticides 
have been specially designed to target the endocrine system of invertebrates, e.g. juvenile 
hormone, which is unique to invertebrates. 
MOA/AOPs 
4. Invertebrate tests that allow definitive ED MoA and adversity characterisation would be of a 
benefit from regulatory perspective. 
5. The development of invertebrate tests that allow definitive ED MoA and adversity 
characterisation may be an interesting goal in terms of testing throughput and 3R policy 
concern. However this is likely to be a medium term research goal rather than a goal closer to 
application.  
6. Yes but it requires a well-founded insight into the biology of the hormonal systems of the test 
organisms. In general, in order to address which in vivo tests to possibly develop, it might be 
feasible to consider development of AOPs as the first step, and target MIEs, KEs and AOs with 
development of promising in vivo tests. 
7. Enhancing the suite of existing test with relevant biomarkers and endpoints would be more 
efficient. 
Bivalves 
8. Need to develop a test using bivalves as this group appears to be the most sensitive to 
vertebrate steroids over a wide range of species.  
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Gastropods 
9. Need to develop a test using a dioecious species of gastropod as this group is also sensitive 
and currently effects on the male, including mating behaviours, are not covered 
Echinoderms 
10. Need to develop a test using an echinoderm species as this group appears sensitive to both 
vertebrate thyriod hormones and sex steroids. 
11. Echinoderms are very important for biodiversity in marine and coastal environments and are a 
phylum with highly specialized characteristics, Yet there are no tests for endocrine disruption 
in echinoderms 
Arthropods 
Crustaceans 
12. The mysid and copepod tests are relevant for effects in the marine environment, but a 
dioecious freshwater equivalent test is needed (other than daphnia, in which effects on the 
male are not addressed). 
Hexapoda 
13. The collembolan reproduction test using the dioecious species (Folsomia fimitaria) would be a 
relevant test for effects on the male, but may need further validation at OECD. (F.D.3 – 1) 
Nematodes 
14. The knowledge for using C. elegans in reprotoxicity testing is available, but standardization of 
protocols/endpoints is needed. 
15. C. elegans reprotoxicity tests could be considered for inclusion. Studies with this nematode 
show good predictivity for DART compounds, can be used for multi-generational studies and 
are relatively easy to perform. Moreover, this nematode is very suitable for pathway 
screening especially when combined with siRNA strategies and/or fluorescent markers. (F.D.3 
– 2) 
 
 
JRC Summary of the comments in free text fields of Question F.D regarding 
invertebrate TMs 
The replies indicate that there is limited knowledge in endocrinology of invertebrates. 
Current tests on reproduction lack effects on males, since the species used are 
parthenogenetic; reproduction test with dioecious species are recommended; however, 
validation of tests would be necessary. 
In general, in order to address which in vivo tests to possibly develop, it might be 
feasible to consider development of AOPs as the first step, and target MIEs, KEs and AOs 
with development of promising in vivo tests.  
 
3.6 Experts final remarks in the survey 
In the last section (section G) of the survey the experts expressed their final remarks in 
the free text fields concerning  
● new / enhanced test methods that could lead to the greatest contribution to the 
protection of human health and the environment in a short-term perspective 
(Table 49)  
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● new / enhanced test methods that could lead to the greatest contribution to the 
protection of human health and the environment in a long–term perspective 
(Table 50) 
● any other issue related to the questionnaire and providing relevant references 
(Table 51). 
 
Table 49: Expert opinions regarding which new or enhanced TMs would lead to the greatest 
contribution to the protection of human health and the environment in a short-term perspective 
(free text comments to question G.1). 
1. Mixture models. In vitro tests for molecular initiating events that perturb thyroid pathways. 
Same comment for corticosteroids. 
2. Enchanced 416, 443 and chronic/carcinogencity assays 
3. Endocrine mechanistic screening tests for invertebrates, and screening tests for interference 
with the adrenal/interrenal stress response in fish and other vertebrates 
4. Any test method with more focus on human, mechanistically relevant endpoints as opposed to 
overt toxicity endpoints in rodents. 
5. Functional in vitro assays using clinically relevant biomarkers; in vitro assays relevant to 
metabolic synrome; juvenile toxicity roent test 
6. human cell culture models and whole blood gene expression 
7. whole animals, behavioral tests 
8. Enhancement of existing methods 
9. The uterotrophic assay is a short-term screening test sensitive enough to detect potent 
substances effects at even low concentrations, but of relevance for mammalians, invertebrates 
and aquatic life. This method could be enhanced with the addition of an anti-estrogenic positive 
control, uterus morphometry and plasma hormone levels quantification. The inclusion of these 
endpoints would better characterize not just estrogenic and anti-estrogenic pathways, but also 
steroidogenesis and HPG axis relation. Another relative short-term assay that could be 
conducted in the same way as the uterotrophic, but in males is a modified Hershberger assay, 
using immature rats and androgenic/antiandrogenic positive controls and other 2-3 doses of the 
test substance only, until the end of one entire period of sperm maturation (52 days). Sperm 
parameters, testes/epididymis morphometry and hormone analysis would complete the test 
evaluation in the same animals at once. The extended one-generation assay (with the 
suggestions of evaluation until F2, multiple time-points of blood and hormone levels 
collection/quantification and gonads morphometry) is the best and most complete experimental 
design evaluation for long-term endocrine disruption analysis of all windows of susceptibility, 
sensitivity and reproductive development. As the current in vivo methods would miss capturing 
effects triggered during pregnancy but showing up very late in life, an enhanced long 
term/carcinogenicity study with exposure in utero (merging developmental and long term 
studies) would be expected to fill this gap. In the pesticides area, long term studies are always 
required and this enhancement would add values without increasing the number of test animals. 
10. As commented earlier, MoA/AOP informed in silico/in vitro focussed IATA development and 
assessment with improved metabolism and human/environment relevance for EATS and non-
genotoxic carcinogenicity should be the high priority focus. See comment to DA7. 
11. A feasibility study for minor enhancements of TG 414 (Prenatal Developmental Toxicity Study) 
with ED-relevant endpoints has been proposed by DK and is now on OECD workplan. Need for 
mode of action data both in vivo and in vitro to validate the AOP approach. 
12. EOGRTS 
13. Biologically relevant in vitro tests in the thyroid signalling pathway, Enhancement of existing test 
methods with ED-specific endpoints, Invertebrate tests, that allow definite MoA and adversity 
characterisation MoA/AOP informed in vitro/in silico based IATA development iucluding improved 
metabolism and non-genotoxic carcinogenicity 
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14. ED related enhancement of existing guidelines which are already part of standard info 
requirements or of relevance for substance evaluation under REACH (e.g. TG414 - which is now 
on the workplan, TG 407, TG 408, TG 426, TG 443,). Guidance on cross species considerations: 
In our view, the current ED CF (Conceptual Framework); GD 150 (Guidance Document on 
Standardised Test Guidelines for Evaluating Chemicals for Endocrine Disruption) should be 
supplemented with some general recommendations in testing strategies to consider ED 
activity/related effects across species. The rat should be considered a model for rodents in the 
environment, not only for human health. Likewise, ED MoA observed in non-rodents vertebrates 
like fish and amphibians should raise a concern for human health. See also our comment in 
F.C.8. The following more general issues which are relevant, but not specific for endocrine 
disruptors, would be valuable to prioritize development of: Inclusion of metabolic capacity in in 
vitro assays and development of better PBTK modelling Guidance on modelling of Bench Mark 
Dose Level in existing in vivo testing to put more emphasis on dose/response characterisation 
Guidance for use of ex-vivo assays and data 
15. We need to add more developmental perspective. mainly prenatal. More behavioral tests are 
needed 
16. Development of more holistic tests conducted with developmental exposures 
17. The AFSS (GD 140) as a test for androgens/anti-androgens 
18. This is highly dependent on the regulatory framework and the possibility to ask /obtain relevant 
information. As long as the REACH Annexes are not updated, and it is and remains very difficult, 
if not impossible, to ask for in vitro screenings methods/information and specific functional 
apical tests, the update of existing methods seems to be the most efficient manner to get 
further information. It is acknowledged,however, that these kinds of updates will not be enough 
to detect developmental neurotoxicity, developmental immunotoxicity, metabolic disorders, 
intermediate epigenetic effects, etc. The same applies for the environment where the 
information is also very limited and the possibility to request mechanistic information is limited 
and the possibility to ask information on various taxa is even more limited. For PPP and biocides 
although the data requirements are different and more information is required for all 
substances, still further information on ED mode of action and/or apical endpoints is only 
triggered. This means that also for PPP it is important that adequate parameters that could 
trigger an ED mode of action are included in the existing TM. So for the short term updating of 
existing methods with relevant parameters to detect potential ED mode of action has high 
priority. 
19. The development of in vitro tests which resemble closest the in vivo situation. Usually these are 
ex-vivo models which also allow to study species differences and may allow to judge on human 
relevance The greatest contribution to the protection of human health in the short-term may not 
be to necessarily add more endpoints or to develop more tests, but to establish clear bounds of 
interpretation for the test methods and endpoints we are currently using. Some measured 
endpoints in OECD tests are still debated as to their biological and toxicological significance (e.g. 
AGD, sperm parameters). If we cannot use the existing approaches to inform decisions, it is 
unclear how new approaches will help clarify matters. 
20. I believe that addressing the data gap regarding MOAs and associated specific endpoints that 
give rise to effects in birds that would not be seen in mammals or other taxa wil provide a 
significant contribution to the protection of birds in short-term and long-term perspective. 
21. At the present time, tests leading to more sensitive detection of gonadal and thyroid disruption 
in the fetus would have the biggest impact. Bearing in mind that for gonadal disruption, besides 
known xenoestrogens, the phthalates are currently the class of chemical with biggest known 
single effect, but are currently without appropriate in vitro tests, then new assays targetting 
Leydig cell differentiation and development should have a high priority. 
22. Thyroid assays, GR Transactivation test and adrenal steroid synthesis 
23. As mentioned above an extended one-generation test with zebrafish would contribute in a short-
term perspective. 
24. incorporation of metabolism into in vitro tests Thyroid hormone pathway in vitro test validation 
MoA/AOP informed in silico/in vitro focussed IATA development and assessment with improved 
metabolism and human/environment relevance for EATS and non-genotoxic carcinogenicity 
should be the high priority focus. 
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25. Please see responses to E.A.3, F.A.3 and F.A.4. 
26. From both a short and long-term perspective, methods that inform modes of action (particularly 
thyroid hormone) and metabolism are the most critical needs for ED assessment. This would 
allow relatively quick screening of the possible universe of chemicals to identify priorities for 
further screening. In addition, this information should be used to improve AOPs and Integrated 
Approaches to Testing and Assessment that would improve the ability to generate useful 
information for risk assessment in the future. 
27. Screen for thyroid disruption 
 
Table 50: Expert opinions regarding which new or enhanced TMs would lead to the greatest 
contribution to the protection of human health and the environment in a long-term perspective 
(free text comments to question G.2). 
1. New in vitro, mechanistic test methods for other pathways than AETS modalities 
2. Invertebrate tests including endocrine specific endpoints are highly needed in both 
environmental protective and regulatory perspectived 
3. For nearly five decades long-term studies in rodents have been the accepted benchmark for 
assessing long-term toxicity, and particularly carcinogenicity, of chemicals. With exposures 
typically lasting about 2 years, long-term bioassays using rats has been a fundamental 
component of toxicity evaluation for food additives, pesticides, pharmaceuticals, 
occupational/industrial chemicals, and all manner of product formulations, byproducts, and 
environmental contaminants. Recently the European Food Safety Authority (EFSA)/ European 
Union (EU) and the World Health Organization (WHO) pointed out that the current set of 
internationally accepted test methods capture only a limited part of the chemicals adverse 
effects, particularly concerning potential endocrine disrupting activities, as current tests are 
inadequate to detect them. Different testing strategies are needed for identifying biologically 
significant adverse effects, including low dose effects, consequences from early life-stage 
exposures, non-monotonic dose response curves, impact of chemical mixtures, or 
neuro/behavioral effects : these end-points. are often not detectable with current range of 
toxicity testing. Testing requirements need to be expanded and validated, for both animal 
testing and alternative in vitro/in vivo methods, in order to generate more adequate and 
inclusive data relevant to protecting public health. We propose an integrated and comprehensive 
long-term toxicity/developmental/carcinogenicity bioassay capable of generating information on 
a broad spectrum of different end-points and relevant hypotheses. Sprague Dawley rat, already 
in use for carcinogenicity bioassays by most organizations including the Ramazzini Institute and 
the National Toxicology Program, and the Endocrine Disruptor Screening Program of the U.S. 
Enviromental Protection Agency [EPA], has been demonstrated as an appropriate and relevant 
model for identifying, extrapolating and predicting several toxic effects in humans. Therefore 
integrated toxicological tests on Sprague Dawley rat represents a unique opportunity for 
investigating multiple toxicological end-points at once, sparing animal lives in accordance to the 
3Rs (replacement, reduction and refinement). An integrated study design based on a stepwise 
process complies and expands the state of the art of current guidelines: the Organization for 
Economic Co-operation and Development (OECD) Guidelines 453, 443 (OECD 2009, 2011) 
4. Life cycle test with amphibians 
5. Test methods to predict epigenetic (transgenerational) effects. 
6. Epigenetic markers in enocrine disruption testing. In the ecotoxicological field assays for 
endocrine disruption in echinoderms 
7. animal models 
8. multigenerational studies 
9. Test methods to evaluate metabolic disturbances 
10. As soon as IATAs have been established for the earlier mentioned fields, the experience and 
resources shall be used to extend to other fields, as Retinoic Acid, HPA axis and others. In long 
term also epigenetic MoA should be targeted by appropriate in vitro focussed IATAs. 
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11. Need for mode of action data both in vivo and in vitro to validate the AOP approach. 
12. Update relevant OECD Test Guidelines to include endocrine disrupting effects taking into account 
Mode of Action. 
13. Methods tackling deseases involving diabetes and obesitas as well as immune system/stress 
related disorders in wildlife animals and humans. Also epigenetic effects should be tackled. 
14. Development of TGs to detect MoA and AO of thyroid disrupting substances predictive for effects 
in humans. More basic longer term research is also needed. 
15. Low-dose developmental exposures in rodents - and translation to primates 
16. HPA and Thyroid axis are way behind and need our attention; 
17. In the long term it is essential that we develop non-animal/in vitro screening batteries to detect 
potential EDs. If possible this should be included in a high throughput system. In addition 
further apical test both for human health and the environment needs to be developed. For 
human health functional tests on for example developmental neurotoxicity, developmental 
immune toxicity and metabolic syndrome are considered essential for regulation according to the 
definition of the WNO/IPCS. For environment new and enhanced test methods to be developed 
should cover the protection of the myriad of species and complex ecosystems. Sensitive species 
of vertebrates and invertebrates including mammals, birds, amphibians, reptiles, fish, insects, 
etc should be taken into account. Besides tests, structured testing strategy is of utmost 
importance. 
18. I believe that addressing the data gap regarding MOAs and associated specific endpoints that 
give rise to effects in birds that would not be seen in mammals or other taxa will provide a 
significant contribution to the protection of birds in short-term and long-term perspective. 
19. As in G.1 
20. Somatotropic (TR and GR transactivation assay) and Vitamin D pathways (VDR, AhR 
transactivation assays and Vitamin D hydroxylase assay) Inclusion of epigenetic studies?? (we 
are not experts in epigenetics, but the approach sounds promising) 
21. see Jacobs et al ALTEX 2013 and Jacobs and Greally ALTEX 2013. As soon as IATAs have been 
established for EATS the experience and resources could be extended to other fields, such as 
Retinoic Acid, HPA axis etc. In long term also epigenetic MoA should be targeted by appropriate 
in vitro endocrine focussed IATAs. 
22. Please see responses to E.A.3, F.A.3 and F.A.4. 
23. Issues that would be better addressed in the longer term are epigenetic effects (once the 
mechanisms are better understood), as well as linkages between the different hormone 
pathways (so that particular adverse outcomes could be better predicted from upstream 
molecular events). 
24. A comprehensive battery of tests to identify effects on brain development re humans 
 
 
Table 51: Expert general remarks and relevant references provided (replies in free text fields to 
question G.3). 
1. The validation of new methods for the study of EDs is a very important issue in which our 
Institute is involved from many years.. 
2. close cooperation with clinical endocrinologists and biobanking 
3. See comment DA7. References: OECD, New Scoping Document on in vitro and ex vico assays for 
the identification of medulators of thyroid hormone signalling. 2014, Series on Testing and 
Assessment. Greally, J.M. and M.N. Jacobs, In vitro and in vivo testing methods of epigenomic 
endpoints for evaluating endocrine disruptors. ALTEX, 2013. 30(4): p. 445-71. Jacobs, M.N., et 
al., In vitro metabolism and bioavailability tests for endocrine active substances: what is needed 
next for regulatory purposes? ALTEX, 2013. 30(3): p. 331-51. OECD, The use of metabolising 
systems for in vitro testing of endocrine disruptors. A detailed review paper for the OECD No. 
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97. Paparella, M., et al., Uncertainty of testing methods--what do we (want to) know? ALTEX, 
2013. 30(2): p. 131-44. WHO, Harmonisation Project Document No 11. 2014. Edler, L., et al., 
Selection of appropriate tumour data sets for Benchmark Dose Modelling (BMD) and derivation 
of a Margin of Exposure (MoE) for substances that are genotoxic and carcinogenic: 
considerations of biological relevance of tumour type, data quality and uncertainty assessment. 
Food Chem Toxicol, 2014. 70: p. 264-89 Meek, M.E., et al., New developments in the evolution 
and application of the WHO/IPCS framework on mode of action/species concordance analysis. J 
Appl Toxicol, 2014. 34(1): p. 1-18 
4. Generally, in vitro screens are relevant for effects in both humans and vertebrate wildlife 
because many of them are based on highly conserved hormone receptors or interaction with key 
enzymes or other key molecules involved in the regulation of hormone levels in all vertebrates. 
Chemicals that bind to these receptors or otherwise interfere with key processes of hormone 
regulation have the potential to cause adverse effects in vivo both in non-mammalian vertebrate 
species and mammalian species (including wildlife species and humans). A novel paper 
concludes that when comparing data from fish and rat assays, a high concordance was seen with 
respect to identifying chemicals that impacted specific endocrine pathways of concern (Ankley 
and Gray, 2013 see below). Although most chemicals were detected as positive in both the rat 
and fish assays, eliminating data from one class of vertebrate would weaken the battery. For 
example, the effects of competitive inhibitors of steroid hormone synthesis were far more 
obvious in the fish assay, whereas the activity of androgen receptor antagonists was clearer in 
mammalian assays (Ankley and Gray, 2013). Due to the similarities between different 
vertebrate species it seems to be relevant to consider ED related concerns identified in one 
species (e.g. in fish or amphibians) as of potential relevance for other species (such as rat or 
humans) - in particular in cases when no or only limited data is available for more than one 
species. The current ED Conceptual Framework and Guidance Document do not at the higher 
levels (from level 3 and onwards) reflect this adequately. Instead the current approach is that 
"human health concerns" are based on rat /rodent TGs/data only, whereas concern for the 
environment is based on available data on fish, amphibian/birds and to some extent 
invertebrates only. In our view, this needs further discussion e.g. of the need for supplementing 
the current Conceptual Framework or GD 150 with some (more) considerations, e.g. for 
substances where there are concerns in fish for estrogenicity or for thyroid effects in amphibians 
and at the same time absence / or clear limitations in availability of relevant data in rodents. In 
such cases there may be concerns for potential ED related effects in mammalians (e.g. rat and 
humans) - and vice versa. Another issue is that currently ED related effects in rodents are 
normally only regarded in the context of their relevance for human health. But, as already 
mentioned some years ago at an EDTA meeting, such rodent data should in general also be 
regarded in the context of their relevance for mammalian wildlife species (i.e. in relation to 
environmental concerns). Reference: Ankley GT, Gray LE. Cross‐species conservation of 
endocrine pathways: A critical analysis of tier 1 fish and rat screening assays with 12 model 
chemicals. Environ Toxicol Chem. 2013 Feb 7. doi: 10.1002/etc.2151. 
5. Development of methods to detect multifactorial disorders like development of hormone related 
cancers after in utero exposure, which are challenging and might require another framework to 
address. More basic longer term research is needed. REFERENCES: Ankley GT, Gray LE. Cross‐
species conservation of endocrine pathways: A critical analysis of tier 1 fish and rat screening 
assays with 12 model chemicals. Environ Toxicol Chem. 2013 Feb 7. doi: 10.1002/etc.2151. Hass 
et al., OECD Conceptual Framework for Testing and Assessment of Endocrine Disrupters as a 
basis for regulation of substances with endocrine disrupting properties, TemaNord 2004:555, 
http://www.diva-portal.org/smash/get/diva2:702046/FULLTEXT01.pdf Hass et al., 
Information/testing strategy for identification of substances with endocrine disrupting properties, 
Danish Centre on Endocrine Disrupters, 2013, http:// 
http://www.cend.dk/files/EDtestingstrategy.pdf Greally & Jacobs. In vitro and in vivo Testing 
Methods of epigenetic Endpoints for evaluating endocrine Disruptors, ALTEX (2014), 7/13. 
6. In my experience the behavior is a very sensitive endpoint that needs to be evaluated always in 
this type of study. 
7. Good luck! 
8. We are looking forward to a fruitful meeting in November 
9. The priority must be given to those axes for which there is a clear understanding of the long 
term adverse effects and the AOPs/MOAs responsible for the effects - ie the focus should 
continue to be on the HPG, HPA, HPT axes. It is currently difficult to say whether the other axes 
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are as relevant due to the paucity of mechanistic data. Relevant test methods cannot be 
developed until AOPs/MOAs are established for a given toxicity and as the scope of each test 
method consequently developed has been ascertained. Evaluation of EDs cannot rest solely on 
the use of in vitro data - characterizing the adverse effects in relevant in vivo studies, 
determining the severity of the effects and whether the observations are reversible as well as 
establishing that the MOA for the adverse effects is ED related are critical elements not only for 
identifying EDs but also determining those which are of greatest regulatory concern. 
10. Birds play a critical role in our ecosystem. We currently do not have a validated test that 
evaluates effects of edcs in birds. Also there is a data gap regarding the MOAs and associated 
specific endpoints that give rise to effects in birds that would not be seen in mammals and other 
taxa. I believe this should be an area of focus for endocrine test development that will make a 
significant contribution in the short and the long term. 
11. Consider that we are not experts for the tests of the OECD conceptual framework, as we do not 
perform the tests ourselves, our answers should provide more a general view from our site as 
all-round regulatory toxicologists. Asking the advice of scientists performing regularly the assays 
could bring high value and strong expertise to the further development of methods for the 
evaluation of ED. 
12. we should go for a step-wise approach developing/validating further in vitro screening methods, 
such as reporter assays for other modes of action than so far developed ER & AR assays, but 
relevant to the whole endocrine axis and hormone signaling pathways (as listed in document). 
Next to that, based on relevant modes of action detected by in vitro assays, verification should 
follow by animal test but considering 3R. Not necessary to develop new in vivo tests, but most 
of current in vivo tests can be upgraded with other apical endpoints (e.g. measurement of 
hormone levels or biomarkers) representing these other pathways. Upgrading test methods for 
other pathways, at different levels (according to OECD framework) will allow to anticipate to the 
AOP concept applicable for EDC evaluation. 
13. UBA scientific report "Substances of very high concern under REACH - an evaluation of 
uncertainties in the environmental risk assessment of endocrine active substances, Oct. 2012"  
14. References: OECD, New Scoping Document on in vitro and ex vico assays for the 39 
identification of medulators of thyroid hormone signalling. 2014, Series on Testing and 
Assessment. Greally, J.M. and M.N. Jacobs, In vitro and in vivo testing methods of epigenomic 
endpoints for evaluating endocrine disruptors. ALTEX, 2013. 30(4): p. 445-71. Jacobs, M.N., et 
al., In vitro metabolism and bioavailability tests for endocrine active substances: what is needed 
next for regulatory purposes? ALTEX, 2013. 30(3): p. 331-51. OECD, The use of metabolising 
systems for in vitro testing of endocrine disruptors. A detailed review paper for the OECD No. 
97. Paparella, M., et al., Uncertainty of testing methods--what do we (want to) know? ALTEX, 
2013. 30(2): p. 131-44. WHO, Harmonisation Project Document No 11. 2014. Edler, L., et al., 
Selection of appropriate tumour data sets for Benchmark Dose Modelling (BMD) and derivation 
of a Margin of Exposure (MoE) for substances that are genotoxic and carcinogenic: 
considerations of biological relevance of tumour type, data quality and uncertainty assessment. 
Food Chem Toxicol, 2014. 70: p. 264-89 Meek, M.E., et al., New developments in the evolution 
and application of the WHO/IPCS framework on mode of action/species concordance analysis. J 
Appl Toxicol, 2014. 34(1): p. 1-18 
15. When pesticides come up for re-authorisation the test data supplied should be as for new 
pesticides. It is important to enforce the re-testing of such substances with updated endpoints 
focused on ED as if only tested in old tests, ED properties will be missed. We need to update and 
find improved test methods, BUT ALSO there is a need to ensure substances at re-authorisation 
are re-tested with the most up to date test methods. 
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4 Conclusions 
The respondents submitted many valuable and detailed comments. We thank all survey 
participants for their contributions.  
The received information was further evaluated and is currently used to develop a 
thought-starter document for the workshop on prioritising test method development for 
the identification of endocrine disrupting substances to be held on 30 May – 1 June 2017 
in Brussels. 
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Annexes 
Annex 1: Overview of the expert relevance rating of test methods included in 
the OECD CF and in OECD DRP No 178 (2012). 
Source or 
Pathway 
Endpoint (EP) or Test Method (TM) 
Relevance 
Ranking 
based on Ratio 
relevant/not 
relevant 
[Eq5, Eq7] 
% 
practical 
problems 
[Eq6]a 
CF Amphibian metamorphosis assay (AMA, TG 231) - b 
CF Fish sexual development test (FSDT, TG 234) - b 
CF 
Medaka extended one-generation reproduction test 
(MEOGRT) - b 
CF 
Extended one-generation reproductive toxicity study 
(TG 443) 29.0 
HPA  (EP) adrenal steroid synthesis (in vivo) 24.0 20.8 
HPG 
gestagenic (EP) reduced fertility in fish (TG229; MEOGRT) 22.0 18.2 
PPAR 
(TM) Adipocyte differentiation in cultured pre-
adipocyte cells 21.0 19.0 
CF 
Larval amphibian growth and development assay 
(LAGDA) 20.0 
CF Xenopus embryonic thyroid signalling assay (XETA) 20.0 
CF Fish short term reproduction assay (FSTRA, TG 229) 17.0 
HPT (TM) neurite extension assay 14.0 28.6 
HPT (TM) neural progenitor cell proliferation assay 14.0 28.6 
HPA (EP) Stress response (in vivo) 12.5 44.0 
retinoid (TM) RXR transactivation assay 12.5 12.0 
HPG 
gestagenic (TM) Progesterone receptor (PR) transactivation test 11.5 17.4 
HPG 
estrogenic 
 (EP) Gonad histopathology in chronically exposed 
amphibians (TG 231 AMA; included in LAGDA) 10.5 14.3 
HPT 
(TM) XETA (Xenopus Embryonic Thyroid Signaling 
Assay) 9.5 10.5 
CF Developmental neurotoxicity (TG 426) 8.7 
HPT (TM) thyroid peroxidase assay 7.7 8.7 
HPT (TM) iodine uptake assays 7.7 8.7 
CF 
Pubertal development and thyroid function assay in 
intact juvenile/peripubertal male rats (OCSPP 
890.1500) 7.7 
HPT (TM) Tadpole tail explant resorption assay 7.5 26.7 
CF 
Detection of endocrine active substances, acting 
through estrogen receptors, using transgenic 
cyp19a1b-GFP zebrafish embryos (EASZY) 7.5 
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CF 
Pubertal development and thyroid function assay in 
intact juvenile/peripubertal female rats (OCSPP 
890.1450) 7.3 
retinoid (TM) RAR transactivation assay 7.0 14.3 
PPAR 
(TM) PPARalpha,beta/delta,gamma transactivation 
assay 7.0 9.5 
retinoid 
(EP) weight gain, increased adipose tissue mass, 
increased lipid accumulation, reduced retinoid levels 
in vivo (TG 415, 416, 443, fish and amphibians) 6.8 14.8 
HPT (TM) dendritic arborization assay 6.0 41.7 
HPT (EP) TH production in thyroid gland explants 6.0 33.3 
HPA (EP) corticotropin (ACTH) release (in vivo) 5.8 21.7 
HPT (TM) T4 binding protein displacement assay 5.8 13.0 
HPG 
gestagenic 
(TM/EP) assessment in exposed oocytes and sperm 
ex vivo or in oocytes/sperm derived from adult fish 
from TG 229 and MEOGRT 5.7 29.4 
HPT (TM) T-screen assay 5.7 17.6 
CF 
Androgenised female stickleback screen (AFSS, GD 
140) 5.3 
HPA 
(TM) adrenal steroid synthesis (in vitro), e.g. 
modified TG 456 5.3 19.0 
Vitamin D (TM) VDR transactivation assay 5.0 0.0 
HPG 
gestagenic (TM) membrane PR binding assay 4.8 21.1 
HPG 
estrogenic 
(EP) GnRH neuron development in brain of 
chronically exposed fish (MEOGRT) 4.7 14.3 
CF 21-day fish assay (TG 230) 4.7 
CF Two-generation reproduction toxicity study (TG 416) 4.6 
CF Prenatal developmental toxicity study (TG 414) 4.4 
Vitamin D (TM) Vitamin D hydroxylase assay (in vivo) 4.3 15.4 
PPAR 
(EP) Weight gain in chronically exposed animals (TG 
415, 416, 443, LAGDA) 4.2 4.8 
HPG 
androgenic (EP) behavioural assessments in any in vivo study 4.2 40.0 
retinoid (EP) EROD induction in in vivo assays 4.0 5.0 
Vitamin D 
(EP) RIA or EIA for serum vitamin D levels (could 
potentially be applied to any in vivo exposure assay) 3.8 13.3 
Vitamin D 
(EP) reduced bone length in juvenile rodent (TG 
416, 443) 3.2 31.3 
HPA  (TM) GR transactivation test (in vitro) 3.2 21.1 
retinoid (TM) AhR transactivation assay 3.2 15.8 
HPT (TM) TR reporter assays 3.2 15.8 
CF Fish reproduction partial lifecycle test (no validation 3.0 
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ongoing) 
retinoid 
(EP) CYP1A mRNA or protein quantification in in vivo 
assays 2.9 10.0 
PPAR (TM) Peroxisome proliferation assay 2.8 23.5 
CF Uterotrophic bioassay in rodents (TG 440) 2.8 
CF Avian reproduction test (TG 206) 2.8 
CF Avian two-generation test (ATGT) 2.8 
CF 
Combined 28 day reproductive screening test (TG 
421+422) 2.7 
HPT (TM) AhR reporter assays 2.7 18.8 
CF Hershberger bioassay in rats (TG 441) 2.6 
HPT (TM) CAR reporter assays 2.3 14.3 
CF 
Combined chronic toxicity / carcinogenicity study 
(TG 453) 2.0 
Vitamin D  (EP) Brain size measurements in rodent offspring 1.9 46.2 
CF One-generation reproduction toxicity study (TG 415) 1.8 
somatotropic 
(EP) Fetal birth weight and length in rodent 
multigeneration tests (TG 416, 443) 1.7 4.0 
CF 
Fish life cycle toxicity test (FLCTT) (no validation 
ongoing) 1.6 
CF Repeated dose 28 day study (TG 407) 1.6 
Vitamin D (TM) AhR transactivation assay 1.6 0.0 
CF Repeated dose 90 day study (TG 408) 1.4 
Vitamin D 
(EP) EROD activity assay (biomarker, could 
potentially be applied to any in vivo exposure assay) 1.3 37.5 
somatotropic 
(EP) analyses of hepatic GR mRNA levels in 
fish/mammals in vivo assays 1.1 23.8 
somatotropic 
(EP) Analyses of hepatic IGF-1 mRNA levels in 
fish/mammal in vivo assays 1.1 14.3 
somatotropic (TM) TR and GR transactivation assays 1.0 25.0 
somatotropic (EP) Growth evaluation in fish assays (MEOGRT) 1.0 20.0 
HPT (TM) EMSA, DNA pull-down assay 1.0 50.0 
a = Experts were asked to address practical problems only for the tests included in the OECD DRP no 178 
(2012). Therefore, for OECD CF included tests no value is presented. 
b = there were no answers stating low or no relevance, therefore no ratio number is given, but tests should be 
considered of high relevance. 
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